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Four different compounds have been investigated for their usefulness as protecting 
groups for the solid phase synthesis of RNA and DNA, covering both 5' and 2' 
protection. 
First is a 5' hydroxyl protecting group containing the highly hydrophobic Tbf 
(tetrabenzO[a,c,g,i]fluorene) moiety based on the trityl protecting group. This new 
group has been successfully incorporated into the synthesis of oligonucleotides pre-
attached to the final nucleotide. The high hydrophobicity of the Tbf moiety is utilised 
to purify the sequence and it is then cleaved using existing protocols intended for 
dimethoxy trityl deprotection. This group could been used for 
oligodeoxyribonucleotides, oligoribonucleotides, peptides and sugars. 
Three separate compounds were tried for the 2' position of ribose and would 
therefore be of general applicability in oligoribonucleotide synthesis. These 
protecting groups were planned to have a two stage deprotection protocol intended to 
be compatible with the synthesis of oligoribonucleotides while also meeting the strict 
steric restraints of the position. 
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Chapter 1 	Introduction 
1.1 Introduction to RNA and DNA 
1.1.1 History of DNA 
In 1869, thirty years after the cell had been identified as the basic unit of life, 
Friedrich Miescher isolated from cell nuclei a phosphorus-containing substance that 
was acidic in nature. Because of its acidity and origin, he named it Nucleinsaure 
(nucleic acid). In the 1920's Phoebus Levene identified the components of nucleic 
acids as four nitrogen-containing bases, a five-carbon sugar and a phosphate group. 
Levene also identified RNA as different from DNA in the sugar component and 
suggested how nucleotides might form long chains. However, he then put forward 
the tetranucleotide theory that has since been shown to be misguided. In this theory 
the bases repeated in regular order. This mistaken belief arose because it was thought 
nucleic acids were too simple to be the genetic information store and could as a 
consequence only play a structural role within the nucleus. Since the twenty amino 
acids offered much more variety than the four nucleic acid bases proteins were at the 
time thought to be the molecules of heredity. Erwin Chargaff first cast doubt on the 
tetranucleotide theory in the 1940's when he showed that nucleotide levels were not 
equal and that the chromosomal DNA of different species had different levels of each 
nucleotide. In the tetranucleotide theory all base levels should be equal and that 
should carry through to all life. One of Chargaff's major discoveries was that 
thymine and adenine levels were equal, as were cytosine and guanine, independent of 
the origin of the DNA. 
The true significance of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) 
was to be realised in 1944 with the discovery by Avery et all that DNA and not 
proteins from one strain of pneumoccus could transform another. This work was 
reinforced in 1952 when Hershey et a12 used bacteriophages to show that viruses 
used their DNA to infect and take over other cells. Hershey was awarded the Nobel 
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Prize in 1969 for this work that finally determined that DNA was the molecule 
responsible for the transmission of inherited characteristics. The next big step 
forward came in 1953 with the publication in the journal Nature of the double helix 
structure of DNA by Watson and Crick 3.  In their model two complementary anti-
parallel strands of oligonucleotides wind around each other with specific base pairs 
interacting across the strands. The implied mechanism for self-replication inherent in 
the structure was significant and subsequent discoveries that the base pair sequences 
directly translate into amino acid sequences for proteins have ensured that DNA has 
been of considerable interest to scientists ever since. 
1.1.2 Biological role of DNA and RNA 
Reverse Transcription 
	
CSelf DNA 	 RNA 	 Protein  ________________ 	_______________ Replication 	  Transcription Translation __ 
Figure 1. The DNA to protein pathway 
Most of all DNA is contained within the nucleus of all cells except for bacteria and 
mitochondria, which do not have nuclei and their DNA moves freely throughout the 
cell. Within the cell DNA can be replicated or transcribed. Replication is where DNA 
is copied and transcription is the process where genetic code from DNA is used to 
produce mRNA as a template for protein synthesis. The first step in this process is 
the production of mRNA (messenger RNA) directly from the sequences of DNA. 
The DNA has encoded within it short sequences to indicate the beginning and end of 
a specific gene. The mRNA is assembled mirroring one of the DNA strands known 
as the template strand. The other strand is identical to the mRNA, except thymines 
are replaced by uridine, and is known as the coding strand. The mRNA then leaves 
the nucleus and moves into the cytoplasm where it is used as a template for the 
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production of proteins in a process called translation. Each three base sequence of the 
coding region of mRNA corresponds to an amino acid in the protein. Since proteins 
perform all functions required for growth and maintenance of the cell then DNA 
holds the code for all these functions. 
Three separate classes of RNA are involved in the transcription and translation of a 
strand of DNA. Messenger RNA is the template onto which small (70 to 90 
nucleotides) RNA molecules called tRNA (transfer RNA) dock. Lastly there are the 
ribosomal RNA's (rRNA) which form ribosomes along with ribosomal proteins. The 
riobosomes are the structure within which the mRNA and tRNA molecules combine 
to build proteins. 
1.1.2.1 The RNA World 
The question of how life evolved from inorganic lifeless matter to organic life has 
dogged science ever since people began doubting the creationist model. The gap 
between nonliving chemicals and bacterial cells is considered wider than that 
between bacteria and humans. Virtually all biologists agree that some sort of 
precellular life must have existed. The essence of the problem is a 'chicken and egg' 
paradox. DNA is a good store of genetic information but cannot carry out the 
functions required for a functioning cell. Proteins are good at carrying out the 
functions but cannot self-replicate and are therefore no use as stores of genetic 
information. The probability that both evolved spontaneously together seems 
unlikely so the question is "which came first?". 
Between the competing camps of proteins first and DNA first has emerged the 
possibility of an RNA world, first proposed by Gilbert4 in 1986. In this model, RNA 
carried out both functions. In recent years it has been shown that RNA molecules can 
do more than simply create proteins. RNA molecules have been shown to behave as 
enzymes in RNA cleavage and ligation reactions. These molecules are termed 
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ribozymes and it has been suggested that RNA molecules play a more active, 
catalytic role in the production of proteins  and crucially RNA can self replicate and 
modify its own sequences 6. Thus opening up the possibility that in the earliest life 
only RNA existed. 5.11 
Mechanisms for recombination and the ability to produce new genetic sequences 
have been suggested which also explain how RNA systems could have evolved. For 
example the difference between an active store of information and an active 
ribozyme may be splicing out of some or all introns. 5 Experiments have also shown 
that short random sequences of RNA can have function. 12  By demonstrating the 
density of reactivity within the range of sequences it is easier to imagine the 
evolution of an RNA world. Then we could presume that over time DNA evolved as 
a more stable store for the genetic information and proteins developed as more 
efficient enzymes, relegating RNA to an intermediate role in most cases. 
A problem of this research is that findings are mostly conjecture as there is no fossil 
record for analysis and any precellular life is unlikely to have left any trace of its 
existence. The earth came into existence 4.5 x 109 years ago and the first evidence of 
cellular life is 3.6 x 10 9 years ago. The window for precellular life is further 
shortened by the fact that for much of earth's early life it was subject to meteoric 
bombardment and geological instability. 13-14 
An early experiment to simulate primordial conditions was the first to shed light on 
this problem. A sealed flask containing methane, ammonia, hydrogen and water was 
subjected to an artificial lightning bolt for several weeks. The electrical discharge 
was used to form free radicals from which a complicated mixture of compounds was 
made. Analysis of the mixture at the end of the experiment revealed the presence of 
13 of the 20 amino acids essential to life. 15  Subsequent experiments and theory have 
shown the possibility of purines and pyrimidines, required for DNA and RNA, being 
present. '6'7 
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There are still problems with these theories. The fragility of RNA and the lack of a 
practical mechanism whereby oligoribonucleotides were made in the primordial soup 
cast doubt over the existence of the RNA world. 13,14,18 
1.1.3 Structure of DNA and RNA 
1.1.3.1 Primary Structure 
The basic structure of DNA and RNA is that of a linear polyester where phosphoric 
acid constitutes the diacid component and a substituted D-ribose or 2'-deoxy-D-
ribose is the diol. All the phosphodiester linkages are 3'-5' in the normal primary 
structure. On each ribose unit at the 1' position is a nucleobase. These are the basis 
of the genetic code and come in two forms. There are the purines adenine (A) and 
guanine (G) and the pyrimidines cytosine (C) and thymine (T). In RNA uracil (U) 
replaces thymine. 
H2 
Figure 2. The primary structure of DNA (left) and RNA (right) 
In descending order the bases shown above are Guanine, 
Thymine (Uracil on the right), Adenine and Cytosine 
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1.1.3.2 Secondary Structure 
The secondary structure of DNA is directed by the hydrogen bonding of the 
nucleobase on one strand with the corresponding base on the other. Thymine couples 
with adenine and cytosine with guanine. The two strands form a right-handed spiral 
around a central axis and run anti-parallel to each other, shown on the left-hand side 
of figure 3. 
Major Gro~ove 
N H"(
%N' 	N yNQJ 
/ flN 
M11nor Groove 
Adenine with Thymine 
, Major Groove N\ 
0'N 	N 0 
\_ y _ T 
o 
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MInor Groove 
	
NfNH q_Jo / 
Guanine with Cytosine 
Figure 3. DNA double helix structure showing the base pairs 
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The main secondary structures are the A-DNA and B-DNA forms which both have 
right-handed helices and Watson-Crick base pairs. The base pairs are shown on the 
right side of figure three, which also shows the major and minor grooves which run 
down the side of the helix. Other types of helix with left-handed spirals, hairpin 
loops and triplexes are also known. 19 Intramolecular base pairing causes hairpin 
loops. Z-DNA has a left-handed helical structure as opposed to the right-handed 
structure of A-DNA and B-DNA. The difference between the A and B forms is in the 
conformation of the sugar unit. In B-DNA it is the C2' carbon which is out of the 
plane of the other carbons whereas in A-DNA it is the C-3' carbon. 
RNA has the added complexity of the hydroxy function at the 2' position and as a 
result cannot easily adopt the helical structures of DNA due to the extra oxygen atom 
making too close a Van der Waals contact. 3 As a consequence RNA has no general 
structure and has greater chemical reactivity than DNA. 
RNA molecules can have some helical domains but they will also have hairpins 
and loops and other less defined motifs. The Watson-Crick base pairs still strongly 
influence the three-dimensional structure but now other less stable pairings (G-U) are 
also involved. The exact three-dimensional structure of the RNA molecule will 
greatly influence its biological function and activity. 4 
1.1.4 DNA Triplex 
The first triple helix was discovered in 1957 when it was noticed that polyuridine 
formed a 2:1 complex with polyadenosine in the presence of MgC12. 20 Later in 1963 
it was found that polycytidine also forms a 2:1 complex either with polyguanosine at 
pH 6.2 or with one of the cytosine strands existing in the protonated form. This 
triplex formation can be made pH independent by using 6-oxocytidine in place of 
cytidine on the third strand . 2 ' Triplex formation has since been shown to inhibit 
activity at the bound sequences. For example inhibition of the restriction 
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endonuclease cleavage enzyme Ksp632 can be achieved with micromolar 
concentrations of an oligonucleotide capable of forming a triplex with protein 
binding sites which regulate specific genes  22  opening up a world of applications. 
The structure of the triple helix was confirmed in the 1970's with x-ray diffraction 
data. In both the above pyrimidine cases the additional strand binds in the major 
groove of the DNA double helix by Hoogsteen (HG) hydrogen bonds. Binding 
causes distortion in the shape of the double helix to give a deeper major groove to 
accommodate the new strand  .23  Cooperative binding effects are observed for triplex 
formation at adjacent sites. 24 
/ 
f\...-O. 	 H3C 
I 
•1_N 	'H 
T :e' N~ 0 





HG type, parallel CG: C 
Figure 4. Hoogsteen hydrogen bonds 
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There are two binding motifs. The pyrimidine (Y-R:Y) type mentioned above 
which uses the HG bonds and the more recently discovered (1988) purine (R-R:Y) 
which uses reverse HG bonding. The common features of both motifs are the central 
purine base and the fact that two hydrogen bonds are formed with the double helix. 
Only two out of the eight possible combinations with a pyrimidine as the central base 
are accommodated with reasonable stability. These triplexes (G-T:A) and (T-C:G) 
only form 'one hydrogen bond with the double helix and are much less stable, 
limiting their usefulness. 24 -29 A single mismatch in the 15 base pair cleavage probe of 
the type [DNA-EDTA-Fe(II)] produces a lowering of efficiency by at least a factor 
















Figure 5. Reverse Hoogsteen hydrogen bonds 
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This limitation of oligonucleotide triplex formation has lead to the investigation of 
unnatural base components designed to selectively interact with thymine and 
cytosine.  30 -32  Attempts to simply miss out a single pyrimidine interruption in a purine 
tract by introducing an abasic group opposite the pyrimidine caused considerable 
destabilisation of the triplex. Therefore groups capable of selective hydrogen 
bonding to pyrimidines are needed. The problem arises largely from the fact that the 
pyrimidines have only one potential site for hydrogen bonding. Several potential 
solutions have been tried to increase the number of hydrogen bonds and thus improve 
triplex stability. 
O'N N N N 
H 
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Figure 6. Attempts to improve pyrimidine strand binding, 
(Top) shows a modified cytosine designed to bind to both bases of the pair for the 
unnatural triplet C*C:G.30  (Bottom) shows an attempt to add an extra hydrogen bond 
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One approach is to design non-natural bases for the third strand, which can 
hydrogen bond with both bases of the pair. An extension of this is to use modified 
pyrirnidiries with additional functional groups capable of hydrogen bonding. 30,31 
Covalently attached intercalating agents are often added at the end of a sequence to 
increase triplex stability. A third approach was discovered by chance when a 
modified base was found to interact with the pyrimidine strand not by hydrogen 
bonding but sequence specific intercalation. 32  Yet another method was the 
development of (3'-3') linked oligonucleotides for alternate strand binding. 33  A final 




Figure 7. Shows a bidirectional pyrimidine oligonucleotide covalently attached to 
EDTA Fe designed to cleave a 4.05 kbp plasmid at the site specific to the sequence. 
Cleavage was observed with no cleavage at partly homologous sites. 33 
Chapter 1 Introduction 
	
12 
1.2 Applications of Synthetic Oligomers of DNA and RNA 
The advance of automated solid phase synthesis of oligonucleotides and the advent 
of molecular cloning technologies have opened up many applications throughout 
biology, chemistry and biochemistry. For example in DNA manipulation, 
synthesised oligonucleotides can be employed as primers 39  or even to produce 
unnatural genes . 40 Using chemical or enzymatic methods, oligonucleotides rich in 
or 15N can be produced. Oligomers produced in this way can then be used as 
probes to examine the interaction between proteins and specific nucleotide 
sequences. 4143 Using the phenomena of triplexes, oligonucleotides can be used to 
determine DNA sequences or for site specific mutagenesis, cleavage or blocking. 44-46 
This can be achieved by producing an oligomer specific to a site on the natural 
sequence and attaching a chemical reagent at the end of the nucleotide. For example 
an iron-containing porphyrin will cleave the target at a specific site and an 
intercalating agent will lock the triplex in place and competitively inhibit replication 
or transcription of the targeted gene. Figure 7 shows how an Iron-EDTA complex 
attached to an oligomer can be used for site specific cleavage of a DNA plasmid. 
Non nucleotide triplexes have also been investigated for the same applications. 34-38 
Perhaps the most significant application to date of oligonucleotides has been their 
use in recombinant DNA technology. This technology was developed in the 1970's 
to produce proteins as an alternative to making them synthetically or extracting from 
a natural source. The genes required for a protein are made chemically then 
introduced to a micro-organism. The organism then produces an excess of the 
corresponding protein in large recoverable yields. An example using this technology 
would be the production of the glucose regulating protein, insulin, in 1982. The gene 
for the protein was introduced to Escherichia Coli, insulin was produced by the 
47 '48 bacteria and subsequently extracted on a large scale.  
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1.2.1 Antisense 
Potentially the biggest application of synthetic polynucleotides and especially their 
analogues in medicine is in the field of antisense and antigene. This area holds the 
promise of drugs of such high selectivity as to be devoid of side effects, drugs that 
would only attack viral RNA or mRNA and not the host cell. Such drugs would 
require much lower doses than drugs that target proteins since they have a smaller 
number of targets within the body. These new pharmaceuticals would not only be 
able to block specific cell functions and gene expression but also promote them. But 
perhaps the greatest advance of antigene drugs would be the ability to design a new 
drug based on the primary structure of the target without the need to be concerned 
with protein active site geographies and the problems associated with designing a 









Figure 8. Antisense translation inhibition 
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In the first step of the production of a protein the cell transcribes the required piece 
of DNA into several copies of mRNA and then ribosomes make several copies of the 
protein from each mRNA, a process called translation. The concept behind antisense 
drugs is to introduce a strand of antisense DNA to hybridise with the target mRNA 
and block translation. An antigene drug would bind with a specific site on the DNA 
of a cell and form a triple helix and block transcription. 
In the formation of triplexes a strand of complementary DNA or DNA analogue 
binds in the major groove of the double helix structure. The triplex is stabilised by 
Hoogsteen hydrogen bonds. Hoogsteen hydrogen bonds are the same as Watson and 
Crick base pairs but have a third base positioned in the major groove and they are (C-
G-C+) and (T-A-T) where the third letter represents the extra nucleobase. Since they 
require the extra cytosine to be protonated these bonds are pH sensitive, forming at 
pH 6.2 and below. 
Figure 9. Triplex transcription inhibition 
Therefore, if the sequence of DNA is known and conserved then a drug would be 
very easy to design and potentially any part of the DNA could be targeted. However 
with RNA, since the structure is less predicable than DNA, similar problems to those 
of proteins arise. Namely not all of the structure will be accessible, some for example 
may have fixed structures incapable of triplex formation and therefore trial and error, 
computer modelling, crystal structures and other techniques will need to be 
employed to produce an active compound. 485° The DNA triplex has also been 
exploited in terms of producing a higher affinity ligand for a single strand of DNA. 
By covalently binding together the two strands required to make the triplex, either at 
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both ends to form a circle or only at one to give a chain which folds over itself to 
form a loop, a new high affinity sequence specific ligand is created. 5 ' Binding is 
tighter than with standard Watson-Crick base pairing, especially with the looped 
oligonucleotides and improved inhibition of enzymatic DNA synthesis has been 
reported. 5 ' 
There is precedence for the antisense approach in the natural world. Cells create 
their own mRNA's which are used as repressors to gene expression and therefore 
regulate the levels of proteins in cells. There are several defined mechanisms by 
which these systems work. In some cases the target rnRNA is permanently altered or 
destroyed. 5253  This also shows how an active antisense drug could promote gene 
expression by blocking the natural antisense inhibitor. However there is no such 
natural system using the antigene approach. 
Statistically an oligonucleotide of between 11 and 15 residues would be specific to 
one sequence in the human genome. The spread of length arises from the fact that 
there are more A-T base pairs than G-C. Therefore a G-C rich sequence is less 
common and a shorter sequence would still be unique whereas an A-T rich sequence 
would need to be longer. 54  In 1978 a synthetic oligodeoxynucleotide containing 13 
residues was made and was the first to be used to selectively inhibit a virus by 
hybridising with the viral RNA. 55 
However there are significant obstacles to be overcome if a practical drug is to be 
designed using these concepts. Measures need to be taken to stop the nucleotide 
sequence from being broken down by the cells' own enzymes and lengthen the 
drug's half-life in the body. One way to overcome these problems is to create a 
situation where the required oligonucleotide is continually produced within the target 
cell. Another solution is to modify the oligonucleotide to make it unrecognisable to 
the enzymes that breakdown such compounds. Backbone modifications at the 
phosphorus and at the sugar moiety as well as alterations of the bases have all been 
investigated. Generally improved resistance to nucleases is observed at the cost of 
poorer rates of triplex formation and hybridisation. 54-61 Oligophosphoramidates 
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perform better than oligophosphodiesters 623  and molecules where the phosphate 
backbone has been replaced by a peptide, N-(2-arninoethyl)glycine backbone 
perform well. These peptide nucleic acids (PNA's) are resistant to the nucleases that 
limit the half-life of oligonucleotides and are sufficiently different from cc-amino 
acid peptide bonds to be resistant to proteases and peptidases. PNA's were originally 
designed for sequence specific triplex formation and as such are good structural 
mimics of DNA. They can form double helices with DNA, RNA and PNA and they 
can bind with double helices by strand displacement. 64  PNA's have been shown to 
exhibit antisense activity in prokaryotic cells, with E. Coil, and eukaryotic cells, by 
injections into rat brains . 65 
Drug delivery is another obstacle. Uptake by and transport within cells, moving 
through the blood brain barrier or transport into the nucleus for antigene therapy are 
all aspects of the same problem. Oligonucleotides delivered using liposomes, low-
density lipoproteins, a composite system consisting of a stearyl-poly-L-lysine 66 , 
biodegradable polyalkyl cyanoacrylate nanoparticles and other systems have all been 
investigated as potential solutions to this problem. 
Several areas of medical research promise to yield antisense drugs in the very near 
future and some already have. The first antisense drug, Vitravene®, was launched in 
the USA in October of 1998 by the Isis pharmaceutical company after clearance from 
the FDA in August of the same year. 67  In August the following year the European 
commission granted a community marketing authorisation for Vitravene®. The drug 
works against the AIDS related eye infection cytomegalovirus retinitis. Human 
cytomegalovirus (HCMV) is a very common virus that is latent (present but inactive, 
like chicken pox) in most people. However those with compromised immune 
systems such as AIDS patients and transplant patients are vulnerable. HCMV attacks 
the light sensitive tissue of the eyes and ultimately leads to blindness, often in both 
eyes. Treatment involves injecting antisense oligonucleotides directly into the 
patient's eyeball. By targeting the mRNA's responsible for two proteins essential to 
the virus the sight of patients suffering from HCMV can be saved. RNA and DNA 
molecules can have physiological effects in other ways. Aptamers 68 ' 69 are nucleotides 
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that can bind and inhibit proteins. Although there is debate as to the mechanism of 
drugs like VitraveneTM an antisense mode of action seems the most likely. 
Cancer is another area where considerable effort has been directed to produce an 
antisense drug. One approach is to activate the natural tumour suppresser gene p53 
by targeting its regulation. One target on this method is the oncoprotein MDM2 that 
downregulates the expression of p53 by binding to the transactivation domain of p53 
blocking transcription. In studies where MDM2 expression was inhibited in different 
tumour types by antisense oligonucleotides, increased levels of p53 were noted 
70-71 
with concomitant depletion of the tumour mass. Other pathways have also been 
investigated and targeted in attempts to encourage growth inhibition and apoptosis. 72 
73 
Further examples of the applicability of antisense technology are in the treatment of 
genetic disorders and in modulating central nervous system functions. The classical 
drugs for blocking the brain dopamine receptors bind to the receptors themselves, 
whereas the new antisense drugs are designed to bind to the receptor-coding mRNA 
and stop the production of the receptor in the first place. 74  There is a range of 
dopamine receptors encoded by different genes and the specificity inherent in the 
antisense approach has the added advantage of being able to determine some of the 
neurophysio logical functions of individual receptors. 75 Dominant genetic disorders 
like Huntingdon's disease and Marfan's syndrome also appear to be amenable to the 
antisense approach. 7679 
Once the problems of cost and delivery have been dealt with for one drug, the 
lessons learned should potentially be easily transferred to every other possible 
antisense or antigene drug. It is then the role of the organic chemist to design more 
efficient and faster syntheses of oligonucleotides for mass screening and mass 
production of drugs. At present each milligram of a typical unmodified 
oligonucleotide cost around US$20. Someone weighing 50kg requires a dose costing 
in the region of US$1000. If antisense drugs are to be widely used chemists need to 
overcome these hurdles. 
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1.3 Chemical Synthesis of Oliodeoxyribonucleotides 
Today DNA and RNA sequences can be synthesised either chemically on solid 
phase or using DNA strands as templates. 80 The development of chemical synthesis 
started with solution chemistry but has since moved on to solid phase synthesis and 
several different approaches have been used. The variation between these competing 
methods lies largely in the type of activated phosphorus unit used. 
Oligodeoxyribonucleotides possess a range of functionalities that complicates their 
synthesis. In the case of oligoribonucleotides the extra hydroxy group at the 2' 
position further complicates matters. The aim of oligonucleotide synthesis is 
normally to join the 5'-hydroxyl position on one nucleoside with the 3' position on 
another via a phosphodiester linkage to form a phosphodiester bridge, the backbone 
of DNA. In the case of RNA it is possible to have branched oligomers using the 2' 
position and occasionally DNA and RNA oligomers will require a 3'-3' linkage. 
Because of the wide range of functionalities present, selective blocking and 
deblocking strategies must be employed. For a completely orthogonal approach two 
different protecting groups for hydroxyl groups as well as groups for the primary 
amino groups and oxygens of the phosphate group are all needed. 
Other problems in producing oligomers are the sensitivity of the glycosidic bonds 
of the purine and pyrimidine groups with the sugar group, which means only mild 
acids can be employed. Stereochemical and neighbouring group effects affect yields 
as the chain grows. With RNA the 2' protection causes even more steric problems 
further affecting yields. Protecting groups need to be removable under mild 
conditions and finally the product needs to be separable from truncated sequences. 
It's clear that a robust and well designed strategy is needed to successfully produce 
oligomers of RNA and DNA. 
Chapter 1 Introduction 
	
19 
The first nucleotide was synthesised by Todd 81  in 1955 and since then considerable 
efforts have been made to refine and improve the chemistry through phosphodiester, 
H-Phosphonate and phosphoramidite methods. 
1.3.1 The Phosphodiester Method 
The phosphodiester method is perhaps the simplest of all coupling techniques for 
use in nucleic acid synthesis. Introduced in 1958, and further developed by Khorana 
et a18283 , it was first used for the synthesis of a dinucleotide and then developed to 
synthesise larger oligomers. 
The phosphodiester method involves the condensation of deoxynucleotides where 
the first nucleotide has a protected 5' hydroxyl and a free hydroxyl at the 3' position 
(1) ready to react as shown in figure 10 and the second nucleotide has a phosphate 
group at the 5' hydroxyl with a protected 3' hydroxyl (2). The exo cyclic functional 
groups on the bases are also protected and the hydroxyl protecting groups for the two 
nucleotides are different. A condensing reagent such as dicyclohexylcarbodiimide 
(DCCI) or 2,4,6-triisopropylbenzenesulfhonyl chloride (TPSC1) is then used to 











(1) 	 (2) 	 (3) 
Figure 10. Khorana's phosphodiester approach 
The chain can be further extended by removing the 5' trityl protection followed by 
phosphorylation and introduction of another nucleotide with a protected 5' position 
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and a free 3' position. However there are problems with this method. The negative 
charge on the phosphate group causes problems with solubility. Yields deteriorate 
and reaction times increase as the chain grows, thus making this method impractical 
for larger polynucleotides. In addition separation of the various condensation 
products required highly time consuming ion-exchange chromatography. 
Despite these problems Khorana et al successfully produced the genes of alanine 
tRNA83 and of tyrosine suppresser tRNA 84 but they needed to use block 
condensation methods. In these syntheses they produced short oligomers of 8 to 12 
residues using the phosphodiester method. These oligomers had free 3' and 5' 
hydroxyls and those of the complementary strand overlapped by four or five residues 
to each side of those oligomers for the coding side. DNA polymerase enzymes were 
then employed to link together the oligomers to produce the whole 50 base pair gene. 
1.3.2 Phosphotriester method 
Although the phosphotriester method can be considered a development of the 
phosphodiester method, Michelson and Todd 81  in fact used it first in 1955 to produce 
a dinucleotide. The advance from the diester method is the introduction of a 
phosphate protecting group. Removing the negative charge removed many of the 
problems of the diester method namely; solubility, and poor yields. 
The original Michelson and Todd phosphotriester approach shown in figure 11 
involved the activation of 5' -O-acetylthymidine-3 '-O-benzyl hydrogen phosphonate 
(4) using N-Chlorosuccinimide (NSC) to produce 5'-acetyl-
3'benzylphosphochloridate (5). This activated molecule was then reacted with a 
nucleotide with a free 5' position and a protected 3' (6) to produce the corresponding 
dinucleotide phosphotriester (7). 
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(4) 	 (5) 	 (6) (7) 
Figure 11. The Michelson and Todd phosphotriester approach 
Improving the phosphate and hydroxyl protecting groups has further developed this 
method. In 1965 Letsinger et a18588 introduced the J3-cyanoethyl phosphate 
protecting group. Using the solid phase synthesis principle they succeeded in a 
stepwise synthesis of oligonucleotides up to tetramers. In the solid phase reactions 
cytidine was used as the anchor bound to the styrene-based solid support via the 
amine group of the base. For oligomers larger than this, solution chemistry was 
required to achieve high enough yields. 89,90 
T1 	 T1 
MMTrO-1 	__________ MMTrO—  






(1) 	 (8) 	 (9) 
T1 	 T1 
Acetic Acid 	
HOT 	 HOT 
0 	0 
T2 H0—'=O 	T2 
OH 	 OH 
(10) 	 (11) 
Figure 12. The Letsinger phosphotriester approach 
2 
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Oligodeoxynucleotides containing nucleosides other than thymidine were 
produced. 88 The first step of Letsinger's approach, shown in figure 12, involved the 
phosphorylation of a 5' -monomethoxytrityl (MMTr) protected deoxyribonucleotide 
(1) with 3-cyanoethyl protected phosphate and 2,4,6-trimethylbenzenesulfonyl 
chloride (MSC1) to give the phosphodiester (8). The next step was the addition of 
thymidine in the presence of 2,4,6-triisopropylbenzenesulfhonyl chloride (TPSC1) to 
give the fully protected dinucleotide phosphotriester (9). Addition of aqueous acetic 
acid to remove the monomethoxytrityl group (10) followed by treatment with 
aqueous ammonia to remove all remaining protecting groups gave the fully 
deprotected dinucleotide (11). 
One problem with this approach is the production of side products, which are 
difficult to separate from the desired product. Incomplete or over phosphorylation is 
the major reason for the production of 3'-3' and 5'-5' by-products. In an effort to 
eliminate these undesired products Letsinger et a189 developed the 13 -
benzoylpropionyl 3'-hydroxy protecting group. This group is removed using 




NC 	N0  
OH 	 Cl 
ço OH 	 C1 	OH 
(12) 	 (13) 	 (14) 
Figure 13. Phosphate protection 
(12) 13-cyanoethyl (13) trichioroethyl (14) 2-chlorophenyl 
Other chemists contributed to the search for better protecting groups, some of 
which are shown in figure 13. Eckstein et a19193 introduced the trichioroethyl 
phosphate protecting group, Reese et a19496 and Van Boom et a197 developed aryl 
phosphate protecting groups with electron withdrawing substituents for increased 
base lability. The best of these was found to be the 2-chiorophenyl group. It was 
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stable during synthesis and could be removed under mild conditions with minimal 
disruption to the oligonucleotide. 98 Reese also suggested methoxytetrahydropyranyl 
as an alternative to the trityl group for 5' protection. 99 
In 1973 Cramer et a110° introduced a two step sequential procedure shown in figure 
14. In this method a nucleoside protected at the 5' position with the acid labile 
dimethoxy' trityl group (DMTr) was first phosphorylated with 2,2,2-
trichloroethylphosphodiimidazolidate then treated with triethylamine and water 
giving (16). 3-Cyanoethano1 is then added with TPSC1 to protect the phosphate 
group to give the fully protected phosphotriester (17). Treatment with dilute aqueous 
trifluroacetic acid (TFA) removes the DMTr to give (18). Compounds (16) and (18) 
are then condensed with TPSC1 to give the protected dinucleotide (19). Treatment 
with TFA, then sodium hydroxide and finally Cu/Zn in ammonia yields the fully 
deprotected dinucleotide. 




















(18) 	 (19) 
Figure 14. Cramer's approach 
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In parallel with progress in protecting groups, the phosphorylation and condensing 
reagents were also developed. Phosphorylation was improved by addition of 
monofunctional reagents such as the phosphorochioridates where two of the oxygens 
are protected.' ° ' 
' / S—N I 
\ / 6 N'JJ 
(21) 
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Figure 16. 1H-Tetrazole as a catalyst 
Improving the activation agent meant improving yields and minimising the 
sulfonylation of the free 5' position of the condensing reagents. In 1975 Narang et 
all 02  introduced arylsulfonyltriazoles later refining this to arylsulfonyltetrazoles) °3 
In 1978 Reese et al introduced the use of 2,4,6-trimethylbenzenesulfonyl-3 -nitro-
1 ,2,4-triazole (MSNT) (21).' 0 The fact that increasing steric bulk decreases the 
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sulfonylation side reaction and lead to other adaptations where arylsulfonyl triazoles 
and tetrazoles were used. 105 
The rate of reaction for the condensation step can be increased by the addition of a 
nucleophilic catalyst. 1 -Methylimidazole when introduced to the reaction produces a 
highly reactive intermediate (23) and this further reduces coupling times.' 06,107  Other 
imidazo1esand tetrazoles have been used in this way, but since it is more acidic, the 
tetrazole is the better activator. 106,107  Figure 16 shows how 1H-tetrazole is 
incorporated in the synthesis as a coupling catalyst. 
All these refinements in protecting groups and reagents have now improved the 
yields and decreased coupling times for the phosphotriester approach beyond those 
of the phosphodiester method. Coupling steps originally taking several hours 85  were 
reduced to five minutes with these advances.' 08  The synthesis of a 20 residue 
oligomer could now be accomplished in under 8 hours. 109 
However there are still problems with side reactions, which ultimately limit the 
applicability of the phosphotriester method. Even with sterically hindered 
condensing reagents the competing side reaction of sulfonylation of the incoming 
nucleoside accounts for about 1% of the reaction. Although not a problem for shorter 
sequences yields of around 97% means that synthesis of longer sequences becomes 
impractical.' 10 Another side reaction involves the phosphorylation and substitution 
with triazole or tetrazole of the position of deoxyguanosine. 
Despite these problems the phosphotriester method has been used successfully to 
produce large and biologically active oligonucleotides." 
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1.3.3 The Phosphite-triester and Phosphoramidite Methods 
The phosphite-triester method, also known as the phosphoramidite method, was 
introduced by Letsinger et af8 in 1975 and is based around the high reactivity of 
phosphorochioridite reagents with alcohols to give phosphite triesters. Coupling 
times between two nucleotides is greatly reduced from hours to minutes due to the 
increased reactivity of the P3 system over the P 5 system. The resulting phosphite-
triester is then easily oxidised up to the natural linker with aqueous iodine. 














(27) 	 (28) 
Figure 17. Letsinger' s phosphite triester approach 
Letsinger's phosphite-triester approach, shown in figure 17, starts with 5'-0-
phenoxyacetyl thymidine (24) reacted with ortho-chlorophenyl phosphodichloridite 
in the presence of 2,6-lutidine to give the phosphtiylated nucleoside (25). Then 3' 
monomethoxytrityl protected thymidine (26) is added to give the phosphite 
dinucleotide (27) within 20 min at -78°C. Iodine and water are then used to rapidly 
oxidise the phosphite to give the protected dinucleotide (28). After removal of the 
phenoxyacetic ester the dinucleotide is ready to be rephosphitylated. However it was 
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found that the phosphate link was unstable with respect to the phosphitylating agent. 
The switch to 2,2,2,-trichioroethyiphosphorodichioridite improved things enough to 
allow the production of tetramers." 2 
Further refinement targeted the phosphate protecting group. Ogilvie et al l  
investigated a range of groups including 2,2,2-tribromoethyl, p-chlorophenyl, 2-
phenylethyl, 2-p-nitrophenylethyl, benzyl, methyl and 3-cyanoethyl and found 
methyl and -cyanoethy1 to be the most effective. These groups remain the most 
widely used today. Matteucci et al l 4"5 demonstrated the solid phase synthesis of a 
dodecamer using methyl protection and tetrazole as a coupling catalyst. Coupling 
times to produce dimers were under two minutes with yields in excess of 90%. 114 
Although a successful method and a suitable one for solid phase synthesis, the 
phosphite-triester method using phosphochloridites still has problems. During 
preparation of phosphoramidites small amounts of Y-3' dinucleotide are formed, 
causing purification problems and reduced yields. Phosphochioridites are very 
moisture, temperature and air sensitive necessitating low temperatures (-70°C) and 
dry, inert conditions for their handling. In 1981 Beaucage and Caruthers introduced 
the deoxynucleotide phosphoramidites as an improvement. These phosphoramidites 
are more stable to hydrolysis and stable at room temperature while still being easily 
activated, forming the dinucleotide in high yields with minimal side reactions. 116 
This development greatly improved the transition from manual to semi-automated 
procedures. 117 
In Caruther's phosphoramidite method, shown in figure 18, a 5'-dimethoxytrityl 
protected nucleotide (15) is reacted with chloro-N, N-dimethylaminomethoxy 
phosphine in the presence of NN-diisopropylethylamine to give the phosphoramidite 
(29). This can be isolated as a powder and is stable enough to be stored. This 
compound is activated with tetrazole (30) and then coupled to 3'-0-
levulinylthymidine to give the phosphite triester dinucleotide (31) in quantitative 
yield. Aqueous iodine is then used to oxidise to give the protected phosphate dimer 
(32). 
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Figure 18. Caruther's Phosphoramidite method 
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(36) 
Figure 19. Phosphitylating agents 
This method was further improved by research into different dialkylaminomethoxy 
phosphines by McBride and Caruthers in 1983.118  The phosphitylating agents 
diisopropylaminomethoxy phosphine (33), morpholinomethoxy phosphine (34), 
pyrrolidinomethoxy phosphine (35) and 2,2,6,6-tetramethylpiperidinomethoxy 
phosphine (36) were evaluated. The diisopropylamino and morpholino derivatives 
were stable to silica gel chromatography with acetonitrile and, because of their 
stability and ease of handling, they have become the reagents of choice.' 19-121 
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Figure 20. Phosphite protection 
The removal of the methoxy phosphorus protection was still seen as a problem in 
this approach and in 1983 Sinha et al  122,123  introduced the 3-cyanoethyl group. The 
advantage the -cyanoethyl has over the methoxy protection is in its removal. 
Concentrated ammonia is used to remove the base protection and under these 
conditions the -cyanoethy1 group is also removed whereas the removal of methoxy 
protecting group requires another step using thiophenol. Other phosphate protecting 
groups have also been tried, including 2,2,2-trichloro-1,1-dimethyl (37),124 
.. 
nitrophenylethyl (38)125  and ally! (39).126  Only the 3-cyanoethyl group (40) meets all 
the criteria and therefore remains the protecting group of choice. 
The only drawback of the -cyanoethyl group is the relatively high production costs 
of the reagent. One alternative that has been suggested by Ravikumar et al  127  is the 
cyanobutenyl group (41). This group has all the advantageous properties of the - 
cyanoethyl group of good phosphitylating properties and easy removal and has the 
added benefit of being 60% cheaper to produce. 127 
A further development of the phosphoramidite approach was introduced by 
Uznanski et al  128  in 1987. In this approach the oxidation of the phosphite triester 
links is performed all at once at the end of the synthesis rather than after each 
reaction cycle. 
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In this approach, shown in figure 21, chiorodimorpholinophosphine (42) is reacted 
with a 5' dimethoxytrityl protected nucleoside (15) to give the 5'-0-
dimethoxytritylnucleoside-3 '-O-phosphorodimorpholidite (43). This reagent is then 
activated with tetrazole and coupled to a solid support bound nucleoside to give the 
dimer (44). Mild acid treatment is used to remove the trityl 5' protection and cleave 
the P-N bond ready for the addition of further monomer. 
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Figure 21. Uznanski's phosphoramidite approach 
The main advantage that the phosphoramidite method has over rival methods 
mentioned is its extremely short reaction times and high coupling efficiencies due to 
the highly reactive, but slightly unstable, P 3 reagents used. The phosphoramidite 
method is the only viable one for oligomers longer than 50 residues. 
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1.3.4 The H-Phosphonate method 
This method was first described by Todd et al in 1957129  but was abandoned in 
favour of the phosphodiester and triester approaches. However in more recent years 
several laboratories have reinvestigated the H-phosphonate method for DNA and 
RNA synthesis. 130-136  This renewed interest stems from the fact that this method 
offers the possibility of combining the advantages of the phosphotriester method, 
speed and efficiency of reaction due to the P3 reactivity, with the stability of 


























(48) 	 (49) 
Figure 22. H-Phosphonate approach 
In this method, outlined in figure 22, the H-phosphonate (46) is activated by rapid 
reaction with pivaloyl chloride to give a mixed anhydride intermediate (47). This is 
then coupled to a 5' unprotected nucleotide bound to a solid support (48) to give the 
dinucleotide (49). Mild acid treatment is employed to remove the trityl protection so 
that another monomer can be attached. Oxidation of all the internucleotide linkages 
is performed at the end of the synthesis using aqueous iodine. By avoiding the need 
for phosphinite protection reaction times are improved and the stability of the 
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phosphorus unit is also improved. H-phosphonate chemistry is also cheaper than 
phosphoramidite chemistry although for routine uses the phosphoramidite approach 
is still preferred. 
1.4 Solid Phase Synthesis (SPS) of Oliodeoxyribonucleotjdes 
Merrifield 137  first developed solid phase synthesis in 1963 and the new approach 
virtually revolutionised peptide synthesis. The technique was quickly extended to 
nucleotides. Letsinger 86 produced the first trinucleotides using this approach in 1965. 
Since then yields and reaction times have improved as the chemistry has been 
developed. The application of solid phase synthesis (SPS) technique in the 
production of DNA and RNA oligonucleotides is now widely accepted, usually 
utilising a phosphoramidite chemistry approach synthesising the polymers in the 3'-
5' direction. 
Essentially the SPS method is the heterogeneous reaction between a growing 
polymer, bound via a linker to an insoluble solid support, and a solution-based 
monomer. At the end of each of the reactions performed it is easy to separate the 
monomers and other reagents in solution from the growing polymer by washing and 
filtration. This allows the use of large excesses of monomers and reagents thus 
optimising the yields. Furthermore, the solid support remains in the same reaction 
vessel through the course of the synthesis allowing for easy automation of the whole 
process. 
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1.4.1 The Solid Support and Linker 
It is essential that solid supports must be inert and insoluble under all the reaction 
conditions to be used in the synthesis. Swelling properties of the support in solvents 
also influence suitability and the polymer must have a mechanically stable form to 
facilitate filtration. It must also have a functional group through which to attach the 
growing polymer via a linker. Merrifield settled on a copolymer of styrene and 
divinylbenzene,' 37 which is still in use today. Another widely used solid support is 
the controlled pore glass (CPG) support.'  38  These supports are manufactured to have 
different particle sizes between 500 and 1000A in pore size. Automated synthesis 
methods typically use scales of between 10 and 50 micromol of nucleotide per gram 
of polymer. Lower level loadings give results that are difficult to reproduce and 
higher levels suffer from steric problems as the polymer grows. 
In the SPS synthesis of oligonucleotides, the first nucleotide is normally attached 
through the 3' position to the solid support via a linker to a functional site on the 
solid support. The linker is incorporated to move the site of reaction away from the 
bulk of the polymer to ensure accessibility for reagents. The linker is therefore 
designed to be long, flexible and cleaved in base. 
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Figure 23. Attachment of the first monomer to CPG 
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1.4.2 Solid phase synthesis reaction cycle 
Figure 24 shows a basic SPS oligonucleotide synthesis reaction cycle using the 
phosphoramidite approach. In step 1 a small column is packed with resin loaded with 
the first nucleotide linked through the 3' position and protected at the 5' position. 
This column is then inserted into the DNA synthesiser through which reagents and 
solvents are passed in an automated sequence. In step 2 mild acid is added to remove 
the 5' trityl protection. In step 3 the second phosphoramidite monomer is then added 
and activated with tetrazole to form the phosphite triester. In step 4 to remove the 
unreacted 5' positions from participating further acetic anhydride is added to cap 
them. In step 5 the phosphite triester is the oxidised to the phosphotriester using 
aqueous iodine. The cycle is then repeated (Steps2-5) until the sequence is finished. 
The oligonucleotide is then cleaved from the resin under basic conditions, which 
simultaneously removes the exocyclic base protection. 
1.4.3 Purification of Oligomers 
Despite the high, near quantitative, yields for each step in the phosphoramidite SPS 
method, the finished product cleaved from the resin is generally not very pure. Since 
not every step goes to completion there will be many truncated sequences. The 
ammonium salts of the removed protecting groups can also often contaminate the 
product. The capping step is introduced to minimise the problem of failed coupling 
reactions. After each coupling reaction every free 5' positions is capped with an 
acetate group to ensure that it takes no further part in any of the synthesis cycle. 
When the polynucleotide is cleaved from the resin using base all protecting groups, 
including the acetates on the truncated sequences, are removed except for the acid 
labile trityl protection of the product sequence. The product sequence is the only 
sequence with the trityl group and the majority of the truncated sequences will be 
sufficiently different in size from the product to be separable by chromatography. 
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Figure 24. Solid phase general reaction cycle 
Chapter 1 Introduction 	 36 
Two effective separation methods have proved popular for the purification of the 
oligonucleotides; electrophoresis and chromatography. 
Polyacrylamide gel electrophoresis (PAGE) is a highly sensitive method that uses 
charge to separate oligomers and can be used to separate fragments with only one 
charge difference. A polymerised, cross-linked acrylamide gel is held between two 
glass plates with each end immersed in buffer chambers containing an electrolytic 
salt solution through which an electric current is applied. The charged 
oligonucleotide fragments then move through the matrix at a speed inversely 
proportional to their mass although shape, size and hydrophobicity can also have an 
influence. UV can be used to follow the progress of the sample through the gel, 
however this requires the presence of standard samples for comparison. 109 There are 
some drawbacks to PAGE in that it is only amenable to small scale work, product 
recovery can be low and it is very time consuming. 
Ion exchange chromatography also separates compounds on the basis of charge and 
mass and in oligonucleotides that basically means the length of oligomer and any 
protecting groups still attached. Separation is achieved by slowly increasing the ionic 
strength of the mobile phases through a macroporous stationary phase. Truncated 
sequences of lower mass are eluted first with the desired oligomer being eluted last. 
This procedure is carried out after the 5' protection has been removed. Ion exchange 
columns have a higher capacity than reverse phase columns but their limitation is 
that compounds are separated solely on the basis of the charge to weight ratio and 
there is no distinction on other criteria. Ion exchange is often used before rp-HPLC 
when high purity is required. 
Reverse phase high performance liquid chromatography (rp-HPLC) is normally 
carried out with the trityl groups still protecting the 5' position. After the final 
monomer has been coupled, the phosphorus bridges have been oxidised and the 
oligomer has been cleaved from the polymer by aqueous ammonia all protecting 
groups except the base stable trityl will have been removed. All the failure sequences 
will have free 5' positions and the only compound retaining the terminal 5' trityl 
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protection is the desired sequence. The hydrophobic nature of the trityl moiety 
compared to the more hydrophilic truncated oligonucleotides allows the product 
sequence to be more easily separated. As the oligonucleotide increases in length the 
difference in polarity enforced by the trityl group diminishes. In rp-HPLC with 
oligonucleotides, a water to acetonitrile gradient is usually used. Under these 
conditions the truncated sequences are eluted first with the lipophilic tritylated 
oligonucleotide being eluted last. 
An alternative application of this approach has also been shown to work. Instead of 
using the lipophilic properties of a trityl-protecting group as the basis for separation, 
failure sequences are capped with a lipophilic group that will not be removed under 
resin cleavage conditions. As this cap need not be removed its stability to reaction 
and purification conditions can be ensured. After the 5' trityl protection of the 
desired oligonucleotide is removed, the desired product will be the only oligomer 
without a lipophilic group attached. 139 
A simplification of rp-HPLC is to use polymeric reverse phase cartridges 140-141  for 
rapid and inexpensive purification. Using resins stable to a wide pH range the 
ammonia solution used in the deprotection can be added directly to the cartridge. 
Failure sequences are eluted then the trityl group is cleaved by the addition of acid 
and the product sequence is then eluted. 
1.4.4 Protecting groups for solid phase synthesis 
Developments in solid phase oligodeoxyribonucleotide synthesis have involved, in 
the main, the development of orthogonal protecting group strategies. An orthogonal 
protecting group strategy is one where different protecting groups can be added or 
removed without affecting protecting groups covering other functional groups. In the 
case of oligonucleotide synthesis this means using a protecting group for the 5' 
alcohol which can be removed without affecting the phosphorus or exocyclic 
protecting groups. The different types of phosphorus coupling strategies and 
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phosphorus protection have already been covered but the other protecting groups for 
the 5' primary alcohol, the exocyclic bases (and the 2' secondary alcohol in 
oligoribonucleotide synthesis) have been developed which have led to much 
improved yields and greater flexibility of the methodology. 
It should be noted that protecting groups need to be designed with several factors in 
mind. Firstly they must be easily introduced with high regiospecificity. Secondly the 
conditions required to remove the group must be sufficiently mild as to leave the 
internucleotide and the glycosidic bonds unaffected. The groups also need to be 
designed to withstand reaction conditions during synthesis and conditions intended to 
remove other intermediate protecting groups. If possible protecting groups should be 
designed to confer other properties to the oligonucleotide they are attached to. 
Increased lipophilicity increases the ease of purification and increased stability 
improves the storage properties of the intermediates. Another extra attribute that a 
protecting group could confer is the addition of a specific chromophoric label that 
enables spectroscopic detection of protected compounds. 
The orthogonal protecting group strategy has lead to the development of two 
categories of protecting groups. The first of these are the permanent protecting 
groups. These are groups designed to stay on the oligonucleotide throughout the solid 
phase synthesis cycles and are removed only at the end of the synthesis. The 
functional groups covered in this way are the exocyclic groups, the 2' ribose 
hydroxyl in RNA synthesis and phosphorus protection. These groups are usually 
designed to be removed at the same time as the oligomer is cleaved from the solid 
support to minimise the number of steps. The second types of protecting groups are 
the temporary protecting groups which are removed as part of the synthesis cycle. 
The trityl protection of the primary alcohol lies in this category. 
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1.4.4.1 Exocyclic base protection 
Adenine, cytosine and guanine bases each have a primary amine group that has to 
be protected during oligonucleotide synthesis but thymidine and uracil bases do not 
require any protection. The amino groups have to be protected throughout the 
synthesis and protection is removed at the same time as the oligomer is cleaved from 
the resin. The amides of dG, dT and U may also have to be protected to avoid side 
reactions with coupling reagents (eg. sulfonylation and 142- 1 44  
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Figure 25. Nucleic Acid protection 
(48) iBu-dG, (49) Bz-dA, (50) Bz-dC, (51) dT. 
The most common way of protecting base amino groups is to convert them to their 
amides, usually benzoyl (Bz) and isobutruyl (iBu). Figure 25 shows each of the bases 
used in this research with their protection. For the production of more sensitive 
oligomers more labile amino protection is sometimes required. N-phenoxyacetyl 
derivatisation can be used for this purpose with all the bases except guanosine since 
N-phenoxyacetyl 2'-deoxyguanosine forms a gelatinous precipitate in acetonitrile 
and, if used, needs DMF to be added as a co-solvent. This is complicated by the fact 
that DMF frequently has free amine contaminants that interfere with the reaction. 
In recent years coupling methods have been developed which avoid the need for 
nucleoside base protection  141 - 141  in both the H-Phosphonate and the phosphoramidite 
methods. In parallel the photocleaveable nucleobase protecting groups such as 6- 
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nitroveratryloxycarbonyl (NVOC) (52) and 2,2'-bis(2-nitrophenyl)ethoxycarbonyl 
(diNPEOC) (53) have also been used in the synthesis of base sensitive products. 
Both these protecting groups have been used in the synthesis of S-pivaloylthioethyl 
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Figure 26. Nucleic Acid photocleaveable protecting groups (52) NVOC and (53) 
diNPEOC, (54) The base sensitive t-Bu-SATE phosphate linker 
A long term problem associated with the handling and synthesis of DNA and RNA 
oligonucleotides is depurination and to a lesser extent depyrimidation. Depurination 
or depyrimidation usually results in chain cleavage at the apurinic, apyrimidinic site. 
The acid catalysed hydrolysis proceeds with a rapid initial protonation of the base 
moiety (Ni position for adenine and N7 for guanine). A second proton can then be 
taken up to form the dication (N7 position for adenine and N3 for guanine). The rate-
limiting step is then the cleavage of the cation or dication to give the free purine base 
and a resonance stabilised glycosyl carbonium ion. 149152 Initially Lewis acids such as 
ZnBr2 were used to limit depurination during the acidic cleavage of 5' protection. 
The improvement in reducing depurination was achieved at the expense of reaction 
times. Attempts to design exocyclic protecting groups to limit this reaction have been 
made as have attempts to optimise conditions for this step using protic 55 
Depurination is a natural occurrence and can be found in living cells. 
Depyrimidation also occurs but about one twentieth of that rate. Depurination is also 
of great interest in the field of biomolecular archaeology. This is the relatively young 
area of research where DNA and protein fragments are extracted from archaeological 
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remains to get information on genetic disease, migration and evolution. DNA 
degradation is the limiting factor governing the age to which DNA can be 





















Figure 27. Acidic depurination 
1.4.4.2 Protection of the 5' position 
Protection of the 5' ribose hydroxyl primary alcohol has changed little over the 
years. The mono and dimethoxy trityl groups introduced in the 1960's by Khorana et 
a1157158 continue to be widely used. The para-methoxy groups were introduced to the 
trityl system to improve the acid lability of the protecting group after it was found 
that the triphenylmethyl ethers were too stable to the acid conditions intended for 
their cleavage. The addition of a single methoxy group increases lability by a factor 
of ten and a second para methoxy group improves lability again up to a point 
suitable for solid phase synthesis. 
4,4'-Dimethoxytrityl (DMTr) protection offers several other advantageous 
properties that have ensured its continued use. Even under mildly acidic conditions 
deprotection is fast and removal can be easily monitored using visible spectroscopy. 
RO—J---f_CI 0 
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Under these conditions depurination is minimised. Additionally the steric bulk of the 
DMTr group ensures selective reaction with primary alcohols. The hydrophobicity of 
the three benzene rings increases the hydrophobicity of the protected nucleotide or 
oligomer to make purification by chromatography or solvent extraction much easier. 
(58) 	 (59) 	 (60) 
Figure 28. Hydrophobic 5' protecting groups 
However this purification advantage diminishes with increasing oligomer chain 
length and once oligonucleotides get beyond thirty bases in length the difference in 
rp-HPLC retention time due to DMTr becomes negligible. Attempts have been made 
to increase the hydrophobicity of terminal protection and thus extend the purification 
advantage into longer oligonucleotides. Selinger and Gortz' 59 adapted MMTr by 
replacing the methoxy with longer alkoxy groups (58). Letsinger and Finnan 160 
substituted one phenyl ring with a napthyl group (59) but strong acid conditions were 
required to remove this group. Fourrey et al'6 ' adapted DMTr by replacing the 
phenyl with the fluorescent pyrenyl group (60) and Caruthers et al 162  have also 
investigated a large variety of triarylmethyl groups with different LTV properties with 
the aim of using UV absorbance of the washings to characterise composition of 
mixed sequence probes. While these derivatives, shown in figure 28, have some 
advantages in certain circumstances the increased steric bulk of the reagents 
effectively reduces coupling yields and the derivatives have not been widely used. 
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Another acid labile 5' protecting group that has been examined is the 9-
phenylxanthen-9-yl (pixyl) group. 163 ' 65 This is more labile than DMTr in acid 
hydrolysis but the conditions required for complete removal also result in partial 
deprotection of 2'-Thp based groups. Pixyl and to a greater extent 9-
phenylthioxanthen-9-yl (S-Pixyl) groups can however be removed by photolysis. 
Although this is orthogonal to acid labile 2' protection (e.g. Thp) it does still have 
problems in that reactive by-products are formed and great care must be taken that 









(61) 	 (62) 
Figure 29: TESC1 (61) and terephthaloyl linker (62) 
Non acid labile groups have been examined with regards to their compatibility to 
Thp. Base labile groups have proven to be poor candidates because of the base 
lability of nucleoside protecting groups and of resin linker. One approach is to use 
silicon chemistry like that of the TBDMS group combined with some of the features 
of DMTr. The reagent 1,1,3,3-tetraisopropyl-3-(2-(triphenylmethoxy) 
ethoxy)disiloxane-1-yl chloride (TESC1) (61), shown in figure 29, modifies 
triphenylmethanol and connects it to a bulky, and therefore primary specific, silicon 
reagent. The incorporation of the triphenylmethanol means the UV monitoring 
qualities are retained and deprotection is achieved using fluoride ions. However in 
practice this group proved unsuccessful due to cleavage of the 3 - cyanoethyl 
phosphate protecting group and of the succinate linker used when attempting to 
deprotect. 166  Moving to a terephthaloyl linker (62) solved the problem of cleavage 
from the support but the phosphate protection problem remains. 
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OyCI 
(63) 	 (64) 
Figure 30. Thf based protecting groups 
In 1992 Ramage et al 167 introduced a new N'-amino protecting group derived from 
the florescent tetrabenzo[a,c,g,i]fluoromethyl moiety for the solid phase synthesis 
and subsequent purification of peptides. The peptides protected with 
tetrabenzo [a,c,g,i]fluorenyl- 1 7-methanol (Tbfmoc) possess stronger hydrophobic 
properties and are retained on porous graphitised carbon (PGC). However the 
Tbfmoc group used in peptide synthesis is base labile and therefore unsuitable for 5' 
protection, although the 9-fluorenylmethoxycarbonyl (Fmoc) has been used for 5' 
protection in solid phase synthesis orthogonal to Mthp 2' protection. 
168 
Ramage and Wahi 169-171 introduced 4-( 1 7-tetrabenzo [a,c,g,i]fluoromethyl)-4' ,4' '-
dimethoxytrityl chloride (Thf-DMTr-Cl) (64) for 5' ribose hydroxyl protection. Here 
the phenyl group of DMTr had been alkylated at the para position with Thf on a one-
carbon spacer. This new protecting group exhibited some useful properties. It 
significantly influenced hydrophobicity to improve purification. However the 
inductive effect from the additional alkyl substitution had further increased the 
group's lability. Also the group was still sterically restricted since the spacer to the 
bulky TV group was one carbon and as a result coupling yields to nucleotides were 
much lower than for DMTr. 
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1.5 Solid Phase Synthesis of Olionbonucleotides 
As the appreciation of the role RNA, both currently and historical in its evolution, 
has grown so has the interest in the chemical and enzymatic synthesis of RNA. The 
success of solid phase synthesis of oligoribonucleotides has however not matched 
that of oligodeoxyribonucleotides. The difference in efficiency stems from the 
additional 2' hydroxyl group on the ribose ring and the problems associated with its 
protection. 
One approach different from the chemical solid phase methods mentioned for DNA 
is to use the natural pathway to RNA from DNA. The enzymatic approach involves 
using two chemically produced DNA sequences annealed together as a template for 
RNA polymerase from bacteriophage T7.' 72 ' 73  This system can be used to produce 
milligram quantities but it does have some drawbacks. Success is highly dependent 
on length and sequence, for example oligomers of less than 12 units give poor yields 
and are difficult to purify to homogeneity. Other problems can occur with abortive 
initiations and faulty insertions. Sequences without a guanine at the 5' terminus have 
proved especially difficult to make and conditions often have to be customised for 
each particular sequence to optimise yields. The enzymatic method is also limited in 
the use of natural RNA monomers and cannot incorporate deoxyribonucleosides or 
unnatural monomers. 
The solid phase synthesis of oligoribonucleotides has largely paralleled the 
methods used for the synthesis of oligodeoxyribonucleotides. In general however 
when the same methodology is applied to RNA the yields are poorer and the 
coupling times longer. This is due to the 2' hydroxyl group and the problems 
associated with its protection. 
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1.5.1 Protection of the 2' position 
There are several problems to be overcome in the successful protection of the 2' 
position. The group chosen must be stable through all stages of the 
oligoribonucleotide synthesis, including successive acid washes. In addition the 
protocol for protection of the monomer units must allow complete separation of the 
3' and 2' protected products to ensure no 5'-2' links in the resulting 
oligoribonucleotide. The group should also be as sterically undemanding as possible 
to minimise the detrimental effect on coupling times for the adjacent hydroxyl group. 
The group should be cleaved in high yield at the very end of the cycle without 
nucleoside base modification or backbone migration or degradation, resulting in a 
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Figure 31. Cleavage and migration of RNA linkages 
In 1956, Brown and Breslow et al  174- 175  showed that acid can catalyse RNA 
phosphoryl migration and that acid and base can cause RNA cleavage in experiments 
involving the partial hydrolysis of cytidine 3' -O-benzylphosphate and cytidine 3'-0-  
methylphosphate under acidic and basic conditions. Figure 31 shows how under 
acidic conditions 3'-*2' migration of the phosphoester can occur. Basic conditions 
produce no migration but both base and acid can hydrolyse the link. Both cleavage 
and migration proceed via a cyclic pentacoordinate trigonal bypyramidal 
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oxyphosphorane transition state (66). This is a significant consideration since no 
purification techniques can differentiate between correctly linked oligomers and 
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Figure 32. Acid labile 5' and 2' alcohol protection 
(68) Thp (69) Mthp (70) DMTr (71) Pixyl 
The development of groups for 2' hydroxyl protection began with attempts by 
Griffin and Reese 176  to use tetrahydropyran-2-yl (Thp) ethers. This group was shown 
to be suitable since it was found to not be prone to migration from the 2' to 3' 
position and cleavage was achieved under conditions mild enough not to disrupt the 
oligonucleotide. While the Thp group was originally viewed as orthogonal to base 
labile 5' protection the acid lability of Thp was a problem as the acid labile trityl and 
9-phenylxanthen-9-yl (pixyl) groups emerged as the standard 5' protection. 177-179 
Normally during the chain elongation phase of the solid phase cycle the 5' protection 
is removed under acidic conditions mild enough to leave Thp in place. However in 
solid phase synthesis the Thp group has to withstand repeated 5' deprotection cycles 
and the differential approach proved to be unsuitable for the synthesis of longer 
oligonucleotides. 
Another problem with Thp is its chirality, which results in the formation of 
diastereoisomers. 4-Methoxytetrahydropyran-2-yl (Mthp) (69) was introduced as an 
achiral alternative to remove this problem. 177-179  Although successful in removing 
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chiral problems Mthp is still moderately acid labile and therefore unsuitable for use 
in conjunction with the highly acid labile pixyl or trityl groups. 
11 
(72) 	 (73) 
Figure 33. Ctmp (72) and Fpmp (73) 
The first protecting group for the 2' hydroxyl position designed to be compatible 
with acid labile 5' protection was the 1-[(2-chloro-4-methyl)phenyl] 4-
methoxypiperidin-4-yl (Ctmp) (72) group.' 80 This group can be seen as a 
development of Mthp where an electron withdrawing group has been attached to 
stabilise the molecule to acid hydrolysis. For example changing the ring oxygen to a 
sulfur increases the rate of hydrolysis by a factor of five but changing it to the more 
electron withdrawing sulfone decrease hydrolysis by a factor of 400. In Ctmp a 
tertiary amine group has been introduced which remains unprotonated under mild 
acid (pH 2-2.5) allowing acid hydrolysis to proceed cleaving Ctmp but leaving 5' 
pixyl protection in place. At lower pH's the nitrogen becomes protonated and the 
electron withdrawing effect inhibits acid hydrolysis of Ctmp but allows removal of 
the 5' Pixyl group. Some acid hydrolysis still takes place at lower pH's however. The 
reaction rate is sufficiently reduced to make Ctmp a suitable protecting group for the 
2' position of RNA using the phosphoramidite or H-phosphonate approach. 
181-183 
A drawback of the Ctmp group is its synthesis, which is long and inefficient. This 
led to the development of similar compounds that would have equivalent protecting 
group properties but also be easier to make. 1-(2-fluorophenyl)-4-methoxypiperidin-
4-yl (Fpmp) was developed from this approach and emerged as an improvement to 
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Ctmp. 184185  This new group was found to be more stable to acid hydrolysis within 
the pH range required for 5' deprotection. RNA sequences can undergo migration 
and in the pH range 2 to 2.5 (0.01M HC1 or dilute acetic acid) previously 
used for Ctmp and Fpmp cleavage. A refinement to Fpmp cleavage was to use a 
solution of sodium acetate (pH 3.25, 30°C, 36 hours). These conditions cleave Fpmp 
without any disruption to the internucleotide bonds.' 86-187  A further recent 
development of this system is the 1-(4-chlorophenyl) 4-ethoxypiperidin-4-yl (Cpep) 
group. ' 78  This protecting group has slightly improved hydrolysis rates compared with 
Fpmp and Ctmp. 
Another group, which uses completely different chemistry, that has been 
successfully applied to the 2' hydroxyl function is the t-butyldimethylsilyl (TBDMS) 
group. First introduced in 1973 by Ogilvie 188  the TBDMS group has the advantage 
that it is relatively stable to acid and base and is therefore compatible with most 
existing protecting group strategies. As with all other silicon-based groups, TBDMS 
is cleaved rapidly by fluoride ions at room temperature. 











Figure 34. TBDMS migration 
One potential problem with TBDMS is 2'-3' migration of the protecting group. 189-  
190 It has been reported that interconversion can occur in a wide variety of media. In 
methanol at 36°C the half-life of 2'-O-tert-butyldimethylsilyladenosine is only 57 
minutes The half-life increases to over six hours in aqueous pyridine with added 
base (0.0IM benzylamine) and approximately 12 hours for aqueous pyridine alone. 
In 80% acetic acid, 0.1M methanolic hydrochloric acid or in the solvents chloroform 
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and anhydrous ME, interconversion is either non-existent or occurs at suitably low 
levels for the purposes of phosphoramidite and H-phosphonate solid phase 
chemistry. 191 
The production of TBDMS protected monomers is performed by first reacting 
TBDMS chloride with the 5'-O-DMTr protected nucleoside in the presence of 
imidazole. The 5' protected nucleoside is used because TBDMS would react 
preferentially with the 5' position if it were left free. The reaction produces a mixture 
of 3' and 2' silylated products which must be separated by silica gel 
chromatography. Care must be taken here as silica can catalyse interconversion. The 
2'-O-silyl product is then phosphitylated and is ready for use. 
In 1987 Usman et al'9 ' carried out the automated synthesis and purification of an 
oligoribonucleotide sequence using the silyl methodology. The oligomer, 43 
nucleotides in length, was based on the 3'-half molecule of an Escherichia coli N-
formylmethionine tRNA and in this synthesis the modified bases were replaced by 
their unmodified counterparts. Coupling steps lasted 15 minutes and the silyl 
protection was removed by treatment with 1M tetrabutylammonium fluoride (TBAF) 
in THF for 4 hours. The strong basic conditions used to cleave the N-acyl protection 
and linker to the solid support were found to cause the removal of the 2' silyl 
protection and also chain cleavage. The problem is most severe when 30% 
ammonium hydroxide is used and was reduced significantly by adding 25% ethanol 
and conducting cleavage at room temperature over 2-3 days although under these 
conditions some cleavage is still detectable. The problem was overcome by using the 
more labile phenoxyacetyl amino protecting groups which can be removed at 55°C in 
3:1 ammonium hydroxide-ethanol over 16 hours without detectable rates of chain 
cleavage' 92 or 4 hours at room temperature with TBAF.' 
Although silyl protection has been used successfully for the synthesis of large RNA 
molecules problems still exist. Cleavage with TBAF is highly sensitive to water and 
leaves fluoride salts that must be removed prior to analysis. An alternative to TBAF, 
triethylamine trihydrogen fluoride TEA.3HF, also has shortcomings and can cause 
Chapter 1 Introduction 
	 51 
degradation of some oligonucleotides. 194 Another persistent problem with silyl 
protection is that coupling times are slower than their DNA equivalents. This has 
been attributed to steric issues resulting from the bulky, lipophilic TBDMS group. 195 
Schwartz et al'95  developed a protecting group designed to overcome the steric 
problems associated with TBDMS. Their new group, o-nitrobenzyloxymethyl, was 
developed from an earlier hydroxyl protecting group, o-nitrobenzyl, which had also 
suffered from steric problems in RNA synthesis. In the new group a carbon and 
oxygen have effectively been introduced as a spacer to move the bulky substituted 
benzene ring away from the 3' hydroxyl function. This approach succeeded in 
reducing steric problems and yields greater than 98% over a two minute coupling 
cycle were observed; rates comparable with those in DNA synthesis. Photochemical 
cleavage is then affected by exposure to long wave UV light for 5 hours at pH 3.7. 
Care does have to be taken to avoid accidental cleavage introduced from ambient 
light. Gough et al 196  introduced the p-nitrobenzyloxymethyl group. This group also 
overcame the steric problems and achieved coupling times of two minutes by using a 
short spacer. Deprotection here was achieved with TBAF in THF at 25°C over 24 
hours. 
Another protecting group developed for the 2' position is the 
(trimethylsilyl)ethoxymethyl ether (SEM) group. 197  This group can be thought of as 
an attempt to combine the silicon protection of TBDMS with the spacer moiety 
successfully used with the nitrobenzyl groups to reduce steric effects on coupling 
times. It also has the advantage over TBDMS in that because there is now a silicon - 
carbon bond, rather than the silicon - oxygen bond, so the group cannot migrate. 
Unlike TBDMS, SEM is stable to base and is removed by treatment with BF 3 .OEt2 in 
acetonitrile for 30 minutes. 
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Figure 35. O-Nitrobenzyloxymethyl (77) and p-nitrobenzyloxymethyl (78) 
Another group to be tried as a 2' protecting group is the 1,1 -dianisyl-2,2,2-
trichioroethyl group (DATE). 198 Chosen for it's orthogonal cleavage and high 
stability to acid and base it does however suffer from problems of steric bulk. 
(79) 	 (80) 
Figure 36. SEM (79) and DATE (80) 2' protection 
Rastogi and Usher 199 introduced the first protecting group requiring a two-stage 
deprotection in 1995. 2-Hydroxyisophthalate formaldehyde acetal (HIFA), as the bis 
ester (81), is relatively stable to the acidic conditions used during repeated removal 
of 5' protecting groups. During the alkali conditions, for cleavage of the exocyclic 
protection and cleavage from the solid support, the bis ester is converted to the bis 
carboxylic acid (82) which can subsequently be easily removed using mild acid (83). 
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Figure 37. HIFA deprotection 
All 2' protection requires the synthesis of pure 2' protected product uncontaminated 
by 3' protected isomers. Most protection reactions produce mixtures of 3' and 2' 
protected products that are then purified by chromatography. Markiewic2 00 offered a 
solution to this difficult and time-consuming problem in the form a reagent for the 
simultaneous protection of the 3' and 5' hydroxyl groups. Known as the Markiewicz 
reagent, 1,1,3,3-tetraisopropyldisiloxane (TIPDSi), makes use of the thousand fold 
higher reactivity of primary alcohols over secondary alcohols with silyl reagents. 
Introduced as 1,3 -dichloro- 1,1,3,3 -tetraisopropyldisiloxane, TIPDSi reacts first with 
the 5' position then intramolecularly with the 3' position to give a 3' -5' protected 
nucleoside (85). The 2' hydroxyl group is then free to react with many of the 
protecting groups mentioned above. TIPDSi is then removed with TBAF to leave the 
2' protected nucleotide (86). 
0 	0 B 
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Figure 38. Markiewicz protection 
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An additional procedure in silicon chemistry is the selective desilyation of 
multisilyated nucleosides at the primary 5' position. 201  Although generally not of 
direct application for 2' protection this technique is important for the production of 
other modified nucleosides. A nucleoside protected by the Markiewicz reagent or by 
multiple TBDMS groups can be selectively deprotected at the 5' position leaving 
TBDMS protection on the 3' and 2' or leaving the Markiewicz reagent still attached 
at the 3' position. 
The large volume of research into RNA and its chemical synthesis has meant that 
large highly modified oligoribonucleotides can now be chemically synthesised in the 
laboratory. 202-203  However scope for refinement and improvement of protecting 
group strategies remains. 
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Chapter 2 	Results and Discussion 
2.1 	Aims of this Research 
Oligonucleotide synthesis has advanced a long way since it's inception in 1955 
when Michelson and Todd 8 ' reported the first chemical synthesis of a dinucleotide. 
Reagents and protecting groups continue to be refined in an effort to improve speed 
and efficiency. The aims of this research were to design and synthesise novel 
protecting groups for the solid phase synthesis of oligonucleotides covering the 5' 
and 2' hydroxyl ribose positions. 
2.1.1 	5' Protection 
Earlier work by Ramage and Wahl 169  resulted in the introduction of 4-(17-
tetrabenzo[a,c,g,i]fluoromethyl)-4' ,4' '-dimethoxytrityl chloride (Thf-DMTr-Cl) for 
the protection of the 5' hydroxyl position. This work had been successful in aiding 
purification but had areas capable of improvement. To overcome these problems we 
envisaged two modifications to the original design to produce a new protecting 
group. 
The first modification was aimed at improving coupling efficiency. The coupling of 
Tbf-DMTr-Cl to thymidine was achieved in 45% yield compared to an average 78% 
yield for DMTr achieved by Khorana using the DMTr group in 1962 (although this 
was later improved to 93%). 157  It was thought that the poor coupling yields for Tbf-
DMTr-Cl were a result of steric effects. If the spacer between the Tbf and phenyl is 
increased from the one carbon previously employed then these steric effects should 
be removed and the reactivity of the new group should be brought closer to that of 
DMTr. Therefore the modification was to increase the length of spacer from one 
carbon to ten or eight. 
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The second modification was to change the substitution pattern on the benzene 
rings of the trityl system. The aim was to make the electronics of the system closer to 
DMTr and therefore subject to the same reaction conditions as DMTr. The para 
methoxy groups were to be removed and replaced with methyl groups also the 
method of synthesis was to be altered such that the linker was to be attached through 
an oxygen atom rather than a carbon. This was done because the original system with 
two methoxy groups combined with the inductive effect of the carbon link to Thf had 
proved too much. With three stabilising forces on the cation it had proved too stable 
and the group became too acid labile. By moving from one methyl and two methoxy 
groups to two methyls and one methoxy group we hoped to get the balance right so 
that the protecting group would have approximately the same lability as DMTr. 
TV 	 Spacer 	 Trityl 
Figure 39. Tbf-C 1 0-DMTr (87) 
The aim in this project was therefore is to produce a new 5' protecting group, 
shown in figure 39, based on Tbf-DMTr with the following properties: 
o The protecting group should be removed under acidic conditions similar to those 
employed for the removal of DMTr or MMTr. 
o The protecting group should be introduced under conditions mild enough to not 
affect the nucleotide or oligonucleotide and should be regioselective for primary 
alcohols in order to leave the secondary hydroxyl functions unprotected. 
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The group should make use of Thf's lipophilic properties to enable purification 
of derivatised oligomers. 
• Yields for coupling the new group to nucleotides should be higher than that for 
Thf-DMTr-Cl. 
• The group should contain no interfering reactive functionalities and should be 
accessible in reasonable yield. 
• The new group should contain the UV/Visible properties of the trityl and Thf 
groups so that its concentration could be easily measured and thus the extent of 
coupling calculated. 
2.1.2 2' Protection 
Three different approaches to preparing an improved protecting group for the 2' 
hydroxyl position were attempted. The first was a development on earlier work by 
Bremner204 based on propargyl alcohol; the second was based on 3-butyn-1-ol and 
the third on o-cresol. 
DMTrO 	B DMTrO 	B 	or 
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Figure 40. Steric hindrance at the 2' position 
The first common feature of the three approaches is the attempt at limiting steric 
interference at the point of nucleotide bond formation. Analysis by Kierzek et a1205 
showed the profound effect on coupling efficiencies that bulky 2' groups can have. 
By looking at the coupling yields from the competitive condensation of four 
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ribonucleoside phosphoramidites (88-91) and a solid support bound deoxythymidine 
he showed the order to be size dependant. The order of reactivity was 88> 89> 90> 
91 (from figure 40) with the relative yield of dimers being 1, 0.7, 0.4, 0.1 
respectively which corresponds directly to the size of 2' protection used. This shows 
the need to keep 2' protection as unobtrusive as possible. All three systems are 
designed to be sterically undemanding at the cc and P position, with respect to the 2' 
oxygen. 
The second feature common to all three proposed systems is the two-stage 
deprotection strategy. In the final deprotection protocol use of base, to remove 
exocyclic and phosphate protecting groups as well as cleaving the oligomer from the 
support, first primes the system so that it can be cleaved under mild acidic 
conditions. Limiting the exposure of completely unprotected RNA and DNA to acid 
or base solutions should minimise sequence degradation. 
The aim therefore is to produce a series of 2' protecting groups with the following 
properties; 
o The groups should be stable to repeated exposure to the acidic conditions used 
for the removal of 5' protection. 
o It should be stable to the alkaline conditions used for the removal of exo cyclic 
deprotection and cleavage from the solid support. 
Conditions for removal should be mild so that there is minimal degradation of 
the oligonucleotide via cleavage, migration or depurination. Reagents used 
should also be easily removed from the oligomer during purification. 
D The groups should have minimal steric bulk to keep coupling yields high. 
The groups should be prepared as alkyl halides for introduction using standard 
Williamson type reactions. 
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2.1.2.1 The Propargyl alcohol system 
The first system designed by the Ramage group to fit the above criteria was 
introduced by Bremner204 and was based on propargyl alcohol. Figure 41 shows two 
of the many compounds investigated, 6-Hydroxy-hex-4-ynyl acetate (92) and - 
Hydroxy-hex-4-ynyl benzoate (93). 
Ho_~ ___O "r 	H 0 	0 YO 
(92) 	 (93) 
Figure 41. Propargyl System 
These groups were designed to be deprotected in a two-stage mechanism. During 
the addition of base, synchronous with cleavage from the solid support and removal 
of the exocyclic and phosphate protection, the ester is hydrolysed to give the free 
acid and the alcohol. During treatment of the intermediate with acid, the alcohol 
undergoes an intramolecular cyclisation to give the unprotected nucleoside. 
The Baldwin Rules  206  classify intramolecular cyclisation reactions that are favoured 
and those that are not. According to these rules Exo. -Dig cyclisations are allowed for 
ring sizes 5 to 7. The cyclisation part of the deprotection for phenyl-7-hydroxy-hept-
5-ynoate follows these rules and is a 5 Exo -Dig reaction. 
X 
Figure 42. Baldwin Rules, 5 Exo -Dig 
It has been shown that hydroxy groups can undergo cyclisation reactions with a 
triple bond to form enynols and furans in a 5 Exo-Dig fashion as shown in figure 
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(43)207208 Intramolecular reactions have also been shown using silyl protected enol 
ethers which react with triple bonds in an aldol fashion, an example of which is 
shown in figure (44)2o9210 
Figure 43. 5-Exo-Dig reaction 
Hg  
Figure 44. 5-Exo-Dig reactions using silyl protection 
To stop this cyclisation reaction happening prematurely the alcohol is protected 
throughout the reaction cycle as the ester. It was found however that cleavage of the 
acetates and benzoates was too slow and the conditions required would result in 
damage to the oligonucleotide. The benzoate was an improvement but cleavage 
conditions were still considered to be too harsh. 
While Bremner proved that the basic premises of the propargyl protection strategy 
were correct, refinements were needed if the group was to be successfully employed 
for solid phase oligoribonucleotide synthesis. Two changes to his system to 
overcome the problems are evident. First of all that the benzoate is changed for a 
para-nitro benzoate group. Since the electron withdrawing nitro group should 
facilitate ester cleavage. The second change would be required to speed up the 
intramolecular cyclisation. If a methyl sub stituent was added to the backbone P to the 
alcohol it should expedite ring closure by decreasing the entropic loss suffered when 
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the ring closes therefore lowering the free energy of reaction. However this addition 
does introduce the added complexity, of a chiral centre to the molecule. Introducing 
two methyl substituents at the same position to remove the chiral problem would 
have resulted in the introduction of excessive steric bulk which would cause 
problems not only in synthesis of the group but may also have reduced coupling 
efficiency. The proposed protecting group is shown below in figure 45 and its 
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Figure 46. Deprotection of new propargyl system 
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2.1.2.2 The 3-Butyn-1-ol System 
Unlike the previous candidate, close analogues of this compound have not been 
made before as candidates for hydroxyl protection. It has been designed to conform 
to the criteria mentioned before and like the propargyl system does contain a triple 
bond close to the point of contact. Based on 3-butyn-1-ol it should be sterically 
undemanding enough and share a similar deprotection mechanism with the previous 
example, in that it would require base conditions followed by addition of acid and is 





Figure 47. Butynol system 
The similarity of deprotection is only superficial however and the mechanism relies 
on a series of different reactions to the propargyl system. A potential deprotection 
mechanism is shown in figure 48, however this is just a proposed mechanism and 
other routes could be suggested. One point of diversity could be the ester cleavage. 
This could happen during the base steps to cleave from the solid support but could 
also happen during the acid step. The ways the molecule might fragment during 
cleavage could differ but the end result is the same. 
After cleavage from the solid support by base the 2' protected oligomer is exposed 
to concentrated ammonia that should aminate the triple bond to give the imine or 
enamine. 211 
One alternative route to the enamine could be through a cycloaddition reaction of 
the triple bond with sodium or alkyl azide to give the 1,2,3 triazole. Heterocycles 
with three adjacent nitrogens are unstable and will degrade with the loss of N 2 . A 
probable product from this degradation would be an imine 212 corresponding to the 
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enamine shown in figure 48. The route through triazole is much more complicated 
and the actual mechanism of degradation would be difficult to follow. 
The Schiff base then reacts with mild aqueous acid to give the 13-keto acid, with the 
loss of ammonia. Imine hydrolysis is a rapid reaction that proceeds via a hemiaminal 
intermediate in mild acid but it should be noted that this is an equilibrium. The 
driving force in this case is the decarboxylation of the 3-keto acid in the following 
step. 3-Keto acids, which are unstable in acid but fairly stable in base, are prone to 
decarboxylation for two reasons. First of all the product of decarboxylation is an enol 
which is stabilised by resonance. Secondly when the 3-keto acid decarboxylates it 
goes through a six membered cyclic transition state with the newly forming OH bond 
in the same plain as the C-C=O system thus producing the enol directly without 
going through a carbanion. 213 In this example as there are no steric constraints to 
formation of this transition state and decarboxylation should proceed in acid at room 
temperature. 213 
If this enol then isomerises by a 1,3-hydride shift the new enol could undergo a 
retro conjugate addition to give the free oligonucleotide. The materials released in 
the breakdown of the protecting group would be ammonia, carbon dioxide and 
methyl vinyl ketone which should all be easy to remove. There is a potential 
complication with methyl vinyl ketone in that it is prone to polymerisation however 
this should not be too problematic due to the low concentrations of potential 
monomer around during cleavage. This property may even be useful in driving the 
equilibrium for the final step. 
















Figure 48. Butynol deprotection 
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2.1.3 The o-Cresol System 
The third system to be evaluated represents a departure from the acetylene-based 
systems and instead moves to a modified benzyl ether. Khorana 214 first introduced 
the benzyl ether as a 2' protecting group for oligoribonucleotide synthesis in 1962, 
shown in figure 49, as an alternative to acid and base labile groups. In 1966 a 2'-5' 
dinucleotide was synthesised using benzyl ether protection. 21 5  Removal of benzyl 
ethers was achieved using mild catalytic hydrogenolysis. One atmosphere of 
hydrogen using palladium black in aqueous ethanol has been successfully used to 
remove benzyl ether protection on a 2'-5' cyclic phosphate. 216 
t o 
(96) (97) 
Figure 49. Benzyl ether (96) and O-Cresyl system (97) 
Base Acid 	' 
 __ 	
Q 	OH 
H 	OH 	 Products 
(97) 
Figure 50. O-Cresyl deprotection 
Instead of using hydrogenolysis the new group will be based on o-cresol and will 
use a two-stage deprotection of base then acid similar to that used for the butynol and 
propargyl systems. The first reagent in deprotection, shown in figure 50, is the base 
used to remove the exocyclic protection and cleave from the support. During this 
step the ortho acetyl protection would be removed to give the ortho hydroxyl group. 
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The second step to deprotection of this group would be acid treatment to give the 
ortho-quinone methide and the deprotected nucleotide. 
2.2 	Protection of 5' position 








Figure 51. Synthesis of ethyl 4-(10 bromodecyloxy)-benzoate 
The first step in our synthesis of Tbf-C 10-DMTrC1 was the synthesis of the 
precursors ethyl 4-(10 bromodecyloxy)-benzoate (98) and tetrabenzo[a,c,g,i]fluorene 
(Tbf) (100) as shown in figures 51 and 52. The synthesis of the alkyl bromide (98) 
was achieved in 78% yield using a Williamson type reaction with an alkyl dibromide 
and ethyl 4-hydroxy-benzoate activated with sodium hydride. To ensure only mono 
alkylation, a 3 to 1 excess of dibromide was used but the dialkylated side product 
was still present at levels about 10% of product formed. The actual level of 
dialkylated product is probably higher as no extra effort was made to isolate and 
measure this byproduct. 
Tetrabenzo[a,c,g,ijfluorene (100) was prepared using the procedure originally 
developed by Wahl and is shown below in figure 52.' ° The Grignard reagent 
prepared from 9-bromophenanthrene was reacted with 0.5 equivalents of methyl 
formate to give bis-phenanthren-9-yl methanol (99) in 81% yield. Treatment with 
trifluroacetic acid results in a [2+2] cyclisation to give tetrabenzo[a,c,g,i]fluorene 
(ThI) (100) in 69% yield. 
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(99) 	 (100) 
Figure 52. Synthesis of tetraberizo[a,c,g,i]fluorene (100) 
However the cyclisation product obtained is a mixture of two isomers (100) and 
(10 1) shown in figure 53. The product formed from the initial acid reaction with acid 
is the unsymmetrical isomer (100) as shown in Figure 53. Base, heat or ultraviolet 
light can then isomerise this to give the thermodynamically favoured symmetrical 
isomer (101). The presence of the symmetrical isomer is not problematic however as 






(Heat or UV light can also cau 
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The next step in the synthesis of Thf C 1 Tr was the coupling of the fragments (98) 
and (100) to make ethyl 4-(10-(tetrabenzo[a,c,g,i]fluorenyl) decyloxy)-benzoate 
shown in figure 54. The procedure of Hay was followed with one alteration. 217 
Previously the initial step was formation, using tetrabutylammonium hydroxide, then 
isolation of the Thf tetrabutylammonium salt precipitate by filtration under nitrogen. 
The anion was then dissolved in a second solvent and the alkyl bromide added. 
Although stable to water, the anion rapidly reacts with oxygen to give the Thf ketone 
so it was felt that the isolation of the anion solid represented an unnecessary 
exposure to air. The procedure was adapted by adding the alkyl bromide (98) after 
ten minutes and attempting the reaction as a suspension because of this high 




Figure 54. Synthesis of Ethyl 4-(l 0-(tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-
benzoate (102) and of 4-( 1 0-( 17' -tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-4' ',4' " - 
dimethyl trityl alcohol (104) 
An excess of p-bromotoluene and magnesium were combined to produce the 
corresponding Grignard reagent and then reacted with the ester (102). This Grignard 
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reaction 	converted 	the 	Thf 	ester 	into 	4-(10-(17'- 
tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-4' ',4 " -dimethyl trityl alcohol (104) in 86% 
yield. Using reactions with ethyl benzoate, p-bromotoluene and magnesium as a 
model system it was found that excess Grignard reagent produced the highest yields. 
Acetyl Chloride 
I. I V'f) 	
Thymidine ./ 
Pyridine 
Figure 55. Attempted synthesis of 4' -(1 0-( 17' -tetrabenzo [a,c,g,i] 
fluorenyldecyloxy)-dimethyl trityl-oxy-5 '-thymidine (106) 
Model studies for the chlorination of (104) and the coupling of the product to 
thymidine were carried out with 4'-4"-dimethyl trityl alcohol as well as on trityl 
alcohol following the literature procedure. 218 These studies were successful but the 
derivatives did show high sensitivity to moisture even under mild acidic conditions. 
Using flash column chromatography over silica the chloride was converted back to 
the alcohol. 4-( 1 0-( 17' -Tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-4' ',4' ' '-dimethyl 
trityl chloride (105) was successfully prepared using the same methodology as the 
models and was then used immediately in attempts, under several different sets of 
conditions, to couple to thymidine to produce bis-(-4-methylphenyl)-4-[10-(17- 
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tetrabenzo [a,c,g,i] fluorenyl)decyloxyj phenylmethyoxy-5 '-thymidine (106), as 
shown in figure 55. 
This reaction was attempted many times using the literature procedure described by 
Strazzolini et a1218 with no success. Chlorine analysis and proton NMR as well as a 
visible change in colour (from pale yellow to bright orange) suggested that the alkyl 
chloride was formed but failed to react with the thymidine. 
Incomplete removal of acetyl chloride after the chlorination and subsequent 
contamination of the coupling step was initially thought to be the cause. Removal of 
the excess acetyl chloride is achieved by repeated co-evaporation to dryness with a 
dry solvent after chlorination. Initially dry THF (3xlOml) was used as the solvent. 
Pyridine (3xlOml), benzene (3xlOml) and toluene (3xlOml) were all investigated but 
no reaction was observed in the coupling reaction. Due to the sensitivity of the 
chloride intermediate, recrystalisation or flash column chromatography are 
unsatisfactory so another method needed to be used to remove the acetyl chloride. 
However the evaporating to dryness technique has been used successfully in the 
literature, using benzene, so it seems unlikely that contamination with acetyl chloride 
is solely responsible for failure of the coupling reaction. 159 
Another potential reason for failure of such reactions can be moisture reacting with 
the alkyl chloride to return the activated trityl system back to the alcohol. This seems 
unlikely given the stringent reaction conditions. However the thymidine was twice 
co-evaporated with dry pyridine to make sure moisture was removed. 
When attempting to recover the trityl alcohol to recycle the material for another 
attempt it was noticed that there was a complicated mixture of compounds with Rf 
values close to that of the starting material. It was clear that the trityl system chosen 
was sensitive to the long exposure to pyridine used in the synthesis. A possible 
mechanism for this degradation is shown in figure 56. 





Figure 56. Possible mechanism of methyltrityl degradation in base 
First of all the chloride is easily lost due to the stability of the carbocation. The 
electron donating effect from the electron rich benzene rings stabilises the positive 
charge. Normally this electrophilic and sterically hindered carbon reacts with 
primary alcohols. However, in this case a faster reaction could be loss of a methyl 
proton to quench the positive charge giving the unsaturated compound shown in 
figure 56. The resulting compound could then undergo all kinds of reactions even 
polymerisation. To test if base sensitivity was the reason for the reaction failure, a 
quantity of alkyl chloride was stirred in pyridine without any other reagent for one 
week. After this time the pyridine was removed and the residue was analysed and 
was shown to have degraded. 
Even if a small quantity of protected thymidine (106) was formed in the early 
stages of the coupling reaction it might still degrade by a similar mechanism. This 
observation led to the redesign of the system with the omission of the two aryl 
methyl groups. The new protecting group will now be analogous to monomethoxy 
trityl and will be less acid labile than the commonly used dimethoxy group. This 
should not present a significant problem however as monomethoxytrityl has been 
used in solid phase synthesis and since this group will only be removed once, the 
increased exposure to acid should not significantly increase depurination levels. 
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2.2.2 Shorter linker approach 
Another possible explanation for the failure of the coupling reaction could be that 
the linker was long enough for the molecule to fold over on itself. It is possible that 
the highly aromatic and hydrophobic Thf and trityl regions are attracted to each other 
and held in place in such a way as to obscure the active site to such an extent that the 
polar thymidine hydroxyl group is unable to penetrate and reach the site of reaction. 




NaH 1) NaH 
BrCH2-(CH2)6-CH2Br / 
	
\2) BrCH2-CH 2-CH 2 Br 
(CH2)5Br 	 (CH2)3Br 
ElO (cI EtO (EIY 
0 	 0 
(107) 	 (108) 
1) Tbf, NBu40H 	 Tbf, NBu40H 
Dioxan 	 Dioxan 
o product (I 10) recovered 
Figure 57. C8 and C3 linker synthesis 
The first step was synthesis of shortened precursors for coupling to Thf, shown in 
figure 57. The C8 fragment ethyl 4-(8 bromooctyloxy)-benzoate (107) was produced 
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in 68% yield and the C3 fragment ethyl 4-(8 bromopropyloxy)-benzoate (108) was 
made in 75% yield. Coupling to Thf was achieved in 83% yield for the C8 linker but 
was unsuccessful for the C3 linker. This might be explained by the fact that ethyl 4-(8 
bromopropyloxy)-benzoate is a low melting point solid and was harder to de-gas and 
purify than the other alkyl bromides used. The procedures used were identical to 
those used to prepare the ten carbon compounds. 
This line of investigation was stopped at this point when the alternative strategy, 
where the aryl methyl groups had been removed, was used to produce a protected 
nucleotide. The C8 fragment was used later for use in purifying 2' cresol protected 
compounds as is described in section 2.3.3. 
2.2.3 Synthesis of Tbf C 10 DMTr 
To test the theory that the methyl groups were responsible for the failure to produce 
the protected thymidine (106) monomethoxytrityl chloride was prepared and coupled 
to thymidine (using the same procedure unsuccessfully used with (104)). First the 
hydroxy group of ethyl 4-hydroxybenzoate was protected as the methyl ether (I 11) 
in 94% yield then a Grignard reaction with bromobenzene produced 4' 
monomethoxy trityl alcohol (112) in 90% yield. This was converted to the chloride 
(113) using acetyl chloride and purified by co-evaporation with benzene. Finally this 
was coupled to thymidine to give the 5' protected thymidine (114) in 57% yield. 
With the success of the model system the synthesis of the new protecting group was 
begun and followed the same lines as the original plan, except that the Grignard 
reaction was carried out with bromobenzene producing (115) in 83% yield. The 
hydroxyl group was then converted into the chloride (116). Chlorine analysis gave 
poor results with values for the percentage of chlorine often well below the 
theoretical value for complete chlorination. There was a strong coloration between 
the age of a sample and the margin of deviation from the expected value. This was 
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not a concern since the combustion of Thf is always incomplete and the alkyl 
chloride is highly sensitive and will revert to the alcohol. The NMR gave more 
encouraging results showing the loss of the hydrogen from the alcohol. Coupling to 
thymidine in pyridine was successful and 4'-(10-(17'-tetrabenzo[a,c,g,i] 









0 	 0 
Mg 	 OH 
(111) 	 (112) 
a
OMe 
Thymidine AcCI 	 ci 	Pyridine 
9(c(0Me 0 
U NJ NH 
HO 
(113) 	 (114) 
Figure 58. Model monomethoxy system (111) - (114) 
The yield of 77% is identical with that originally achieved by Khorana' 57 with 
DMTr and is a distinct improvement on the 45% achieved by Wahl with the one 
carbon linker. 170  Therefore the move from a one carbon spacer to a ten carbon spacer 
has removed the steric effects almost completely for coupling to thymidine. This 
yield represents unoptimised conditions and higher yields should be achievable. 
Coupling to uridine to produce 4'-(10-(17'-tetrabenzo[a,c,g,i] fluorenyldecyloxy)-
trityl-oxy-5'-uridine (118) was achieved in 46% yield. N 2-Isobutyryl-2'-
deoxyguanosine (119), N4-Benzoyl-2 ' -deoxycytidine (120), N 6-Ben.zoyl-2 ' - 
deoxyadenosine (121) were all protected in 68%, 83% and 70% yields respectively. 
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In early coupling reactions it was noticed that even after the extensive measures 
used to remove acetyl chloride the products were acylated at the 2' position. The 
probable reason for this lies in the nature of the solid chloride. It becomes a thick and 
sticky foam under vacuum and even after hours under a high vacuum there can be 












Figure 59. Synthesis of 4' -(1 0-( 17' -tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy - 
5'-thymidine (117) 
It was observed that there was no noticeable acylation in the production of 
protected deoxycytidine (120). The quality of starting material N4-benzoyl-2'- 
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deoxycytidine was worse than those of the other nucleosides and a small excess had 
been added to compensate. This excess had been enough to remove the remaining 
acetyl chloride by acylation of the 5' position and therefore an excess of nucleotide 
was added to the procedures for the other deoxynucleotides. The excess used appears 
to relate to the yield produced, thymidine excess 14% gave a 77% yield, guanosine 
21% excess gave a 68% yield, cytidine 37% excess gave an 83% yield and adenosine 
12% excess gave 70%. The protected nucleotides are expensive so a refinement of 
this procedure would be the introduction of a simple alcohol to trap the acetyl 
chloride. This could be added before the nucleoside and would be sufficiently 
sterically demanding, a secondary or tertiary alcohol for example, to be unable to 
form an ether with the trityl chloride. This should be achievable since 
triphenylmethanol will not form an ester and trityl systems will not easily form ethers 
with secondary alcohols. 
The next step was to convert the 3' hydroxyl groups into their phosphoramidites for 
use in solid phase synthesis. The 5' protected nucleosides were stirred in alcohol-free 
dichioromethane (DCM) with tetrazole diisopropylammonium salt (DIHT) and 
tetraisopropyl cyanoethyiphosphoramidite. Sodium bicarbonate solution was then 
used to quench the reaction and the organics were extracted with more DCM. The 
DCM was washed with brine then dried and the solvent removed by vacuum. The 
solid residue was dissolved in the minimum of DCM and precipitated in hexane then 
dissolved in the minimum of ethyl acetate and precipitated in pentane. When using 5' 
MMTr thymidine as a test system the crude 'H and 31 P NMR showed the reaction to 
be successful. It was clear that some oxidised P 5 compounds were also present but an 
attempt to purify by column chromatography destroyed the sample. 
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Figure 60. Synthesis of the protected nucleosides 
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The four deoxynucleotides were synthesised and purified using precipitation as 
described above. Mass spectroscopy and NMR were used to measure the purity of 
the products. 4' -(1 0-( 17' -tetrabenzo{a,c,g,i] fluorenyl)decyloxy)-trityl-oxy-5 '-N 4-
benzoyl-2' -deoxycytidine-3 '-O-N,N-diisopropyl-3-cyanoethy1 	phosphoramidite 
(123) was produced in 90% yield, 4'-(l 0-(l 7' -tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-
trityl-oxy-5 '-thymidine-3 '-O-N,N-diisopropy1--cyanoethyl phosphoramidite (124) 
in 72% yield, 4' -(1 0-( 17' -tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-trftyl-oxy-5 '-N 6- 
benzoyl-2'-deoxyadenosine-3'-O-N,N-diisopropyl-3-cyanoethyl 	phosphoramidite 
(125) in 91% and 4' -(1 0-( 17' -tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-trityl-oxy-5 ' - 
N2-isobutyryl-2' -deoxyguanosine-3 '-O-N,N-diisopropyl-3-cyanoethyl 
phosphoramidite (126) in 94%. 
NC 
Tbf(H2C) 1 
Compounds (118-121) 	 Compounds (123-126) 
Figure 61. Phosphoramidite synthesis 
2.2.3.1 Solid phase Synthesis 
The 5' Tbf C10Tr nucleoside phosphoramidites were thus ready for testing in a solid 
phase synthesis. Four sequences of seven thymidines were synthesised with the final 
nucleoside being one of the four Thf protected nucleosides. Standard monomer 
couplings last thirty seconds. The final step involved the addition of the Thf trityl 
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protected monomers, dissolved in 1:1 alcohol-free DCM and dry acetonitrile, and 
lasted ten minutes. The following sequences were prepared by this method: 
(127) 5'-Thf-DMTr-TT-TTT-TTT-3' 
(128)5' -Thf-DMTr-CT-TTT-TTT-3' 
(129) 5' -Thf-DMTr-AT-TTT-TTT-3' 
'(130) 5'-Tbf-DMTr-GT-TTT-TTT-3' 
At the end of each synthesis the sequences were cleaved from the solid support 
using concentrated aqueous ammonia in 20 minutes and the exocyclic amine 
protecting groups were removed by heating the solution overnight (16hrs) at 45°C. 
Standard dimethoxytrityl protocol is 40°C for 24hrs. The samples were then 
evaporated to dryness in vacuo at 45°C over three hours and the crude residue was 
analysed by HPLC at this point. 
The samples were purified using a polypak, a pre-packed small column. The crude 
sample solutions were eluted (and the run off was reapplied), ammonium hydroxide 
solution and water were then used as eluants to remove truncated sequences. 
Trifluroacetic acid (TFA) was added to cleave the 5' Tbf protection and, to elute the 
purified oligonucleotide, 2m1 of 20% acetonitrile was washed through and collected. 
These samples were then analysed by HPLC and LCMS. 
Figure 62a. HPLC traces for (127) before [left] and after [right] purification 
[A] shows the 7 thymidine sequence 
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Figure 62b. HPLC traces for (128) before [left] and after [right] purification[A] 




Figure 62c. HPLC traces for (129) before [left] and after [right] purification[A] 
shows the 7 thymidine sequence 
317.3 
233.5 
Figure 62d. HPLC traces for (130) before [left] and after [right] purification[A] 
shows the 7 thymidine sequence 
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The HPLC was an Aquapore reverse phase silica column (300A particle size) 10cm 
C4, internal diameter 4.1mm. and using a flow rate of 1 ml/min. The gradient used was 
(1) 0-4mm 50%A; 4-24mm 50-90%A; 24-28mm 90%A; 28-30mm 90-50%A for 
reverse phase with samples dissolved in Acetonitrile and a minimum of Dioxan 
where (A) is Acetonitrile and (B) is water. 
Base 	Final Step Yield % of 7mer's relative to 8mer's 
Before purification After purification 
Thymidine 34% 47% 1% 
Deoxycytidine 55% 7mer peak off scale 18% 
Deoxyadenosine 12% 37% 13% 
Deoxyguanosine 33% 61% 26% 
Figure 63. Table containing yields for Tbf group coupling and levels of 7mer post 
and pre purification relative to 8mer 
Despite the lengthened coupling times the final step yield is disappointing. The 
large variation between the bases is probably partially down to the quality of the 
phosphoramidite and repeated experiments should produce better results. The 
phosphoramidite samples were made two days before use and purified on the day 
before use. If the samples were made and purified on site and used immediately a 
better result might be seen, or alternatively stored under Argon before use. However 
the yield may be inherently limited due to the nature of the Tbf group. Solubility was 
a problem and DCM had to be added to the procedure to compensate. Investigation 
of different linker sizes should be able to find the optimal linker size where solubility 
in acetonitrile is improved but the steric problems are still eliminated. 
The large amounts of the T 7  truncated sequence observed in this reaction is a direct 
consequence of the poor coupling for the final step. Using the DMTr polypak 
technique a significant reduction was made in contamination of the final product 
sequence. Optimising the purification protocol should eliminate the presence of the 
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7mer material completely from the final product. Optimising purification could also 
raise the yield of the final step if it is found that there is incomplete cleavage of the 
Thf 5' protecting group. Monomethoxytrityl esters are less acid labile than the 
dimethoxy esters and therefore Thf C 10Tr will also be less labile. Different 
deprotection conditions should be investigated to ensure maximum yield and 
minimal depurination. 
2.2.4 Structural motit 
P 	 oH 0.78-0.84 
0.30 to 0.40 
10 to 12 Hz 
4/) (trans) 
]I 2.60 to 2.70 
4to5Hz 
(cis) 
.00 to 5.10 
Figure 64. Proposed structure derived from the NMR evidence 
Over the course of the synthesis of many Thf containing compounds a common 
structural motif was noticed from the proton NMR. Every compound containing the 
moiety Tbf-CH2-CH 2-R exhibited the same signal in the region OH 0.3-0.4. Using 
two dimensional 'H - 'H correlated spectroscopy (COSY) NMR it was shown that in 
every case this two hydrogen multiplet signal was attributable to the hydrogen on the 
second carbon of the linker relative to the Tbf group. The first and third carbons in 
the chain could also be assigned using this technique. Attempts to discern the 
coupling constants between the hydrogens and therefore know the cis - trans 
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relationship between them were complicated but we propose the following structure 
to describe the NMR evidence. 
The cis relationship from Thf to C 1 was always clear, however the relationship from 
CI to C2 was less clear and the coupling constant was more variable. Beyond this 
stage coupling constants couldn't be individually assigned and C2 is itself a 
complicated multiplet. 
Therefore after the first two carbons the chain becomes flexible. This fixed cis then 
trans structure for Thf to Ci to C2 is consistent with the low chemical shift for the 
hydrogens on the second carbon. The hydrogens are held in a position where they are 
slightly shielded by the induced field of the Tbf system. 
2.3 	Protection of 2' position of ribonucleotides 
2.3.1 	Propargyl system 
The proposed synthesis for this compound followed the same route taken by 
Bremner 204  but with two changes. First the bromochioropropane used by Bremner 
was replaced by bromochloro-2-methylpropane. Secondly a para-nitro group was 
introduced on the sodium benzoate used in the final step. 
The first step is the protection of the propargyl alcohol function with dihydropyran 
to produce prop-2-yn-1-yloxytetrahydropyran (131) following a literature 
procedure. 21 9  For this reaction pyridiniump-toluenesulfonate (PPTS) (132) was used 
as a catalyst and was prepared beforehand with p-toluenesulfonic acid monohydrate 
and pyridine. Removing acetylene hydrogen with butyl lithium has been achieved 
with high yield .201,220,221  But the second step proved harder to optimise and yields fell 
well below the 84% achieved by Bremner for his analogous system. The product, 1-
chloro-2-methyl-6-tetrahydropyranyloxy-hex-4-yne (133) proved difficult to separate 
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from the unreacted acetylene, although the reagent 1-bromo-3-chloro-2-methyl-
propane is easily removed. Yields were highly variably with no discernible reason 
for the variations and the best yield achieved was only 43%. One point noted was 
that partially active butyl lithium (samples which had lost >30% of their original 
activity) produced the worst results. Any unprotected alcohol would also hinder the 
reaction and excess dihydropyran was used in the first step to ensure the reaction 
went to completeness. Another point noted was that fresher samples of prop-2-yn-l-
y1oxytetrahydropyran usually worked better than older samples. It may be that this 





















Figure 65: Synthesis of 6-Hydroxy-2-methyl-hex-4ynyl p-nitrobenzoate 
The coupling of sodium p-nitrobenzoate and subsequent deprotection of THP was 
completed and gave (135) with 85% yield. The unreacted prop-2-yn-l-
yloxytetrahydropyran, which was not removed from the earlier reaction, was easily 
removed at this stage. 
The next step towards coupling the protecting group to thymidine was to convert 
the alcohol into the alkyl iodide. Propargyl systems have been coupled to nucleosides 
before as the alkyl bromide 222  and protecting groups are commonly coupled in their 
halide form. Bremner successfully made alkyl iodides and coupled them to 
thymidine. The same procedures were attempted on (135) with no success at all. In 
these reactions imidazole, triphenyiphosphine and iodine were combined with (13 5) 
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in ether and acetonitrile under an atmosphere of nitrogen. The order of addition was 
changed, as were reaction times and temperatures with no effect. 
A possible explanation for this failure is starting material contamination so every 
reagent was purified by recrystalisation and anhydrous solvents were used, the 
acetonitrile was distilled fresh and the diethyl ether was purchased in anhydrous 
form. Fresh highly pure iodine was used and compound (13 5) was purified by flash 
column chromatography many times. All these developments failed to produce any 
alkyl iodide (136). 
PPh3 , 12, 
Imidazole 




Figure 66. Synthesis of alkyl iodide tried and proposed (136) 
This reaction was repeated multiple times without positive results. I now feel that 
this reaction scheme should have been abandoned at an earlier stage. Attempts to 
take a different route through a mesylate or tosylate system, detailed in the next 
section, could perhaps have been investigated further and sooner. 
2.3.2 Butynol system, 5-Hydroxy-pent-2-ynoate ethyl ester 
The proposed route to compound (140) is shown above in figure 67. Protection of 
butynol with dihydropyran and PPTS proceeded in high yield following the same 
procedure as used for the propargyl system. As with the propargyl system removal of 
the acetylenic proton proved a difficult reaction. Treatment with butyl lithium and 
reaction with ethyl chloroformate to give (138) was a low yield reaction with 
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multiple side reactions. The butynol reaction was worse than the propargyl system 
and yields were variable. Even in larger scales the best yield achieved was only 14%. 
One reason for this low yield could be the quality of the ethyl-chioroformate used. 
Although it was freshly distilled it was an old sample and may have had reduced 
activity. It was also found that reduced activity butyl lithium had a negative effect on 
yields, even when it still showed strong activity. Despite the very low yields a low 
yield reaction at the beginning of the synthesis can be accommodated and the 
reaction was not investigated further. 
OH 
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Figure 67. Synthesis of 5-hydroxy-pent-2-ynoate ethyl ester (139), and attempted 
synthesis of iodide (140) 
Deprotection to give (13 9) proceeded in high yield but the same problems with the 
iodination reaction as the propargyl system stopped the synthesis at this stage. 
Repeated attempts using increasingly pure reagents produced no iodide. Analysis of 
the products from the reaction showed the presence of possible elimination products. 
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If this is the case then iodine could be being successfully attached but in the 
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Figure 68. Mesylate and Tosylate alternative pathways 
As with the propargyl system I feel that I spent too long trying to get the iodination 
reaction to work and attempts to work around the impasse should have started earlier. 
A different route to (140) through a mesylate or tosylate system was only attempted 
when stocks of pure (139) were limited and only one attempt at producing the 
mesylate could be attempted and gave inconclusive results. The reaction could only 
be run on a small scale and no pure product was obtained however the hydrogen 
NMR did show strong evidence of product. Figure 68 shows the route that would 
have been attempted had more (139) been produced and is based on a literature 
precedent for a butynol type system. 223 
2.3.3 	o-Cresol system 
With the propargyl and butynol systems failing to reached the stage of producing a 
protected ribonucleoside a third system was investigated in which the chemistry 
involved in synthesis and coupling was known to work. This system was based on 
the simple bromination of cresol. 224  In the synthesis for this linker ortho-cresol is 
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first protected with acetic anhydride to give (141). The methyl group was then 
brominated using N-bromosuccinimide activated with dibenzoyl peroxide to give 
(142). 
CH 3 













Figure 69. O-Cresol System synthesis 
Dibutyltin oxide 









   
145a RCH2CH4O2CCH3 RH 
145b RH W=CH2C6H4O2CCH3 
(144a) 
	 (144b) 
Figure 70. Coupling to uridine 
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The next step after successful bromination is to attach the protecting group to the 2' 
position of a ribonucleoside. The method chosen followed the example of Bremner 
and other syntheses of benzyl ethers 
225  Uridine is first activated by reaction with 
dibutyltin oxide to produce the complex (143). The solvent is then changed from 
benzene to DMF and the alkyl bromide (142) is added. This should give a mixture of 
2' and 3' protected products (144). 
Initial attempts used unprotected uridine and it was envisaged that the two isomers 
might be separable by column chromatography. If not then tritylating the 5' position 
or adding the Markiewicz reagent should allow separation of 3' and 2' protected 
nucleotides. Instead of the mixture of two isomers expected, the reactions produced a 
complicated mixture of at least four uridine-containing compounds. Attempts to 
isolate the isomers by chromatography were unsuccessful. An attempt to react the 
mixture with dimethoxytrityl chloride to produce the tritylated mixture (145) was 
unsuccessful and the mixture appeared unaltered. 
The facts that dimethoxytrityl had not reacted with the mixture and that more 
isomers were present than there should be suggested that the acetyl group was mobile 
during the reaction and was transferring to the hydroxyl positions of the ribose. This 
explains why 5' protection had appeared to have little effect. The acetyl group may 
transfer inter or intra-molecularly but either way it is possible to get a large number 
of combinations. For example compound 144a could have an acetyl group, having 
transferred from (142), covering the 5' hydroxyl group or the 2' hydroxyl group or 
both. When taken with 144b this gives eight possible compounds, only half of which 
would have a free 5' position to react with a trityl group. 
A small sample of 5' Thf-C 10-Tr-Urdine was then used in the coupling reaction. By 
covering the 5' position at the start it should greatly reduce the number of isomers 
and correctly protected uridine might be recoverable. Unfortunately the small amount 
of product recovered (146) was difficult to characterise. As the stock of Thf-C 10-Tr 
(115) and its precursors was very low the Tbf C8 ester material (109) was used 
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instead. The Grignard reaction with bromobenzene proceeded in good yield to give 
the alcohol (147). Coupling to uridine was completed in very good 75% yield to give 
4' -(1 O-( 1 7'-tetrabenzo [a,c,g,i]fluorenyloctyloxy)-trityl-oxy-5 '-uridine (148). The 
marked improvement over the C10 system is probably an indication in improvement 
in technique and the addition of the excess nucleotide and not an inherent difference 







(146) 	 (146) 
Figure 71. Coupling to Tbf C 1 Tr protected Uridine 
Coupling of bromo cresol to (148) produced a much simpler mixture of isomers 
(149) but purification was still extremely difficult and a wide range of solvent 
mixtures were tried in an effort to achieve separation. Mass spectrometry was used to 
identify the correct molecular weight compound. It was noticed during this process 
that the major product was mono acetylated Tbf-C 1 0-Tr-uridine with a trace amount 
of diacetlyated product present. This suggests that the transfer of acetate groups 
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could occur by an intermolecular process as well as intra-molecularly. Eventually 












0 OH 	 HO 0 
io 
(149a) 	 (149b) 
Figure 72. Synthesis and coupling of Thf C8 Tr protected Uridine 
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An excess of the protecting group was used for most of these coupling reactions 
due to the reactivity of the alkyl bromide. Rapid deterioration is marked by 
discolouration and increased acidity. This excess would have hindered the reaction 
due to the fact that acetates were migrating and potentially blocking both free sites 
on the uridine. This probably accounts for the very low yields and in future reactions 
the level of uridine and protecting group should be equivalent. 
Despite the potential doubt over the material collected being protected and 
acetylated in the correct position, the compound was subjected to a simulation of 
deprotection techniques, the results of which were followed by mass spectrometry. 
The compound was stirred as a suspension in 30% ammonia solution at 55°C 
overnight. After this time the mass spectrum showed the elimination of the acetate 
protection. The material was then added to 2% TFA in 50ml water for one hour at 
room temperature. Thin layer chromatography showed that the sample had been 
broken down further and included a spot consistent with uridine. Attempts to isolate 
uridine were unsuccessful, due to the very small quantity available. Although this is 
far from a rigorous proof of the mechanism, it does give encouragement that this 
system could be refined to produce a feasible protecting group. 
2.4 Conclusion and Future work 
2.4.1 5' Protection 
5' Thf C 1 0 trityl protected nucleosides have been successfully synthesised in good 
yields. They have been incorporated into an oligomer and used to purify that 
oligomer to a high degree in a single step using the existing deprotection protocol 
designed for the dimethoxy trityl group. Some further developments could be 
investigated to improve coupling yields and purification. 
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Introducing a simple alcohol to trap the traces of acetyl chloride and the use of a 
coupling catalyst such as N,N-dimethylaminopyridine (DMAP) should significantly 
improve the coupling yields and raise then from the 68-83% range and closer to the 
90+ achieved for dimethoxy trityl. 
Some alterations to the protocol may improve yields. Steps such as taking greater 
care with the phosphoramidites keeping the samples cold and oxygen free before 
their use on the automated instrumentation may improve the yield for addition to the 
growing solid phase chain. The effect on yield of the lengthening the coupling time 
for the final step could also be furthered investigated. These steps might improve the 
yield for this crucial reaction. 
Optimising the purification protocol to take full advantage of the properties of Tbf 
should eliminate the presence of truncated sequences completely from the final 
product. The protocol used was designed to take advantage of the small increase in 
hydrophobicity from DMTr and not the larger influence of Tbf. Optimising 
purification could also raise the recovered yield of the final step if it is found that 
there is incomplete cleavage of the Tbf 5' protecting group. If this were the case then 
some of the product sequence would have remained attached to the Tbf group and 
would not have been recovered. Monomethoxy trityl is less acid labile than the 
dimethoxy trityl and therefore Tbf C 10Tr will also be less labile. Different 
deprotection conditions should be investigated to ensure maximum yield and 
minimal depurination. 
Finally, different linker sizes should be investigated with respect to the coupling of 
the protected oligonucleotide on the solid support. One carbon has been proved to be 
too short and ten carbons have been shown to work. An optimum chain length may 
exist where yields for coupling and synthesis are maximised. 
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2.4.2 2' Protection 
The concept behind the butynol and propargyl systems was never tested due to the 
failure to solve the problem of converting the hydroxyl group to a leaving group 
suitable for coupling to a nucleotide. The decision to look for a way around the 
problem was taken too late when time and stocks were depleted. If this project was to 
be taken further, the tosylate or mesylate system should be investigated and then 
either used directly or first converted to the alkyl iodide. It would also be worth 
looking at the butyllithium step, as the yields were variable but constantly poor. 
The cresol system has successfully been coupled to uridine but with disappointing 
results. A small amount of pure material was collected and its deprotection did 
appear to work but the scale was small and the results are inconclusive. If this system 
was to be reinvestigated an alternative protection should be placed on the hydroxyl 
group of the benzene ring. The acetate protection proved too labile under the 
conditions used and even with 5' protected nucleotides, produced low yields and 
multiple isomers. Before attempting to alter the hydroxyl protection, a test system 
should be made to evaluate the deprotection. For example coupling the protecting 
group to a 5' protected thymidine, where the acetate has no place to migrate, should 
allow higher yields of protected nucleoside to be obtained for testing the theory of 
deprotection in a more rigorous fashion. If this proves encouraging then various base 
labile groups could be used to protect the hydroxyl group and investigated. 
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Chapter 3 Experimental 
3.1 Notes on Instrumentation and General TechniQues 
Nuclear Magnetic Resonance Spectroscopy 
'H NMR 
Routine proton nuclear magnetic resonance spectra were measured on a Varian 
Gemini 200 (200MHz) spectrometer. Higher field spectra for characterisations were 
measured on BrUcker AC250 (250MHz) spectrometer. Deuterated solvents were used 
as indicated and samples contained no external reference. 
' 3C NMR, 31P NMR and 2D ('H-'H and 'H-' 3 C) NMR 
Carbon, Phosphorus and two dimensional nuclear magnetic resonance spectra were 
run on a Brucker AC250, DPX360 or AC200 spectrometers. Carbon spectra were run 
at 62MHz, Phosphorus at 100MHz, 'H-'H COSY at 250MHz or 360MHz and 1 H-' 3 C 
at 360MHz and 91MHz. Deuterated solvents were used as indicated and samples 
contained no external reference. 
Infra-Red Spectroscopy 
Infrared spectra were obtained using a Bio-Rad FTS-7 spectrophotometer. Samples 
were prepared as indicated as either Nujol mulls, KBr discs, between KBr discs neat 
if a liquid or dissolved in Bromoform if a solid. 
Mass Spectrometry 
High and Low Mass Spectra using Fast atom bombardment (FAB) techniques were 
recorded on a Kratos MS50 TC spectrometer. Electron impact (El) analyses were 
recorded on a Kratos analytical profile spectrometer. Experiments were run using 3- 
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nitrobenzyl alcohol (NOBA) or a-monothioglycerol as the matrix. LCQ negative 
ionisations were recorded on a Finnigan MAT LCQ spectrometer. 
Liquid Chromatography Mass Spectroscopy 
Liquid Chromatography Mass Spectroscopy (LCMS) was performed on a Waters 
Alliance 2690 HPLC system with the gradient 100% water to 100% Acetonitrile over 
30 minutes. Negative ionisation was created with 50 Volts. The Mass Spectrometry 
was a micromass platform 2. 
Ultraviolet Spectroscopy 
Ultraviolet spectra were run using dichloromethane as the solvent on a Perkin 
Elmer Lambda 11 spectrophotometer. 
Elemental Analysis 
Elemental analysis for carbon, hydrogen, nitrogen and chlorine was performed on a 
Perkin Elmer 2400. Compounds containing the polycyclic aromatic structure 
Tetrabenzo[a,c,g,ifluorene routinely afforded low carbon values due to incomplete 
combustion. Studies with extended combustion times and the use of catalysts such as 
vanadium oxide did not improve the results obtained for the carbon values of such 
systems. 168 
Melting Points 
Melting points were determined on a Buchi 510 apparatus using open capillaries 
and are reported uncorrected. 
High Pressure Liquid Chromatography 
Reverse-phase high performance chromatography (RP-HPLC) was used for all 
I-IPLC except for the testing of the oligonucleotides at Link Technologies Ltd where 
a normal phase Hypersil C18 4.6x150 mm HPLC column at a flow rate of lmllmin 
was used. The RP-HPLC was performed using a Gilson system comprising of two 
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306 solvent delivery systems, an 81 1C dynamic mixer, an 805 manmetric module, a 
119 UV/VIS detector and a Gilson software driven gradient controller. An Aquapore 
reverse phase silica column (300A particle size) 10cm C 41  internal diameter 4.1mm 
using a flow rate of lmllmin was used. 
Gradients used (A) Acetonitrile, (B) water. 
(1) 0-4mm 50%A; 4-24mm 50-90%A; 24-28mm 90%A; 28-30mm 90-50%A for 
reverse phase with samples dissolved in Acetonitrile and a minimum of Dioxan and 
(2) 0-30mm 10-100%A, 30-35mm 100%A for normal phase with the samples 
dissolved in Acetonitrile DCM 10/1. 
Thin Layer Chromatography and Flash Column Chromatography 
All thin layer chromatography samples were run on precoated plastic sheets with 
Kiesogel 60 1254. Solvent systems used (a) DCM, (b) DCM/ Hexane 3:1, (c) DCMI 
Hexane 1:1, (d) 10% Methanol in DCM, (e) 5% Methanol in DCM (f) 1:1 Ethyl 
Acetate and Hexane (g) 30% Hexane in Ethyl Acetate. Spots were identified using 
ultra violet light at 254nm or 352nm or using a Potassium Permanganate dip. 
For flash column chromatography, Silica gel 60 (230-240 mesh) was used. 
Solvents and Chemicals used 
All chemicals were purchased from Acros Ltd or Aldrich Ltd and used without 
further purification unless stated, except for tetrazole diisopropylarnmonium salt 
(DIHT) and Tetraisopropyl cyanoethyl phosphoramidite which were obtained from 
Link Technologies Ltd and the protected nucleotides, which were from Raylo 
chemicals Ltd. Dry solvents were distilled in the presence of the following drying 
agents. THF (Sodium wire and Benzophenone as indicator), DCM (Calcium 
Hydride) and Pyridine (Phosphorus pentachioride). 
The pre-packed polypack columns were proprietary products from Glen Research, 
Sterling, Virginia, USA. 
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3.2 Synthetic Procedures 
Ethyl 4-(10 bromodecyloxy)-benzoate (98) 
Ethyl 4-hydroxybenzoate (5.13g 3 immol) in DMF (50m1) was added dropwise to a 
suspension of sodium hydride (1.69g 60% by weight 42mmol) in DMF (50m1). After 
1.5 hours stirring at RT dibromodecane (31.2g 1 O4mmol) in DMF (1 40m1) was 
added and the reaction stirred at RT for a further 19 hours. The reaction was then 
quenched with 1 00m of water and 1 00m saturated solution of NH 4C1. The products 
were extracted with 3x1 OOml of diethyl ether. The organics were dried with 
magnesium sulfate and the solvent removed under high vacuum. The product was 
then purified by flash column chromatography (using Hexane till the dibromodecane 
was removed, DCMJHexane 3:1 then DCM) and recrystallised from ethanol to give a 
colourless powder. (9.3g 78%); m/z HRMS (FAB) found 385.13660 C 19H2903Br 
requires 385.13783; C.H.N. found C, 59.46 H, 7.98 required C, 59.4 H, 7.60; Vmax ; 
(KBr Disc) 2992, 2926, 2850, 1708, 1605, 1512, 1467 cm'; 2 max ; 258.7nm; Rf (A) 
0.60; 811  (CDC13 250 MHz); 7.98-7.94 (2H, m, aromatic), 6.89-6.86 (2H, m, 
aromatic), 4.36-4.28 (2H, q, COO-CH 2), 4.00-3.95 (2H, t, O-CH 2), 3.41-3.36 (2H, t, 
R-CH2-Br), 1.86-1.72 (4H, m, alkyl), 1.4301.25 (15H, m, alkyl); 5 c (CDCl 3 63 MHz); 
166.3 (ci), 162.7 (q), 131.3 (CH), 122.5 (ci) 113.8 (CH), 68.0 (CH 2), 60.4 (CH203.8-
28.0 (9 x CH2), 14.2 (CH3). 
Bis-phenanthren-9-yl methanol (99) 
9-Bromophenanthrene (50g 194mmol) in dry THF (120m1) was added dropwise to 
magnesium turnings (5g 207mmol) and some crystals of iodine. The solution was 
allowed to stir at RT for 2.5 hours. Methyl formate (4.3m1) was then added dropwise 
and the reaction stirred for 3 hours. The mixture was then poured into 200ml of 2M 
HCI solution and ice. Diethyl ether (200m1) was added and the entire solution 
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filtered. A white solid was collected which was washed with more water and ether. It 
was then dried with magnesium sulfate to give a fine colourless powder (31g 83%); 
mlz (El) 384 (M) HRMS (FAB) found, 384.15101 C2911200  calculated as 384.15142; 
C.H.N. found C, 85.22 H, 5.77 required C, 90.625 H, 5.21; Vmax ; (DCM) 3583, 3063, 
2963, 2856, 1603, 1495, 1450 cm'; Xmax ; 255, 278, 299 & 331m; Rf(A) 0.45; Mp 
-P240°C; 8, (CDC1 250 MHz); 8.80-8.79 (211, dd, aromatic), 8.76-8.70 (211, dd, 
aromatic), 8.14 (211, dd, aromatic), 7.81-7.51 (12H, m, aromatic), 7.25 (111, s, 
aromatic), 2.5 (1H, s, CH); & (CDC1 3 63 MHz); 136.3, 131.2, 130.8, 130.3, 130.0, 
129.0, 126.9, 126.7, 126.4, 126.1, 124.3, 123.2, 122.3, 69.7, 67.0. 
Tetrabenzo [a,c,g,ilfluorene (100) 
Triflouroacetic acid (3 Omi) was added to bis-phenanthren-9-yl methanol (31g) in 
DCM (200m1) and the suspension was stirred for 1.5 hours. After which time the 
solution was filtered and the precipitate was washed with more DCM and with water. 
The powder was then dried to give a fine yellow powder. (20.5g 69%); m/z (El) 366 
(M) FIRMS (FAB) found, 3 66. 14191 C 29H18 calculated as 366.14085; C.H.N. found 
C, 93.93 H, 4.86 C 29H 18 required C, 95.08 H, 4.91; V max ; 3060, 1610, 1500 cm'; Xmax ; 
377, 338, 303, 251 nm; Rf (A) 0.82; Mp -265 °C; oH (CDC13 250 MHz); 8.84-8.56 
(21-1, m, aromatic), 8.29-7.08 (15H, m, aromatic), 5.39 (1H, s, CH); 8 (CDC1 3 63 
MHz) 148.3, 141.3, 138.0, 137.3, 136.7, 136.0, 135.4, 135.3, 134.1, 133.2, 132.4, 
130.7, 130.7, 130.3, 129.4, 128.6, 128.4, 128.2, 127.9, 127.5, 127.5, 127.2, 126.9, 
126.6, 126.6, 126.5, 126.3, 126.2, 126.0, 125.8, 125.6, 125.3, 125.1, 124.9, 124.6, 
124.2, 123.6, 123.5, 123.2, 121.2, 87.2, 53.1. 
(Note: there are two isomers of Tbf present leading to a greater number of signals in 
the NMR) 
Chapter 3 Experimental 
	
100 
Ethyl 4-(10-(tetrabenzo [a,c,g,i] fluorenyl)decyloxy)-benzoate (102) 
Tetrabenzo[a,c,g,i]fluorene (2.00g 5.5mmol) was suspended in dioxan (lOOmi) and 
was heated to 80°c while being flushed with nitrogen for -2hrs. Ethyl 4-(10 
bromodecyloxy)-benzoate (2.07g 5.4mmol) was dissolved in dioxan (30m1) and 
Nitrogen was bubbled through for -2hrs. A solution of NBu 4OH (3.88g 6.Ommol) 
was prepared in the same way with dioxan (30m1). All three solutions were kept 
under Nitrogen before being used. 
The Tbf suspension was heated to reflux. The Thf dissolved at -70 0c to give a clear 
deep blue solution. The NBu4OH solution was then added via a syringe and the 
mixture allowed to reflux for ten minutes. The ethyl 4-(10 bromodecyloxy)-benzoate 
solution was then added in the same manner and the mixture was refluxed for a 
further 2 hours, after which time the reaction was allowed to cool overnight before 
being filtered. The solvent was removed in vacuo to leave a dark red oil. The product 
was isolated by flash column chromatography. Beginning with DCMlhexane 3:1 then 
progressing up to DCM then finally 5% methanol in DCM. The product was a foam 
and could not be recrystallised (3.1 Og 86%). m/z (FAB) 670 (M) C 48H4603 ; HRMS 
(MH) found 671.35267 requires 671.352352; C.H.N. found C, 85.15 H, 6.95 
C48H4603 required C, 85.97 H, 6.87; max (KBr) 3066, 2919, 2848, 1701, 1605, 
1508, 1498 cm'; X max ; 255, 289, 301, 365, 381m; Rf(A) 0.6; Mp -60 °C; H (CDC1 3 
250 MHz); 8.83-8.77 (4H, m, aromatic), 8.71-8.66 (2H, m, aromatic), 8.28-8.23 (2H, 
m, aromatic), 7.99-7.93 (2H, m, aromatic), 7.73-7.57 (8H, m, aromatic), 6.87-6.81 
(2H, m, aromatic), 5.06-5.01 (1H, t, tbf alkyl CH), 4.40-4.29 (2H, q, COO-CH 2), 
3.90-3.84 (2H, t, O-CH2), 2.66-2.56 (2H, m, alkyl), 1.69-0.35 (19H, m, alkyl); 
(CDC13 63 MHz); 166.2, 162.5, 144.1, 136.5, 135.8, 131.2, 130.1, 128.6, 127.8, 
127.2, 126.5, 125.6, 125.4, 124.8, 124.2, 123.2, 122.3, 113.7, 67.8, 60.3, 47.0, 33.3, 
29.1, 28.9, 28.8, 28.7, 28.5, 25,5, 21.9, 15.0, 14.1. 
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4-(1O-(1 7'-Tetrabenzo [a,c,g,iI fluorenyl)decyloxy)-4' ',4' ' '-dimethyl 	trityl 
alcohol (104) 
4-Bromotoluene (5.54g 32.4mmol) in THF (20m1) was added via a syringe to 
magnesium turnings (0.79g 32.5mmol) and a catalytic amount of iodine in THF 
(40m1). The syringe was then washed through with more TI-IF (20m1). The solution 
was then refluxed for one hour. Ethyl 4-(10-(tetrabenzo[a,c,g,i]fluorenyl)decyloxy)-
benzoate (2.17g 3 .24mmol) in TI-IF (60m1) was then added dropwise. The dropping 
funnel was then washed through with a further 60m1 of THF. The mixture was then 
refluxed for another three hours The reaction was then quenched with a saturated 
solution of NH4C1 (-100m1). The organics were extracted with dichioromethane and 
dried (MgSO4). After removal of the solvent a yellow oil remained (3.7g). The 
product was then isolated by flash column chromatography using 1:1 DCMlhexane. 
The product was a foam which could not be recrystallised (2.23g 85%); m/z (El) 808 
(M) HRMS (El) found 808.42587, C 60H5602 calculated as 808.42803; C.H.N. found 
C, 86.56 H, 7.22 required C, 89.07 H, 6.98; max;  (KBr) 3382, 3057, 2921, 2850, 
1605, 1503, 1436 cm'; X max; 254, 289, 301, 365, 381 nm; Rf (A) 0.54; 6 H (CDC13 250 
MHz); 8.84-8.78 (4H, m, aromatic), 8.72-8.69 (2H, m, aromatic), 8.28-8.24 (2H, m, 
aromatic), 7.74-7.60 (8H, m, aromatic), 7.37-7.10 (1 OH, m, aromatic), 6.81-6.77 (2H, 
m, aromatic), 5.05-5.01 (1H, t, Tbf alkyl CH), 3.86-3.81 (3H, t, CH 3), 2.71 (1H, s, 
OH), 2.66-2.58 (2H, m, alkyl), 2.35-2.33 (6H, m, alkyl), 1.68-0.36 (16H, m, alkyl); 
(CDC1 3 63 MHz); 158.0, 144.3, 144.3, 139.1, 136.7, 136.5, 131.1, 130.3, 128.9, 
128.7, 128.2, 128.2, 127.9, 127.6, 127.3, 126.7, 125.7, 125.5,- 124.9, 124.3, 113.5, 
81.3, 67.7, 47.1, 33.4, 29.2, 29.0, 29.0, 28.6, 25.7, 22.0, 20.9. 
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4-(10-(17'-Tetrabenzo a,c,g,iJfluorenyl)decyloxy)-4' ' ,4' ' '-dimethyl 	trityl 
chloride (105) 
4-( 1 O-( 1 7'-Tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-4' ',4' ' '-dimethyl trityl alcohol 
(0.719g 0.89mmol) and acetyl chloride (1.7g 21.7mmol) were combined in dry 
DCM(20m1) and stirred under nitrogen overnight (18 hours) at room temperature, 
after which time the solution was evaporated to dryness. Dry THF (lOmi) was added 
and the solution evaporated to dryness again. An orange yellow foam remained 
(0.78g N/A %). (The product is -0.04g over a 100% yield). C.H.N. and Cl found C, 
85.67, H, 6.68, Cl 4.24, C 60H550C1 required C, 87.08, H, 6.70, Cl, 4.28; max;  (Nujol) 
2919,2850, 1502, 1454 cm'; Xmax; 254, 289, 301, 365 and 381m; 8H  (CDC1 3 250 
MHz); 8.84-8.78 (4H, m, aromatic), 8.72-8.69 (2H, m, aromatic), 8.28-8.24 (2H, m, 
aromatic), 7.74-7.60 (8H, m, aromatic), 7.37-7.10 (1 OH, m, aromatic), 6.81-6.77 (2H, 
m, aromatic), 5.05-5.01 (1H, t, Tbf alkyl CH), 3.86-3.81 (3H, t, CH 3), 2.66-2.58 (2H, 
m, alkyl), 2.35-2.33 (6H, m, alkyl), 1.68-0.36 (16H, m, alkyl); & (CDC1 3 63MHz) 
144.3, 142.7, 137.3, 137.0, 131.1, 130.8, 130.3, 129.5, 129.1, 128.8, 128.4, 128.2, 
127.9, 127.6, 127.4, 126.7, 125.8, 124.9, 124.3, 123.4, 113.2, 67.8, 47.1, 33.4, 29.2, 
29.02, 28.99, 28.6, 25.7, 22.0, 21.6, 20.9. 
Ethyl 4-(10 bromooctyloxy)-benzoate (107) 
Ethyl 4-hydroxybenzoate (8.611 g 51 .9mmol) in DMF (lOOmi) was added dropwise 
to a suspension of sodium hydride (2.566g 60% by weight 64.1mmol) in DMF 
(lOOmi). After 1.5 hours stirring at RT dibromooctane (41.4g 151.6mmol) in DMF 
(lOOmi) was added and the reaction stirred at RT for a further 24 hours. The reaction 
was then quenched with 1 OOml of water and 1 OOml NH 4C1 saturated solution and the 
products were extracted with diethyl ether. The organics were dried with Magnesium 
Sulfate and. the solvent removed under high vacuum. The product was then purified 
by flash column chromatography, beginning with DCM/Hexane 3:1 then progressing 
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up to DCM then finally 5% Methanol in DCM, and recrystallised from methanol to 
give a colourless powder. (12.69g. 68%); mlz HRMS (El) found 356.09871 and 
358.09790 C 17H2503Br requires 356.09939 and 358.09679; C.H.N. found C, 57.33 H, 
7.35 required C, 57.15 H, 7.05; Mp 39°C; Vmax ; (DCM solution) 2932, 2855, 1705, 
1604cm'; Rf (A) 0.73; H  (CDC13 250 MHz) 8.00-7.94 (2H, dt, 9.00Hz and 2.43Hz), 
6.91-6.85 (2H, dt, 8.99Hz and 2.42Hz), 4.37-4.29 (2H, q, 7.13Hz), 4.01-3.96 (2H, t, 
6.49Hz), 3.42-3.37 (2H, t, 6.81Hz), 1.88-1.73 (4H, m), 1.46-1.34(11H, m); & 
(CDCI3  63 MHz); 166.3, 162.7, 131.4, 122.5, 113.9, 67.9, 60.5, 33.9-25.8 (7 peaks), 
14.3 
Ethyl 4-(10 bromopropyloxy)-benzoate (108) 
Ethyl 4-hydroxybenzoate (8.78g 52.9mmol) in DMF (lOOml) was added dropwise 
to a suspension of sodium hydride (2.589g 60% by weight 64.7mmol) in DMF 
(1 OOml). After 1 hour stirring at RT dibromopropane (32.2g 1 59mmol) in DMF 
(lOOmi) was added and the reaction stirred at RT for a further 48 hours. The reaction 
was then quenched with lOOmi of water and lOOml NH 4C1 saturated solution and the 
products were extracted with diethyl ether. The organics were dried and the solvent 
removed. The high vacuum was required to remove all the DMF. The product was 
then purified by flash column chromatography, beginning with DCMlhexane 3:1 
then progressing up to DCM then finally 5% methanol in DCM. The final product 
was a clear liquid. (1 1.34g, 74.7%) m/z HRMS (El) found 286.02036 and 288.01855 
C 12H1503Br requires 286.02046 and 288.01854; C.H.N. found C, 50.11 H, 6.40 
required C, 50.19 H, 5.27; max;  (KBr Disc) 3076, 2977, 1709, 1606cm'; R f (A) 
0.71; H  (CDC13 250 MHz) 8.00-7.96 (2H, 9.00Hz), 6.92-6.88 (2H, 9.00Hz), 4.37-
4.29 (2H, q, 7.13Hz), 4.16-4.11 (2H, t, 5.8Hz), 3.61-3.56 (2H, t, 6.39Hz), 2.37-2.27 
(2H, 6.11Hz), 1.39-1.33(3H, 7.12Hz); o (CDC1 3 63 MHz) 166.2, 162.2, 131.4, 
123.0, 113.9, 65.3, 60.5, 32.0, 29.6, 14.2. 
Chapter 3 Experimental 
	
104 
Ethyl 4-(10-(tetrabenzoa,c,g,ifluorenyl)octyloxy)-benzoate (109) 
Tetrabenzo[a,c,g,i]fluorene (5.02g 13.7minol) was suspended in dioxan (200m1) 
and was heated to 800c while being flushed with nitrogen for —2hrs. Ethyl 4-(10 
bromooctyloxy)-benzoate (4.82g 13.5mmol) was dissolved in dioxan (50m1) and 
nitrogen was bubbled through for 2hrs. A solution of NBu 4OH (9.73g 15.Ommol) 
solution was prepared in the same way with dioxan (50m1). All three solutions were 
prepared then kept under Nitrogen before being used. 
The Tbf suspension was heated to reflux. The Thf dissolved at -70 0c to give a clear 
deep blue solution. The NBu4OH solution was then added via a syringe and the 
mixture allowed to reflux for ten minutes. The ethyl 4-(10 bromooctyloxy)-benzoate 
solution was then added in the same manner and the mixture was refluxed for a 
further 2 hours, after which time the reaction was allowed to cool overnight before 
being filtered. The solvent was removed in vacuo to leave a dark red oil. The product 
was isolated by flash column chromatography , beginning with DCM/hexane 3:1 
then progressing up to DCM then finally 5% methanol in DCM, to give a foam 
which could not be recrystallised. (7.07g 81.6%); mlz (FAB) 642 (M); HRMS (M) 
found 642.31334 C 46H4203 requires 642.31340 (MH) found 643.32125 requires 
643.32122; C.H.N. found 82.93 C, 6.45 H required 85.95 C, 6.59 H; Vmax ; (DCM) 
3018, 2970, 1701, 1604 cm'; Rf (A) 0.77; H  (CDC13 250 MHz); 8.82-8.75 (6H, m), 
8.70-8.67(2H, dd, 1.48Hz and 8.00Hz), 7.98-7.92 (2H, d, 9.00Hz), 7.73-7.58 (8H, 
m), 6.8 1-6.75 (2H, d, 8.99Hz), 5.02-4.99 (1H, t, 4.37Hz), 4.39-4.31 (2H, q, 7.13Hz) 
3.75-3.70 (2H, t, 6.59Hz), 2.64-2.56 (2H, dt), 1.49-0.75 (13H, m) 0.37-0.31 (2H, m); 
(CDC13 63 MHz); 166.3, 162.6, 144.2, 136.7, 131.3, 131.1, 128.7, 127.9, 127.3, 
126.7, 125.8, 125.5, 124.9, 124.3, 123.4, 122.4, 113.8, 67.8, 60.4, 47.1, 33.3, 29.1, 
28.6, 28.5, 25.3, 22.0, 14.3. 'H-'H COSY Spectra (CDC1 3 250MHz) See Appendix. 
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Ethyl 4-(10-(tetrabenzo [a,c,g,ilfluorenyl)propyloxy)benzoate (110) 
Tetrabenzo[a,c,g,i]fluorene (2.01g 5.5mmol) was suspended in dioxan (100m!) and 
was heated to 80°c while being flushed with nitrogen for -'-2hrs. Ethyl 4-(10 
bromopropyloxy)-benzoate (1.611g 5.61mmol) was dissolved in dioxan (30m1) and 
Nitrogen was bubbled through for -2hrs. A solution of NBu 4OH (3.87g 6.Ommol) 
solution was prepared in the same way with dioxan (30m1). All three solutions were 
prepared then kept under Nitrogen before being used. 
The Thf suspension was heated to reflux. The Tbf dissolved at -70 °c to give a clear 
deep blue solution. The NBu4OH solution was then added via a syringe and the 
mixture allowed to reflux for ten minutes. The ethyl 4-(10 bromopropyloxy)-
benzoate solution was then added in the same manner and the mixture was refluxed 
for a further 2.5hours, after which time the reaction was allowed to cool overnight 
before being filtered. The solvent was removed in vacuo to leave a dark red oil. 
Attempts to isolate the product by flash column chromatography, using a range of 
different solvent combinations. Crude NMIR does however show product. Reaction 
repeated with the same result. 
Ethyl 4-methoxy benzoate (111) 
Potassium carbonate (50g. 363mmol) methyl iodide (45m1, 722mmo1) and ethyl 4-
hydroxybenzoate (12.Og 72.3mmol) were stirred together as a suspension in acetone 
(300ml) for 17 hours overnight at RT under Nitrogen. After this time the t.l.c. 
showed no Ethyl 4-hydroxybenzoate remaining. The acetone was removed before 
water and ether were added. The organic extracts were dried washed with Na 2 S203 
solution and solvent removed. (12.26g 94.2%) mlz HRMS (FAB) found 180.07792 
C 10H1203 requires 180.07864; V max ; (KBr plates) 3072, 2977, 2838, 1708, 1605cm'; 
R1 (A) 0.63; oH  (CDC13 250 MHz) 7.99-7.95 (2H, dd, 6.9Hz 2.1Hz) 6.91-6.85 (214, 
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dd, 6.911z 2.1Hz), 4.36-4.27 (211, q, 7.13Hz), 3.81 (311, s), 1.37-1.32 (3H, t, 7.13Hz); 
(CDC13 63 MHz) 166.2 (C=O), 163.0 (aromatic C-0), 131.3 (aromatic CH), 
122.7(aromatic C-CO), 113.3 (aromatic CH), 60.4 (CH 2), 55.1 (CH3-0) 1  14.2 (CH3-
C). 
4- Methoxy triphenyl methanol (112) 
Bromobenzene (7.64g 48.7mmol) in THF (40m1) was added dropwise to 
magnesium turnings (1.22g 50.2mmol) and a catalytic amount of Iodine also in THF 
(40m1) at RT under nitrogen. The solution was refluxed for 45mins then ethyl 4-
methoxy benzoate was added in THF (40m1) and the solution was refluxed for a 
further 3.5 hours. The reaction was quenched by the addition of NH 4C1 solution and 
the organics were extracted with ether. The ether was dried and solvent removed to 
give the product which was recrystallised from propan-2-ol. (4.23g 89.8%); m/z 
HRMS (FAB) found 290.13147 C20H1802 requires 290.13068; C.H.N. found C, 
82.63 H, 6.11 required C, 82.73 H, 6.25 max;  (KBr Disc) 3434, 3017, 2969, 1605, 
1507, 1444, 1247cm'; Rf (A) 0.50; H  (CDC13 250 MHz); 7.31-7.25 (1011, m) 7.20-
7.16 (21-1, d, 9.03Hz), 6.86-6.82 (21-1, d, 9.03Hz), 3.80 (311, s), 2.85 (11-1, s); 6(CDC1 3 
62 MHz), 15 8.5, 146.9, 13 9.0, 129.1, 124.74, 127.71, 127.0, 113.0, 81.6, 55.1. 
4 Methoxy triphenyl methyl chloride (1 13)226 
4-Methoxy triphenyl methanol (2.00g 6.9mmol) and acetyl chloride (5m1 70mmol) 
were combined in dry Benzene (lOmi) and stirred under Argon overnight (22 hours) 
at room temperature, after which time the solution was evaporated to dryness. Dry 
Benzene (1 Omi) was added and the solution evaporated to dryness again. An orange 
yellow powder remained. This was used without further purification or 
characterisation. 
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5'-4-Methoxy trityl thymidine (114) 158 
Thymidine (1.60g 6.63mmol) was twice co-evaporated with dry Pyridine (-5m1) 
then added to 4-Methoxy triphenyl methyl chloride (6.90mmol) in dry pyridine 
(6m1). The reagents were then stirred under Argon for seven days. Solvent was then 
removed under high vacuum and the residue was dissolved in water and DCM. The 
organics were separated, dried with magnesium sulfate and purified by flash column 
chromatography, using DCH/hexane 3:1 then progressing to DCM and DCM with 
methanol from 1 to 5%. giving a white solid (3.90g 57%); m/z (FAB) 537 (Me  and 
Na) C30H30N206 calculated as 514; C.H.N. found, C, 68.94 H, 6.12 N, 4.99 required 
C, 70.02 H, 5.88 N, 5.44; Mp 96-98°C, literature Mp 102-105°C V max  (CBr4, KBr 
plates) 3384, 3019, 1682, 1508, 1250cm'; H  (CDC13 250 MHz) 9.47 (1H, s), 7.60-
7.59 (1H, d, 1.08Hz), 7.42-7.14 (12H, m) 6.85-6.81 (2H, d, 8.91Hz), 6.46-6.40 (1H, 
t, 5.95Hz), 4.56 (1H, m), 4.08-4.07 (1H, m), 3.77 (3H, s), 3.49-3.32 (2H, m) 3.21 
(1H, broad), 2.42-2.30 (2H, m), 1.43 (3H, d, 0.74Hz); E (CDC1 3 62 MHz) 163.9, 
158.6, 150.5, 143.7, 143.6, 135.6, 134.7, 130.2, 129.0, 128.2, 127.9, 127.7, 127.1, 
127.0, 113.1, 113.0, 111.2, 87.0, 86.1, 84.6, 72.3, 63.6, 55.1, 40.8, 11.7. 
4-(10-(17' -Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl alcohol (115) 
4-Brombenzene (15.9g, lOimmol) in THF (50m1) was added via a syringe to 
magnesium turnings (2.40g 97.2mrnol) and a catalytic amount of iodine in THF 
(50m1). The solution was then refluxed for 30mins. Ethyl 4-(10-
(tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-benzoate (6.52g 9.73mmol) in THF (13 Omi) 
was then added dropwise. The mixture was then refluxed for another five hours The 
reaction was then quenched with a saturated solution of NH 4C1 (-400m1). The 
organics were then extracted with dichioromethane and dried (MgSO 4). After 
removal of the solvent a yellow oil remained. The product was then purified by flash 
column chromatography using 1:1 DCM/Hexane. (6.29g 82.8%) m/z HRMS (FAB) 
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found 780.39841 C 58H5202 calculated 780.39673; C.H.N. found C, 90.23 H, 7.02 
required C, 89.19 H, 6.71; Mp 75-76°C; V max ; 3419.6, 3017.6, 2970.0, 1640.1, 
1140.7cm'; X max; 288.7, 301.3, 365.1, 381.5nm; Rf (A) 0.76 (B) 0.59; H (CDC1 3 250 
MHz); 8.83-8.78 (4H, m), 8.71-8.67(211, dd, 7.97Hz and 1.39Hz), 8.28-8.24 (2H, m), 
7.74-7.59 (8H, m), 7.35-7.24(1011, m), 7.17-7.11 (2H, d, 8.89Hz), 6.81-6.75 (211, d, 
8.91Hz), 5.07-5.03 (1H, t, 4.30Hz), 3.85-3.80 (2H, t, 6.56Hz), 2.77 (1H, broad), 
2.66-2.58 1(2H, dt, ll.85Hz and 4.47Hz), 1.67-1.56 (2H, m), 1.27-1.15 (2H, m), 1.05-
0.73 (10H, m), 0.38-0.32 (211, m) ö (CDC1 3 63 MHz); 158.1, 147.0, 144.3, 138.8, 
136.7, 131.1, 130.3, 129.0, 128.7, 127.9, 127.7, 127.4, 127.0, 126.7, 125.8, 125.5, 
124.9, 124.4, 123.4, 113.6, 81.6, 67.8, 47.1, 33.4, 29.2, 29.0, 28.6, 25.7, 22.0; 1 H - 
COSY (CDC13 360MHz) - See appendix. 
4-(10-(17'-Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl chloride (116) 
4-( 1 0-( 17' -Tetrabenzo[a,c,g,i]fluorenyldecyloxy)-trityl alcohol (1.00g 1 .28mmol) 
and acetyl chloride (5ml 70mmol) were combined in dry Benzene (20ml) and stirred 
under nitrogen for 22 hours at room temperature. After which time the solution was 
evaporated to dryness. Dry benzene (lOmI) was added and the solution evaporated to 
dryness again. An orange yellow foam remained (1.02g 100%). C.H.N. and Cl 
found C, 87.98 H, 6.40, Cl, 1.46, C 58H51 0C1 required C, 87.13, H, 6.43, Cl, 4.43; 
Vmax ; 3017, 2925, 2853, 1714, 1605, 1503 cm'; H (CDC1 3 250 MHz); 8.83-8.78(411, 
m), 8.71-8.67(2H, dd, 7.97Hz and 1.39Hz), 8.28-8.24 (2H, m), 7.74-7.59 (811, m), 
7.35-7.24 (10H, m), 7.17-7.11 (2H, d, 8.89Hz), 6.81-6.75 (2H, d, 8.91Hz), 5.07-5.03 
(1H, t, 4.30Hz), 3.85-3.80 (2H, t, 6.56Hz), 2.66-2.58 (211, dt, 11.85Hz and 4.47Hz), 
1.67-1.56 (2H, m), 1.27-1.15 (211, m), 1.05-0.73 (10H, m), 0.38-0.32 (211, m) 
(Note: The t.1.c. of the product did show two spots, consistent with product and 
starting trityl alcohol being present. However, it was shown that in the solvent 
system used silica can convert the chloride back to the alcohol.) 
Chapter 3 Experimental 
	
109 
4'-(10-(17'-Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5 '-thymidine (117) 
4-( 1 0-( 1 7'-tetrabenzo{a,c,g,i]fluorenyldecyloxy)-trityl alcohol (2.0179g 2.5 8mmol) 
and acetyl chloride (I ml 14mniol) were combined in dry benzene (lOmi) and stirred 
under nitrogen for 24 hours at room temperature, after which time the solution was 
evaporated to dryness. Dry Benzene (lOmi) was twice added and the solution 
evaporated to dryness again to leave 4-(10-(17'-tetrabenzo[a,c,g,i] 
fluorenyldecyloxy)-trityl chloride as an orange solid. 
Thymidine (0.708g 2.94mmol) was twice co-evaporated with dry pyridine (-5m1) 
then added to the 4-(10-(17'-tetrabenzo[a,c,g,i]fluorenyldecyloxy)-trityl chloride 
(2.58mmol) in dry pyridine (15m1). The reagents were then stirred under argon for 
seven days. Solvent was then removed under high vacuum. The residue was 
dissolved in water and DCM. The organics were separated, dried with calcium 
carbonate and purified by flash column chromatography, using DCM and methanol 0 
to 10%, to give a colourless powder as product, which could not be recrystallised. 
(2.Og 77%); mlz HRMS (FAB) found 1004.47666 C 68H64N206 requires 1004.47644; 
Mp 123-125°C; C.H.N. found C, 78.19 H, 6.33 N, 2.64 required C, 81.25, H, 6.42 N, 
2.79; "'max,  (DCM) 3387, 3018, 2924, 2855, 2360, 1683, 1247 cm'; V max  (CBr4 , KBr 
plates) 3379, 3187, 3017, 2924, 2851, 1692, 1679, 1504, 1468, 1248cm'; X max; 301.4, 
364.94, 380.8 nm; Rf (A) 0.00 (D) 0.73; 5 11 (CDC13 250 MHz); 9.06 (1H, s), 8.81-8.76 
(4H, m), 8.69-8.65 (2H, dd, 7.97Hz and 1.27Hz), 8.27-8.23 (2H, m), 7.72-7.57 (9H, 
m), 7.41-7.19 (12H, m), 6.79-6.75 (2H, d, 8.90Hz), 6.44-6.38 (1H, t, 5.91Hz), 5.06-
5.02 (1H, t, 4.28Hz), 4.59-4.57 (1H, m), 4.08-4.02 (1H, m), 3.83-3.78 (2H, t, 
6.52Hz), 3.52-3.32 (2H, m), 2.65-2.56 (2H, m), 2.45-2.29 (2H, m), 1.65-1.53 (2H, 
m), 1.41-0.71 (17H, m) 0.33 (2H, m); 8 c (CDCI 3 63MHz) 163.7, 158.2, 150.4, 144.2, 
143.8, 143.7, 136.7, 135.6, 134.3, 131.2, 130.25, 128.7, 128.2, 127.9, 127.8, 127.7, 
127.3, 127.1, 126.7, 125.8, 125.5, 124.9, 124.3, 123.4, 113.6, 111.1, 87.1, 86.0, 84.5, 
72.2, 67.8, 64.3, 63.6, 62.9, 52.7, 47.1, 40.8, 33.4, 29.2, 29.0, 28.6, 25.7, 25.2, 22.0, 
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11.6, 7.7; 'H - COSY (CDC1 3 360Mhz) and 'H / 13C Correlation Spectra (CDC1 3 
360MHz and 901v[Hz) - See appendix. 
4 1 -(10-(17'-Tetrabenzo [a,c,g,iJ fluorenyldecyloxy)-trityl-oxy-5'-uridifle (118) 
4-( 1 O-( 1 7'-tetrabenzo [a,c,g,i]fluorenyldecyloxy)-trityl alcohol (0. 508g 0.65mmol) 
and acetyl chloride (3m1 42mmol) were combined in dry benzene (lOmi) and stirred 
under Nitrogen for 24 hours at room temperature, after which time the solution was 
evaporated to dryness. Dry benzene (lOmi) was twice added and the solution 
evaporated to dryness again to leave 4-(10-(17'-tetrabenzo{a,c,g,i] 
fluorenyldecyloxy)-trityl chloride as an orange solid. 
Uridine (0.1 62g 0.66mmol) was twice co-evaporated with dry pyridine (-'5 ml) then 
added to the 4-( 1 0-( 17' -tetrabeazo [a,c,g,ifluorenyldecy1oxy)-trityl chloride 
(0.65mmol) in dry pyridine (lOmi). The reagents were then stirred under Argon for 
seven days. Solvent was then removed under high vacuum. The residue was 
dissolved in water and DCM. The organics were separated, dried with calcium 
carbonate and purified by flash column chromatography using DCM and methanol 0 
to 10%, to give a colourless powder as product, which could not be recrystallised. 
(0.30g 46%); m/z HRIvIS (FAB) found 1007.4633 1 C 67H62N207 requires 1007.46318; 
C.H.N. found C, 74.03 H, 6.42 N, 2.78 required C, 79.92 H, 6.46 N, 2.78; (CBr 4 KBr 
Disc) 3388, 3018, 2923, 2851, 1681, 1461, 1247, 1141cm'; Rf(A) 0.00 (D) 0.57; 5H 
(CDCI3  250 MHz); 8.83-7.18 (29H, m), 6.79-6.76 (211, d, 8.90Hz), 5.85-5.81 (111, d 
2.4Hz) 5.06-5.03 (1H, t, 4.3Hz), 4.41-4.37 (1H, m), 4.25-4.21 (114, m), 4.13-4.11 
(1H, d, 4.33Hz), 3.84-3.77 (2H, m), 3.46 (2H, m), 2.62-2.56 (2H, m), 2.17-0.71 
(16H, m), 0.35-0.25 (2H, m); 8 c (CDC13 62 MHz) 163.5, 158.2, 150.8, 144.2, 140.2, 
136.7, 134.0, 131.8, 131.1, 130.3, 130.2, 129.7, 128.7, 128.2, 127.9, 127.8, 127.7, 
127.3, 127.3, 127.0, 126.7, 126.1, 125.8, 125.5, 124.9, 124.3, 123.4, 121.9, 113.6, 
Chapter 3 Experimental 
	 111 
102.0, 90.1, 87.1, 83.6, 75.4, 69.7, 67.7, 61.9, 47.1, 45.2, 33.4, 29.6, 29.3, 29.2, 29.0, 
28.8, 28.5, 25.7, 22.6, 22.0, 14.0, 8.5. 
4'-(10-(1 7'-Tetrabeiizo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5'-N 2-isobutyryl-
2 '-deoxyguanosine (119) 
4-( 1 0-( 17 '-Tetrabenzo[a,c,g,i]fluorenyldecyloxy)-trityl alcohol (1.53 68g 1 .9mmol) 
and acetyl chloride (1.5m1 21mmol) were combined in dry benzene (5m1) and stirred 
under Nitrogen for 24 hours at room temperature, after which time the solution was 
evaporated to dryness. Dry benzene (lOml) was twice added and the solution 
evaporated to dryness again to leave 4-(10-(17'-tetrabenzo[a,c,g,i] 
fluorenyldecyloxy)-trityl chloride as an orange solid. 
N2-Isobutyryl-2'-deoxyguanosine (0.76g 2.3mmol) was twice co-evaporated with 
dry pyridine ('--5m1) then added to 4-(10-(17'-tetrabenzo[a,c,g,i]fluorenyldecyloxy)-
trityl chloride (1.9nimol) in dry pyridine (15m1). The reagents were then stirred under 
Argon for seven days. Solvent was then removed under high vacuum. The residue 
was dissolved in water and DCM. The organics were separated, dried with calcium 
carbonate and purified by flash column chromatography, using DCM and methanol 0 
to 10%, to give a colourless powder as product, which could not be recrystallised. 
(1.4g 68.2%); inlz FIRMS (FAB) found 1100.53541 C721170N506 requires 
1100.53261; Mp 152-153°C; C.H.N. found C, 76.42 H, 6.48 N, 6.04 required C, 
78.59 H, 6.32 N, 6.36; V max  (CBr4, KBr plates) 3361, 3187, 3017, 2925, 2851, 1947, 
1673, 1605, 1559, 1248cm'; 2 max  301, 365, 381m; Rf (A) 0.0 (E) 0.75; ö (CDCI 3 
250 MHz) 12.30 (1H, s, NH), 9.9 (1H, s, NH), 8.78-8.64 (6H, m), 8.25-8.19 (2H, m), 
7.78-7.11 (21H, m), 6.70-6.66 (2H, d, 8.89Hz), 6.15 (1H, broad), 5.00-4.97 (1H, tbf 
alkyl CH, t, 4.21Hz), 4.70 (1H, m), 4.48 (1H, broad), 4.17 (1H, m), 3,75-3.70 (2H, t, 
6.16Hz), 3.29 (211, m), 2.58-2.24 (5H, m), 1.56-1.50 (2H, m), 1.26-0.67 (18H, m), 
0.31 (2H, m). & (CDCI 3 63Hz) 179.8, 158.0, 155.7, 149.9, 148.3, 147.6, 144.2, 
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144.0, 143.9, 137.8, 136.6, 134.8, 131.1, 130.2, 130.0, 128.6, 128.2, 127.9, 127.6, 
127.3, 126.8, 126.7, 125.7, 125.5, 124.9, 124.3, 121.0, 113.4, 86.4, 84.4, 71.7, 67.7, 
64.1, 47.1, 40.3, 35.9, 33.4, 29.2, 29.0, 28.6, 25.7, 22.0, 18.7. 'H - COSY (CDC13 
360MIHz) - See appendix 
4'-(10-(17'-Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5'-N 4-benzoyl-2 '-
deoxycytidme (120) 
4-(10-(17'-Tetrabenzo{a,c,g,i]fluorenyldecyloxy)-trityl alcohol (1.517g 1 .9mmol) 
and acetyl chloride (1.5m1 21mmol) were combined in dry benzene (5m1) and stirred 
under nitrogen for 24 hours at room temperature, after which time the solution was 
evaporated to dryness. Dry benzene (lOml) was twice added and the solution 
evaporated to dryness again to leave 4-(10-(17'-tetrabenzo[a,c,g,i] 
fluorenyldecyloxy)-trityl chloride as an orange solid. 
N4-Benzoyl-2'-deoxycytidine (0.86g 2.6mmol) was twice co-evaporated with dry 
pyridine (-5m1) then added to the 4-( 1 0-( 17' -tetrabenzo [a,c,g,i]fluorenyldecyloxy)-
trityl chloride (1.9mmol) in dry pyridine (lOmi). The reagents were then stirred under 
Argon for seven days. Solvent was then removed under high vacuum. The residue 
was dissolved in water and DCM. The organics were separated, dried over calcium 
carbonate and purified by flash column chromatography, using 0 to 10% methanol in 
DCM, to give a colourless powder as product, which could not be recrystallised. 
(1.72g 83.2%); mlz HRMS (FAB) found 1094.51081 C 74H68N306 requires 
1094.51082; Mp 136°C; C.H.N. found C, 78.72 H, 6.22 N, 3.74 required C, 81.22 H, 
6.17 N, 3.84; max  (CBr4, KBr plates) 3649, 3389, 3060, 3018, 2925, 2852, 1949, 
1811, 1697, 1649, 1481, 1391, 1310, 1249cm'; max 3014, 365.0, 381.7nm; Rf (A) 
0.0 (E) 0.78; H  (CDC1 3 250 MHz); 8.81-8.76 (4H, m) 8.69-8.65 (2H, dd, 7.99Hz and 
1.47Hz), 8.27-8.23 (2H, m), 7.92-7.11 (27H, m) 6.83-6.80 (2H, d, 8.95Hz), 6.33-6.24 
(1H, m), 5.05-5.02 (IH, t, 4.36Hz) 4.37-4.36 (1H, m), 4.26-4.25 (1H, m), 3.86-3.80 
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(2H, t, 6.49Hz), 3.47-3.46 (2H, m), 2.88-2.75 (2H, m), 2.64-2.56 (2H, m), 1.65-1.53 
(2H, quintet, 7.02Hz), 1.37-0.70 (8H, m), 0.33 (2H, m); 6 (CDC1 3 62 MHz); 162.1, 
158.2, 144.6, 144.2, 143.7, 143.6, 136.6, 134.4, 132.8, 131.1, 130.2, 128.7, 128.2, 
127.9, 127.4, 127.3, 127.0, 126.6, 125.7, 125.5, 124.9, 124.3, 123.3, 113.6, 96.5, 
87.2, 87.0, 86.3, 70.7, 67.7, 65.7, 62.6, 47.0, 41.9, 33.3, 29.2, 29.0, 28.6, 25.7, 22.0, 
15.1. 'H-COSY (CDC1 3 360MHz) - See appendix 
4'-(10-(17'-Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5 '-N 6-benzoyl-2'-
deoxyadenosine (121) 
4-( 1 0-( 1 7'-Tetrabenzo [a,c,g,i]fluorenyldecyloxy)-trityl alcohol (2.00g 2.5 7mmol) 
and acetyl chloride (imI 14mmol) were combined in dry benzene (lOmi) and stirred 
under Nitrogen for 24 hours at room temperature, after which time the solution was 
evaporated to dryness. Dry benzene (lOmi) was twice added and the solution 
evaporated to dryness again to leave 4-(10-(17'-tetrabenzo[a,c,g,i] 
fluorenyldecyloxy)-trityl chloride as an orange solid. 
N6-Benzoyl-2'-deoxyadenosine (0.95g 2.8mmol) was twice co-evaporated with dry 
pyridine (-'5m1) then added to the 47.(10-(17'-tetrabenzo[a,c,g,i]fluorenyldecyloxy)-
trityl chloride (2.6mmol) in dry pyridine (15m1). The reagents were then stirred under 
Argon for seven days. Solvent was then removed under high vacuum. The residue 
was dissolved in water and DCM. The organics were separated, dried wioth calcium 
carbonate and purified by flash column chromatography, using 0 to 10% methanol in 
DCM, to give a colourless powder as product, which could not be recrystallised. 
(2.Og 70.4%); mlz HRMS (FAB) found 1118.52248 C 75H68N505 requires 
1118.52205; Mp 130°C; C.H.N. found, C, 75.30 H, 5.94 N, 8.17 required C, 80.55 
H, 6.04 N, 6.26; (CBr4, KBr plates) 3662, 3373, 3017, 2925, 2852, 1949, 1816, 
1692, 1681, 1608, 1504, 1452, 1249cm';A. max ;301.0,365.3,381.0nm;R f (A)0.0(E) 
0.73; H  (CDC1 3 250 MHz); 8.80-8.64 (814, m), 8.30-7.94 (8H, m), 7.71-7.14 (1914, 
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m), 6.75-6.71 (2H, d, 8.97Hz), 6.50-6.42 (1H, m), 5.06-5.02 (1H, t, 4.22Hz), 4.40-
4.32 (1H, m), 3.80-3.76 (2H, t, 4.68Hz), 3.44-3.36 (2H, m), 2.97-2.75 (2H, m), 2.69-
2.50 (2H, m), 1.60-1.51 (2H, m) 1.26-0.69 (12H, m), 0.33 (2H, m); 5 c(CDC13 
63MHz) 170.6, 164.6, 158.1, 152.3, 151.1, 149.3, 144.2, 141.4, 136.6, 134.5, 133.4, 
132.7, 132.6, 131.1, 130.2, 130.1, 128.7, 128.1, 127.7, 127.3, 126.9, 126.7, 125.7, 
125.5, 124.9, 124.3, 113.5, 86.7, 84.5, 72.1, 67.7, 63.7, 63.6, 47.1, 45.6, 39.9, 33.4, 
29.2, 29.0, 28.9, 28.6, 25.7, 22.0. 'H - COSY (CDC1 3 360MHz) - See appendix 
4-Methoxy-trityl-oxy-5'-thymidine-3 '-O-N,N-diisopropy1--cyanoethy1 
phosphoramidite (122) 
4-Methoxy-trityl-oxy-5 '-thymidine 	(0.39g 	0.75 Snmiol) 	and 	tetrazole 
diisopropylammonium salt (DIHT) (0.068g 0.40mmol) were dried by co-evaporating 
with dry acetonitrile (--40m1) three times and then dissolved in dry alcohol-free DCM 
(6m1) and stirred under Argon. Tetraisopropyl .cyanoethyl phosphoramidite (0.38g 
1 .25mmol) was then injected and the solution was stirred at RT for 48 hours. HPLC 
monitoring showed the reaction had gone to completion. Sodium Bicarbonate 
solution was added to quench the reaction then the organics were extracted with 
DCM. The DCM was washed with brine then dried and the solvent removed by 
vacuum. The solid residue was dissolved in the minimum of DCM and precipitated 
in hexane then dissolved in the minimum of ethyl acetate and precipitated in pentane. 
31 P and 'H NIMR were taken at this point. An attempt to further purify using flash 
column chromatography, using 0 to 10% methanol in DCM, was undertaken which 
destroyed the sample. Crude ö (CDC1 3 200 M1-Iz); 7.58 (1H, s), 7.42-7.26 (12H, m), 
6.86-6.82 (2H, d, 8.79Hz), 6.41 (1H, t), 4.57 (1H, m), 4.06-4.05 (1H, d, 2.92Hz), 
3.79 (3H, s), 3.45-3.38 (2H, dq, 11.4Hz and 2.4Hz), 2.37 (2H, m), 1.62-0.82 (21H, 
m); 8P (CDC1 3 101MHz) 149.64, 149.21. 




deoxycytidine-3 '-O-N,N-diisopropy1-3-cyanoethyI phosphoramidite (123) 
4'-(l 0-(I 7'-tetrabenzo{a,c,g,i] 	fluorenyldecyloxy)-trityl-oxy-5 '-N 4-Benzoyl-2 ' - 
deoxycytidine (1.54g 1 .4lmmol) and tetrazole diisopropylammonium salt (DIHT) 
(0.128g 0.748mmol) were dried by co-evaporating with dry acetonitrile (—lOmi) 
three times and then dissolved in dry alcohol-free DCM (8m1) and stirred under 
argon. Tetraisopropyl cyanoethyl phosphoramidite (0.679g 2.26mmol) was then 
injected and the solution was stirred at RT for 24 hours. Sodium bicarbonate solution 
was added to quench the reaction then the organics were extracted with DCM. The 
DCM was washed with brine then dried and the solvent removed by vacuum. The 
solid residue was dissolved in the minimum of DCM and precipitated in hexane then 
dissolved in the minimum of ethyl acetate and precipitated in pentane to give a 
colourless powder that was then dried at RT under vacuum. (1.64g 89.9%); mlz 
(FAB) 1293 (M) C 83H84N507P; FIRMS (MH) found 1294.61869 requires 
1294.61866; Mp 112°C; C.H.N. found C,72.59 H, 6.60 N, 5.73 required C, 77.01 H, 
6.54 N, 5.41; Vmax  (CBr4, KBr plates) 3018, 2925, 2253, 1696, 1656, 1609, 1555, 
1480, 1393 cm'; 2 max ; 301.4, 365.0, 381.lnm; 3 H (CDC13 250 MHz); 8.77-8.66 (6H, 
m), 8.34-8.22 (3H, m) 7.88-7.85 (211, d, 7.2711z), 7.66-7.25 (24H, m), 6.83-6.28 (2H, 
d, 5.92Hz), 6.29-6.28 (1H, d, 4.82Hz), 5.01 (1H, br.$), 4.65-4.63 (1H, m), 4.34-4.08 
(1H, m), 3.94-3.30 (8H, m), 2.83-2.30 (611, m), 1.60 (211, m), 1.36-0.71 (24H, m), 
0.33 (2H, m); 5 c (CDC13 62 MHz); 168.8, 162.1, 158.3, 155.0, 144.3, 143.7, 143.5, 
136.7, 134.4, 132.9, 131.2, 130.3, 128.8, 128.3, 127.9, 127.5, 127.4, 127.2, 127.0, 
125.8, 125.5, 124.9, 124.4, 123.4, 117.8, 115.0, 113.6, 96.5, 87.1, 85.7, 72.5, 71.9, 
67.8, 62.2, 62.1, 60.6, 58.3, 58.0, 47.1, 46.5, 45.6, 43.3, 41.1, 40.9, 40.8, 33.4, 29.3, 
29.0 (m), 28.6, 24.5, 22.4, 22.1, 20.2, 20.1, 19.1;(CDC1 3 101MHz) 150.00, 149.43. 
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4'-(1O-(17'-Tetrabenzo [a,c,g,i]fluorenyl)decyloxy)-trityl-oxy-5'-thymidine-3' - 
O-N,N-diisopropy1--cyanoethy1 phosphoramidite (124). 
4' -(1 O-( 1 7'-Tetrabenzo[a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5 '-thymidine (1 .526g 
1 .5l9mmol) and tetrazole diisopropylammonium salt (DIHT) (0.130g 0.761mmol) 
were dried by co-evaporating with dry acetonitrile (-.iOml) three times and then 
dissolved in dry alcohol-free DCM (8m1) and stirred under Argon. Tetraisopropyl 
cyanoethyl phosphoramidite (0.680g 2.26 immol) was then injected and the solution 
was stirred at RT for 24 hours. HPLC monitoring showed the reaction had gone to 
completion. Sodium Bicarbonate solution was added to quench the reaction then the 
organics were extracted with DCM. The DCM was washed with brine then dried and 
the solvent removed by vacuum. The solid residue was dissolved in the minimum of 
DCM and precipitated in hexane then dissolved in the minimum of ethyl acetate and 
precipitated in pentane to give a colourless powder that was then dried at RT under 
vacuum. (1.324g 72.3%); m/z (FAB) 1293 (M) C771181N407P; HRMS (MH) found 
1205.592 11 requires 1205.59212; Mp 108°C; C.H.N. found C, 72.76 H, 6.69 N, 4.72 
required C, 76.72 H, 6.77 N, 4.65; Vmax  (CBr4, KBr pates) 3019, 2926, 2853, 2256, 
1687cm'; max;  301.3, 365.1, 381.2 Mn; oH (CDCI3 250 MHz); 8.81-8.67 (6H, m), 
8.27-8.23 (211, m), 7.72-7.58 (911, m), 7.43-7.24 (12H, m), 6.81-6.77 (211, dd, 
8.89Hz and 2.58Hz), 6.46-6.38 (1H, m), 5.04-5.01 (1H, t, 4.24Hz), 4.66 (1H, m), 
4.17-4.11 (111, m), 3.85-3.30 (8H, m), 2.64-2.27 (6H, m), 1.64-1.56 (2H, m), 1.43-
0.73 (27H, m) (prominent peaks at 1.18 and 1.15), 0.34 (2H, m).; 6 c (CDC'3 63NIHz) 
163.7, 158.2, 150.3, 144.2, 143.7, 143.6, 136.6, 135.4, 134.2, 131.1, 130.2, 128.7, 
128.2, 127.8, 127.3, 127.1, 126.6, 125.7, 125.5, 124.9, 124.3, 123.4, 117.4-117.2 
(NC-C-C-O-P, d, 14.811z), 113.5, 111.1, 87.0, 85.5-85.2 (CH-C-O-P, d, 14.2Hz), 
84.5, 73.4-73.1 (CH-O-P, m, 16.3Hz), 67.8, 63.2-63.0 (P-O-CH 2 , d, 15.2Hz), 60.3, 
58.3-57.8 (CH2-O-P, m), 47.1, 43.2-43.0 (CH-N-P, m), 33.4, 29.2, 29.0, 28.6, 25.7, 
24.4 (CH3-C-N-P), 22.0, 20.3-20.1 (P-0-C-CH 2-CN, d, 12.3Hz), 11.6 (CH3-C-CO); 
6P (CDC1 3  101MHz) 149.57, 149.14;'H - COSY (CDC13 360IVIIHz) - See appendix 
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4'-(1O-(17'-Tefrabenzo[a,c,g,i] fluorenyl)decyloxy)-trityl-oxy-5'-N 6-benzoyl-2'-
deoxyadenosine-3'-O-N,N-diisopropyI--cyanoethy1 phosphoramidite (125) 
4'-(10-(1 7' -Tetrabenzo [a,c,g,i] 	fluorenyldecyloxy)-trityl-oxy-5 '-N 6-Benzoyl-2 ' - 
deoxyadenosine (1 .56g 1 .39mmol) and tetrazole diisopropylanmionium salt (DIRT) 
(0.130g 0.763mmo1) were dried by co-evaporating with dry acetonitrile (—lOmi) 
three times and then dissolved in dry alcohol-free DCM (8m1) and stirred under 
Argon. Tetraisopropyl cyanoethyl phosphoramidite (0.705g 2.34mmol) was then 
injected and the solution was stirred at RT for 24 hours. Sodium Bicarbonate solution 
was added to quench the reaction then the organics were extracted with DCM. The 
DCM was washed with brine then dried and the solvent removed by vacuum. The 
solid residue was dissolved in the minimum of DCM and precipitated in hexane then 
dissolved in the minimum of ethyl acetate and precipitated in pentane to give a 
colourless powder that was then dried at RT under vacuum. (1.66g 90.6%); mlz 
(FAB) 1317 (M) C 84H84N706P; HRMS (MH) found 1318.62992 requires 
1318.62990; Mp 103-105°C; C.H.N. found C, 72.43 H, 6.85 N, 8.22 required C, 
76.51 H, 6.42 N, 7.44; V max  (CBr4, KBr plates) 3193, 3018, 2927, 2853, 2255, 1682, 
1605, 1557, 1249cm'; X max ; 301.2, 365.1, 381.2nm; 5H (CDC13 250 MHz); 8.80-8.65 
(6H, m), 8.31-7.92 (4H, m), 7.80-7.19 (25H, m), 6.77-6.71 (2H, m), 6.49 (lH, m), 
5.03-5.00 (1H, t, 4.16Hz), —4.8 (1H, m), 4.32 (1H, m), 3.85-3.35 (10H, m), 2.75-2.55 
(4H, m), 1.61-1.56 (2H, m), 1.34-0.71 (24H, m), 0.33 (2H, m); E (CDC1 3 63 MI-Iz); 
158.0, 125.4, 153.0, 151.2, 149.3, 144.2, 143.8, 141.3, 136.6, 134.5, 133.5, 133.2, 
132.5, 131.1, 130.2, 128.9, 128.6, 128.2, 127.9, 127.7, 127.3, 126.8, 126.6, 125.7, 
125.5, 124.8, 124.3, 123.3, 123.2, 117.4-117.3 (CN, d, 8.5Hz), 113.4, 86.6-84.6 
(CH-C-O-P and N-CH-C-C-O-P, m), 73.3-73.0 ( CH-O-P, m), 67.7 (CH 2-0-Ph), 
63.2-63.0 (CH2-C-C-O-P, m), 58.3-57.9 (CH2-0-P, m), 47.1, 43.43.0 (CH-N-P, d, 
12.211z), 39.3 (CH 2-C-0-P), 33.9-25.7 (9 alkyl chain CH2), 20.0-19.7 (CH2-CN), 
14.0-13.9 (CH3); 5(CDCl3 101MHz) 149.94-148.53 (m). 
Chapter 3 Experimental 
	
118 
4'-(1O-(17'-Tetrabenzo [a,c,g,il fluorenyl)decyloxy)-trityl-oxy-5'-N 2-isobutyryl-
2' -deoxyguanosine-3 1 -0-N,N-diisopropy1--cyanoethy1 phosphoramidite (126) 
4' -(1 O-( 1 7'-Tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5 ' -N 2-Isobutyryl-2' - 
deoxyguanosine (1.528g 1 .389mmo1) and tetrazole diisopropylammonium salt 
(DIHT) (0.136g 0.793mmo1) were dried by co-evaporating with dry acetonitrile 
(--i Omi) three times and then dissolved in dry alcohol-free DCM (8m1) and stirred 
under Argon. Tetraisopropyl cyanoethyl phosphoramidite (0.686g 2.278minol) was 
then injected and the solution was stirred at RT for 23 hours. Sodium bicarbonate 
solution was added to quench the reaction then the organics were extracted with 
DCM. The DCM was washed with brine then dried and the solvent removed by 
vacuum. The solid residue was dissolved in the minimum of DCM and precipitated 
in hexane then dissolved in the minimum of ethyl acetate and precipitated in pentane 
to give a colourless powder that was then dried at RT under vacuum. (1. 701 g 94.1%); 
m/z (FAB) 1299 (M) C 81 H86N707P; HRMS (MH) found 1300.64016 requires 
1300.64046; Mp 83-85°C; C.H.N. found C, 72.13 H, 6.80 N, 7.45 required C, 74.80 
H, 6.67 N, 7.54; Vmai  (CBr4, KBr plates) 30147, 2926, 2853, 2254, 1700, 1687, 1607, 
1507, 1452, 1248cm'; Xmax ; 301.2, 365.0, 381.0nm; oH (CDC1 3 250 MHz) 8.80-8.66 
(6H, m), 8.26-8.21 (2H, dd), 7.80-7.19 (21H, m), 6.77-6.71 (211, dd), 6.21-6.16 (114, 
t, 6.68Hz), 5.02-4.99 (1H, t, 4.21Hz), 4.81-4.66 (1H, m), 4.28-4.23 (1H, m), 3.88-
3.25 (8H, m), 2.97-2.89 (1H, m), 2.76-2.24 (6H, m), 1.62-1.54 (2H, m), 1.40-0.72 
(30H, m), 0.33 (2H, m); O (CDC1 3 63 MHz) 178.61-178.58 (NH-CO-R, d, 1.6411z), 
158.1-158.0 (0-C aromatic, d, 3.77Hz), 155.53-155.48 (NH-CO-C-N, d, 3.08Hz), 
147.7-147.0 (1C, m), 147.7-147.0 (1C, m), 144.2, 144.1, 144.0, 143.9, 138.0, 137.1, 
136.6, 134.9, 134.6, 131.1, 130.2, 130.1, 128.6, 1283, 128.2, 128.1, 127.9, 127.7, 
127.6, 127.3, 126.9, 126.8, 126.6, 125.7, 125.4, 124.8, 124.3, 123.34, 123.31, 122.2, 
121.6, 117.57-117.47 (CN, d, 6.8Hz), 113.44-113.34 (aromatic CH, d, 6.29Hz), 
86.44-84.67 (2C, m), 74.43-73.27 (1C, m), 67.7 (CH 2-0-Ph), 57.69-57.17 (CH2-0-P, 
m), 47.0 (tbf-CH-alkyl), 43.07-42.87 (CH-N-P, d, 12.49Hz), 39.80-39.32 (CH 2-C-O-
P, d, 10.33Hz), 35.76-35.63 (CO-CH-C, d, 8.28Hz) 33.3, 30.8, 29.18-22.16 (6C, m), 
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22.0, 20.90-19.84 (CN-CH2-C-O-P, m), 18.61-18.57 (CH 3-C-CO, d, 2.18Hz); 
(CDCI3 101MHz) 149.2, 124.8. 
Prop-2-yn-1-yloxytetrahydropyran (131) 
Dihydropyran (4.31g 51.3mmol) and propargyl alcohol (3.36g 59.9mmol) and a 
catalytic amount (-200mg) of pyridinium p-toluenesulfonate were stirred in an open 
flask with DCM (50m1) for 2.5 hours. The reaction was then added to 200m1 of 2M 
KOH solution and extracted with ether. The ether extracts were then dried and the 
solvent removed in vacuo to leave a clear oil (6.6g 93%). m/z 357, 179 (M) C 8H 1202 
requires 140; C.H.N. found C, 49.41 H, 6.31 C 8H1202 required C, 68.54 H, 8.63 
(sample losing weight); V max; (KBr plates) 3289, 2942, 2853, 1441 cm'; H  (CDC13 
250 MHz); 4.81-4.78 (1H, t, thp), 4.32-4.13 (2H, q, CC-CH 2), 3.87-3.75 (1H, m, 
thp), (3.56-3.45 (1H, m, thp), 2.41-2.38 (1H, t, 2.43Hz CCH), 1.83-1.48 (6H, m, 
thp); 6c (CDC13 63 MHz); 96.7 (CH), 79.6 (CH), 73.8(-CE), 61.8 (CH 2), 53.8 (CH2), 
30.0(CH2), 25.1 (CH2), 18 .8(CH2). 
Pyridinium p-toluenesulfonate (132)227 
p-Toluenesulfonic acid monohydrate (2.32g 12.2mmol) was added to distilled 
pyridine (5.12g 65rmnol) and the mixture was stirred at RT for 30 minutes. The 
excess pyridine was then removed in vacuo to leave a colourless powder. This 
powder was then recrystallised from acetone to give white flakes which were then 
dried (2.21g 72%). oH (CDC13 250 MHz) 8.97-8.94 (2H, d, pyr), 8.43-8.35 (1H, t, 
pyr), 7.96-7.89 (2H, t, pyr), 7.79-7.75 (2H, d, aromatic), 7.14-7.11 (2H, d, aromatic), 
2.30 (3H, s, alkyl). Mp 116°C, literature Mp 117-119°C. 




Each of the reagents had been purged of air by bubbling Nitrogen through for —2 
hours before use. Prop-2-yn-1-yloxy tetrahydropyran (8.05g 57.5mmol) in THF 
(lOmi) was stirred under nitrogen in an acetone I dry ice bath. Butylithium (22m1 of 
2.2M solution 48.4mmol) in THF (lOmi) was then added dropwise. After 20 minutes 
the acetone / dry ice bath was removed. After another 50 minutes l-chloro-3-bromo-
2-methyipropane (10.52g 61.5mmol) in THY (lOml) was added dropwise. The 
solution was then refluxed for 20 hours. After which time 30m1 of ether and 30m1 of 
water were added and the layers separated. The water was washed with more ether 
and the extracts were combined and dried. The solvent was removed in vacuo to give 
an orange solution (9.6g). NMR analysis showed this to be a mix of starting materials 
and the product. Column chromatography, using hexane/DCM progressing to just 
DCM, removed the chloro-3-bromo-2-methylpropane to leave a pale yellow oil 
(6.62g) this was analysed as (71% product and 29% unreacted starting material, 
(prop-2-yn-1-yloxy tetrahydropyran) this was carried through to the next stage 
without further purification. (4.7g 42%), m/z (El) 230 (M-H) 229.09947 found 
C 12H 1802C1 requires 229.09953; max; (KBr plates) 2941, 2869, 1442, 1347, 1264, 
1202, 1120, 1025, 901cm'; 6 H (CDC13 250 MHz); 4.79-4.76 (1H, m), 4.29-4.12 (211, 
m), 3.84-3.75 (1H, m), 3.53-3.39 (3H, m), 2.32-2.27 (2H, m), 2.08-1.98 (1H,m) 1.84-
1.43 (6H, m), 1.05-1.03 (3H, d, 6.73 Hz); 8 c (CDC13 63 MHz); 96.4, 83.4, 73.8, 61.8, 
54.3, 49.3, 34.8, 30.0, 25.2, 23.2, 18.9, 17.2. 
6-Hydroxy-2-methyl-hex-4ynyl p-nitrobenzoate (134) and (135) 
Unpurified 	I -Chloro-2-methyl-6-tetrahydropyranyloxy-hex-4-yne 	(2.00g 
—5.8mmol) and p-nitro sodium benzoate (1.02g 5.4mmol) were refluxed together 
under Nitrogen in DMF (40m1). After six hours the reaction was allowed to cool. 
Ether was added and the solution was filtered. The solvents were removed in vacuo 
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(High vac required) to give a dark red oil (1 .7g). The oil was partially purified by 
flash column chromatography at this stage, using hexanefDCM progressing to just 
DCM, and characterised. mlz (El) 362 (M)' HRMS found 361.15187 C 19HNO6 
requires 361.15254; Vmax ; (KBr plates) 3109, 2942, 2869, 2223, 1724, 1604, 
1528cm'; H  (CDC1 3 250 MHz); 8.30-8.15 (4H, m), 4.78-4.76 (1H, t, 3.2Hz), 4.31-
4.13 (4H, rn), 3.85-3.76 (1H, m); 3.54-3.45 (1H, m); 2.42-2.32 (2H, m), 2.26-2.15 
(1H, m), 1.83-1.47 (6H, m), 1.11-1.09 (3H, d, 6.7Hz); 5 c (CDC13 63 MHz); 164.4, 
150.4, 130.5, 123.4, 83.3, 77.7, 69.1, 61.9, 54.3, 32.1, 30.1, 25.2, 22.9, 18.9, 16.3. 
The oil (1.7g) was then dissolved in methanol (80m1) and added to 15m1 of 5% 
solution of oxalic acid. This mixture was then stirred for 50 hours. The methanol was 
removed before ethyl acetate and water were added and the products extracted. The 
organic layer was dried (MgSO 4) and the solvent removed in vacuo to give an orange 
oil which was then purified by flash column chromatography, using hexane/DCM 
progressing to just DCM, to give a pale orange oil. (1.37g 4.9mmol); mlz (FAB) 279 
(M) C 14H15N05 calculated as 277 C.H.N. found C, 59.21 H, 5.62 N, 4.75 C 14H 15N05 
required C, 60.64 H, 5.45 N, 5.05; max;  (KBr plates) 3418, 3109, 2963, 2925, 2874, 
2221, 1721, 1604, 1527cm 1 ; oH (CDC13 250 MHz); 8.31-8.16 (4H, m, aromatic), 
4.31-4.28 (2H, d, CH2-CO2R), 4.24-4.23 (2H, t, O-CH2-CC), 2.38-2.32 (2H, m, 
C=C-CH2-R), 2.30-2.11 (1H, m, CHR3), 1.77 (1H, s, OH), 1.13-1.10 (3H, d, CH3); & 
(CDC13 63 MHz); 164.5 (C=O), 150.4 (q), 135.4 (q), 130.6 (ar), 123.4 (ar) , 83.2 
(CEC), 80.2 (CC), 69.0 (CH 2), 51.1 (CH202.1 (CH), 22.8 (CH2), 16.3 (CH 3 ). 
But-3-yn-1-yloxytetrahydropyran (137) 
Dihydropyran (6.73g 80mmol) and but-3-yn-1-ol (5.25g 75mmol) and a catalytic 
amount (-200mg) of pyridinium p-toluenesulfonate were stirred in an open flask 
with DCM (40m1) for 6 hours, after which time a t.l.c. showed butynol to still be 
present so an extra 1 .Og of dihydropyran was added and the reaction allowed to run 
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overnight (another 18 hours). The reaction was then added to 200m1 of 2M KOH 
solution and extracted with ether. The ether extracts were then dried with calcium 
carbonate and the solvent removed in vacuo to leave a yellow oil (1 1.39g 
98.6%); nilz 369, 269 (M) C9H1402 requires 154; C.H.N. found C, 58.08 H, 7.67 
C9H1402 required C, 70.10 H, 9.15 (sample losing weight); max;  (KBr plates) 3291, 
2941, 2872, 2119, 1465, 1351 cm-1 ; Rf(A) 0.30; H (CDCl3 250 MHz); 4.63 (1H, t, 
thp) 3.84-3.83 (2H, m, thp), 3,57-3.51 (2H, m, thp), 2.51-2.43 (2H, dt, CH 2-CC), 
1.97-1.95 (1H, t, CC-H), 1.59-1.49 (6H, m, alkyl); 5 c (CDC13 63 MHz); 98.6, 81.3, 
69.0, 65.3, 62.0, 30.4, 25.2, 19.8, 19.2. 
Pent-2-yn-5-oxytefrahydropyran ethyl ester (138) 
Butylithium (21m1 of 2M soP' 42mmol) was added in imi portions slowly to but-3-
yn-1-yloxytetrahydropyran (6.5g 42mmol) in THF (30ml) with a dry ice / acetone 
bath. After addition of the butylithium and solution was stirred for 2 hours then the 
dry ice bath was removed and the reaction was allowed to warm to RT. Then freshly 
distilled ethyl chioroformate (4.9g 45mmol) was added dropwise. The solution was 
left stirring for 1 hour at RT. Ethyl Acetate and brine were then added and the layers 
separated. Organic extracts were dried over MgSO 4 . The solvent was then removed 
in vacuo to give a dark oil. (1.29, 5.7mmol, 13.5%); mlz HRMS (El) found 
226.12071 C 12H1804 requires 226.12051; C.H.N. found, C 62.88, H 8.07 required C 
63.70, H. 8.02; V max ; 2942, 2873, 1710, 1445, 1364, 1253, 1128, 1076, 1039cn1 1 ; Rf 
(A) 0.56 (D) 0.92; 6H (CDC13 250 MHz); 4.63-4.60 (lH, t, 3.3Hz), 4.22-4.13 (2H, dd, 
7.14Hz), 3.89-3.44 (4H, m), 2.64-2.58 (2H, t, 6.9Hz), 1.81-1.47 (6H, m) 1.29-1.24 
(3H, 7.14Hz) E (CDC13 63 MHz); 153.5, 98.6, 86.0, 73.7, 64.2, 62.1, 61.7, 30.0, 
25.2, 20.1, 19.1, 13.9. 
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5-Hydroxy-pent-2-ynoate ethyl ester (139) 
5-Hydroxy-pent-2-ynoate ethyl ester (ig) was dissolved in methanol (40m1) and 
added to 20m1 containing oxalic acid (ig). This mixture was stirred for —50 hours. 
The methanol was removed before ethyl acetate and water were added and the 
products extracted. The organic layer was dried with magnesium sulfate and the 
solvent removed in vacuo to give an oil. (0.6g 93%); mlz HRMS (El) found 
142.063 18 C7H 1003 requires 142.06299; Vmax ; 3400, 2938, 2237, 1708, 1437, 1367, 
1253cm'; Rf (A) 0.1, (D) 0.52; 6H  (CDC13 250 MHz); 4.22 - 4.14 (2H, q, 7.15Hz), 
3.77 - 3.72 (2H, t, 6.36Hz), 2.84 - 2.81(1H, broad), 2.58 - 2.53 (211, t, 6.46Hz) 1.39 - 
1.23 (3H, t, 7.14Hz); 5 c (CDCl3 63MHz) 153.5, 86.1, 74.1, 61.8, 59.7, 22.8, 13.8. 
0-Cresyl acetate (141) 
ortho-Cresol (47.7g 0.42mo1) and acetic anhydride (60m1 0.64mol) were stirred 
together in pyridine (50m1) at RI under air for 48hours. Volatiles were then removed 
by vacuum and the product was distilled (-20mm Hg at 105°C) to give a clear oil 
(61.6g 93%); m/z HRMS (FAB) found 150.6806 C 9H1002 requires 150.6808; Vmax ; 
(KBr plates) 3060, 3029, 2930, 2863, 1759, 1585cm'; oH  (CDC1 3 360 MHz); 7.3 1-
7.18 (3H, m), 7.08-7.06 (1H, m), 2.37 (3H, s), 2.25 (3H, s); O (CDC1 3 63 MHz) 
169.7, 149.8, 131.6, 13 0.5, 127.4, 126.5, 122.3, 21.2, 16.6. 
a-Bromo o-cresyl acetate (142) 
A trace of dibenzoyl peroxide was added to o-Cresyl acetate (20.Og 1 34mmol) and 
N-Bromosuccinimide (23.8g 134nimol) in carbon tetrachloride (60m1) then refluxed 
under air for I .5hours. The solution was then cooled, filtered and the solvent 
removed by vacuum. The product was then distilled. (25.5g 82.7%) m/z HRMS (El) 
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found 229.97665 and 227.97843 C 9H9O2Br requires 229.97667 and 227.97859; V max ; 
(KBr Plates) 3493, 3303, 3062, 3033, 2933, 1763, 1584cm';R f (A) 0.58 (D) 1.0; oH 
(CDC13 250 MIHz); 7.43-7.10 (4H, m), 4.42 (2H, s), 2.36 (3H, s); O (CDC1 3 63 MHz) 
168.8, 148.8, 130.6, 129.7, 129.4, 126.1, 122.9, 27.5, 20.8. 
Mixture of 3'-0 and 2'-O-o-cresyl acetate uridine (143) 
Uridine (2.68g 1 immol) and dibutyltinoxide (2.79g 11 .2mmol) were refluxed 
together in benzene for 3.5hours with continuous extraction of water. The solvent 
was removed by vacuum and bromo o-cresyl acetate (2.90g 12.65mmol) and DMF 
(15m1) were added and the suspension heated to 85°C for 18 hours under Argon. 
Solvent was removed and the product purified by flash column chromatography, 
using hexane/DCM progressing through DCM to DCMlmethanol combinations. 
(1.62g 37%) After columning a complicated mixture of isomers still remained. 2D 
NMR showed the presence of at least four compounds containing Uridine. 
Mixture of 2'-0 and 3'-O-o-cresyl acetate-5'-4 1 , 4"dimethoxy-trityl-oxy-
uridine (145) 
A mixture of 3'-0 and 2'-O-o-cresyl acetate uridine (1.04g 2.6mmol) and 4', 4" 
dimethoxy trityl chloride (1.04g 3 .2mmol) were combined with pyridine (5m1) at 0°C 
under Argon. The solution was allowed to warm to RT and left stirring for 18 hours. 
Methanol was added and then the solvent removed by vacuum. The residue was 
dissolved in DCM and washed with NaHCO 3 solution, dried with calcium carbonate 
then purified by flash column chromatography, using hexane/DCM progressing 
through DCM to DCMlmethanol combinations. Resulted in a complicated mixture of 
compounds largely unchanged from the initial mixture. 
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Mixture of 2'-0 and 3'-O-o-cresyl acetate 4'-(10-(1 7'-tetrabenzo [a,c,g,il 
fluorenyldecyloxy)- 5 1 -trityl-oxy-uridine (146) 
4' -(1 0-( 17' -tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl-oxy-5 ' -uridine (0.14g 0.14 
mmol) and Dibutyltinoxide (0.33g 1.3 immol) were refluxed together in Benzene 
(20m1) for 3.5hours with continuous extraction of water. The solvent was removed 
by vacuum and Bromo o-Cresyl acetate (4.8mmol) and DMF (lOml) were added and 
the suspension heated to 85°C for 20 hours under Argon. Solvent was removed and 
the product purified by flash column chromatography (0.104g 66%). Material 
difficult to characterise. Remade with different linker group. 
4-(10-(17'-Tetrabenzo [a,c,g,ilfluorenyloctyloxy)-trityl alcohol (147) 
4-Bromobenzene (19.Og 121mmol) in THF (50m1) was added via a syringe to 
magnesium turnings (2.97g 121mmol) and a catalytic amount of iodine in THF 
(50m1). The solution was then refluxed for 30mins. Ethyl 4-(10-
(tetrabenzo[a,c,g,i]fluorenyl)octyloxy)-benzoate (7.93g 12.4mmol) in THF (50ml) 
was then added dropwise. The mixture was then refluxed for another four hours after 
which the reaction was then quenched with a saturated solution of NH 4C1 and ice 
(200ml). The organics were then extracted with dichloromethane and dried (MgSO 4). 
After removal of the solvent a yellow oil remained. The product was then isolated by 
flash column chromatography using 1:1 DCM/Hexane. (8.70g 93.6%) mlz (FAB) 
752, 364. HRMS found 752.36533 C56H4802 calculated 752.36543; C.H.N. found C, 
88.63 H, 6.53 requires C, 89.33 H, 6.43; Mp 82-85°C; V max ; cm-'; ?Max;  nm; Rf (A) 
0.72; 8H (CDC13 250 MHz); 8.83-8.70 (6H, m), 8.27-8.23 (2H, m), 7.74-7.60 (8H, m), 
7.38-7.25 (10H, m), 7.17-7.13 (211, d, 9.0011z), 6.76-6.71 (211, d, 8.98Hz), 5.01-4.98 
(11-1, t, 4.30Hz), 3.73-3.67 (2H, t, 6.62Hz), 2.79 (1H, s), 2.66-2.57 (214, m), 1.57-0.76 
(I OH, m), 038-0.37 (214, m); 5 c (CDC13 63 MHz); 158.0, 147.0 5  144.2, 138.7, 136.6, 
131.1, 130.2,129.0, 128.7 5 127.9, 127.7, 127.3, 127.0, 126.6 5 125.7, 125.5, 124.9, 
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124.3, 113.5, 81.6, 67.6, 47.0, 33.3, 29.1, 28.8, 28.7, 28.5, 25.4, 22.0; 'H - COSY 
(CDC1 3 360Mi11z) - See appendix. 
4'-(1O-(17'-Tetrabenzo [a,c,g,ilfluorenyloctyloxy)-trityl-oxy-5'-uridine (148) 
Uridine (1.764g 7.2mmol) was twice co-evaporated with dry Pyridine (-5m1) then 
added to 4-(10-(17'-tetrabenzo[a,c,g,i]fluOrenyloctyloxy)-trityl chloride (2.49g 
3.3mmol) in dry pyridine (lOmi). The reagents were then stirred under Argon for 
seven days. Solvent was then removed under high vacuum. The residue was 
dissolved in water and DCM. The organics were separated, dried with magnesium 
sulfate and purified by flash column chromatography, using DCM/methanol going 
from DCMto 10% methanol. (2.44g 75.3%); mlz 978, 735, 364 FIRMS (FAB) found 
978.42498 C 65H58N207 requires 978.42440; Mp 134°C; C.H.N. found 75.03 C, 5.80 
H, 2.23 N requires 79.73 C, 5.97 H, 2.86 N; Rf (D) 0.44 (F) 0 (H) 0.25; 6H  (CDCI 3 
250 MHz) 10.38 (111, s), 8.84-8.71 (611, m), 8.29-8.27 (211, m), 8.05-8.02 (111, d, 
8.05Hz), 7.74-7.25 (20H, m), 6.78-6.76 (211, d, 8.8911z), 5.92 (1H, s), -5.5 (111, 
broad), 5.37-5.34 (111, d, 8.0411z), 5.08-5.06 (111, t, 4.25Hz), 4.46 (1H, br.$), 4.35 
(111, br.$), 4.19-4.17 (lH, t, 4.9011z), 3.73-3.69 (2H, t, 6.35Hz), 3.57-3.51 (211, m), 
2.64-2.62 (2H, m), 1.48-0.77 (10H, m), 0.38 (211, m); 8 c (CDC13 62 MHz) 163.8, 
158.2, 150.1, 144.2, 144.0, 143.6, 140.3, 136.7, 133.9, 131.1, 130.3, 130.2, 129.0, 
128.7, 128.2, 127.9, 127.7, 127.3, 127.1, 126.7, 125.8, 125.5, 124.9, 124.3, 123.4, 
113.6, 102.1, 90.3, 87.1, 83.4, 75.2, 69.4, 67.6, 61.7, 47.1, 33.36, 29.1, 28.8, 28.7, 
28.5, 25.5, 22.0. 'H-COSY (CDC13 360MHz) - See appendix 
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Mixture 	of 	2'-0 	and 	3 1 -0-o-cresyl 	acetate 	4'-(10-(17'- 
tetrabenzo [a,c,g,i] fluorenyloctyloxy)-trityl-oxy-5'-uridine (149) 
4'-(l O-( 17' -Tetrabenzo[a,c,g,i]fluorenyloctyloxy)-trityl-oxy-5 '-uridine 	(1.00g 
1 .O2nmiol) and Dibutyltinoxide (0.265g 1 .O6mmol) were refluxed together in 
Benzene (15) for 3 hours with continuous extraction of water. The solvent was 
removed by vacuum and Bromo o-Cresyl acetate (0.320g 1.40mmol) and DMF 
(lOmi) were added and the suspension heated to 85°C for 20 hours under Argon. 
Solvent was removed and the product purified by flash column chromatography, 
using DCMlmethanol going from DCM to 10% methanol, leaving (0.372g 32.4%) a 
complex mixture of products. After repeated purification 40mg of pure product was 
isolated (3.5%). m/z HRMS (FAB) found 1127.48588 C 74H67N209 requires 
1127.48466; Rf (F) 0.27 (H) 0.76; H (CDCl3 250 MHz); 10.17(1H, br.$), 8.83-8.72 
(6H, m), 8.31-8.29 (2H, m), 8.01-6.76 (28H, m), 6.03-5.87 (1H, m), 5.41-5.30 (1H, 
m), 5.10 (IH, m), 4.60-4.18 (3H, m), 3.91-3.53 (6H, m), 2.66 (2H, m), 2.37-2.10 
(311, m), 1.71-0.80 (10H, m), 0.40 (2H, m). 
3.2.1 Deprotection Test 
Only 40mg of (149) was collected so deprotection studies were limited in scope. To 
prove the basic theory this sample was subjected to the acid and base conditions 
associated with the intended solid phase synthesis deprotection protocol. 
The 	mixture 	of 	2'-0 	and 	3'-O-o-cresyl 	acetate 	4'-(10-(17'- 
tetrabenzo [a,c,g,i]fluorenyloctyloxy)-trityl-oxy-5 '-uridine was stirred as a suspension 
in 30% ammonia solution at 55°C overnight. The sample was then vacuumed to 
dryness. Dissolved in a minimum of ethyl acetate then precipitated in hexane. T.l.c. 
showed that the majority of starting material had been broken down. The solid 
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collected was analysed by mass spectrometry. mlz 1126 (starting material), 1084 
(Phenol), 1067 (Phenol minus OH). 
The sample was then stirred in 2% TFA 50m1 for one hour at room temperature. 
T.l.c. showed that the sample had been broken down further and included a spot 
consistent with Uridine. Precipitation in hexane from ethyl acetate produced a solid 
as before. Mass spectrometry showed that the phenol has been mostly removed. 
Attempts to isolate Uridine were unsuccessful. 
3.3 Oligodeoxyribonucleotide Synthesis 
3.3.1 Synthesiser details and procedure 
The synthesis of oligodeoxyribonucleotides was performed on an Applied 
Biosystems 380B DNA Synthesiser. The solid support was the silica based Link 
Technologies SynBase support. The linker to the support was a standard succinyl 
group. Thymidine monomers were prepared as their phosphoramidites these were 
then activated with 0.45M tetrazole / acetonitrile solution. Each monomer coupling 
lasted thirty seconds except the final step of addition of the Thf trityl protected 
monomers, which lasted ten minutes. The Thf trityl protected monomers were 
dissolved in 1:1 alcohol-free DCM and dry acetonitrile. Each synthesis was run on a 
0.2 p.mol scale. Acetic anhydride and lutidine in T}{F were used as the capping 
reagents. Oxidation was achieved using a 0.1M Iodine / THF / Pyridine and water 
solution. Acid deprotection was performed using 3% trichloroacetic acid in DCM. 
The cycle details are listed in the appendix. 
At the end of each synthesis the sequences were cleaved from the solid support 
using lml concentrated aqueous ammonia for 20 minutes and the exocyclic amine 
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protecting groups were removed by heating the solution overnight (16hrs) at 45°C. 
The standard protocol designed for dimethoxy trityl suggests 40°C for 24hrs. The 
samples were then vacuumed to dryness at 45°C over three hours and the crude 
residue was analysed by HPLC. 
3.3.2 Purification procedure 
The sample was then dissolved in 1 .5ml of 0. 1M triethylammonium acetate 
(TEAA). The polypak was prepared by running through 2m1 of acetoriitrile then 2m1 
of TEAA. The sample was then loaded onto the polypak. The run off was collected 
and added again to ensure that the entire sample was loaded. The polypak was then 
eluted with 3m1 of ammonium hydroxide (1:20) solution then 2m1 of HPLC water. 
Trifluroacetic acid 2m1 was then added and allowed to elute over two minutes, this 
was repeated three times. Next 2m1 of HPLC water was added and washed through. 
Finally 2m1 of 20% acetonitrile was eluted and collected to wash off the purified 
oligonucleotide. This sample was then analysed by HPLC and LCMS. 
3.3.3 Results 
Overall yield and the average yield per-cycle were measured by analysing the 
absorbance at 490nm of the acid cycle washes, thus measuring the quantity of 
dimethoxy trityl removed. These figures therefore do not include the final addition of 
Tbf trityl protected monomer, which was not removed in this way. Concentration of 
the final oligomer is measured using the absorbance at 260nm using the known 
absorbance of the monomers. Using this figure for the final concentration of 
oligomer and knowing the average yield per-cycle for the dimethoxy trityl steps 
allows the yield for the final step to be calculated. Crude refers to samples before 
purification and therefore still contains the TV trityl-protecting group. Purified refers 
to samples after purification and therefore have had the group removed. 




Crude HPLC; (Area %, retention time in minutes) 7mer sequence (40.8%, 4.53), 
8mer sequence plus protecting group (45.0%, 24.78); Purified IIIPLC; 7mer 
sequence (1.18%, 6.60), 8mer sequence (96.69%, 6.86); Overall yield 95.2%; 
Average yield per cycle 98.8%; yield of 8mer sequence 0.065 p.mols; Final step 
yield 34.0%; Purified mlz 2370.98 (M), 2067.27 (7mer). 
Cytidine (12 8) 
Crude HPLC; (Area %, retention time in minutes)) 8mer sequence (73.5%, 23.49); 
Purified HPLC 7mer sequence (16.6%, 6.57), 8mer sequence (75.3%, 6.88); 
Overall yield 96.3%; Average yield per cycle 99.1%; yield of 8mer sequence 
0.1062 j.tmols; Final step yield 55.1%; Purified mlz 2355.87(M 1), 2067.20 (7mer). 
Adenosine (129) 
Crude HPLC; (Area %, retention time in minutes)) 7mer sequence (30.3%, 4.57), 
8mer sequence (10.0%, 23.13 and 25.3%, 23.67), solvent peak (21.7%, 33.10-33.22); 
Purified HPLC 7mer sequence (11.7%, 6.63), 8mer sequence (76.4%, 6.88); 
Overall yield 94.3%; Average yield per cycle 98.5%; yield of 8mer sequence 
0.0234 j.tmols; Final step yield 12.4%; Purified m/z 2380.14 (M), 2067.04 (7mer). 
Guanidine (13 0) 
Crude HPLC; (Area %, retention time in minutes)) 7mer sequence (29.4%, 4.59), 
8mer sequence (18.9%, 23.19), solvent peak (42.8%, 33.16); Purified HPLC 7mer 
sequence (23.2%, 6.58), 8mer sequence (67.1%, 6.83); Overall yield 95.1%; 
Average yield per cycle 98.8%; yield of 8mer sequence 0.062 j.tmols; Final step 
yield 32.7%; crude in/z 3158.25 (M+), 2066.38 (7mer); Purified mlz 2396.00 (M), 
2066.99 (7mer). 
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Chapter 5 	Appendices 
5.1 Abbreviations 
2D NMR 2 dimensional NMR 
A Adenine 
AIDS Acquired Immune Deficiency Syndrome 
Bz Benzoyl 
br.s Broad singlet 
C Cytosine 
CPG Controlled pore glass 
Ctmp 1 -[(2-chloro-4-methyl)phenyl] 4-methoxypiperidin-4-yl 
Cpep 1 -(4-chlorophenyl) 4-ethoxypiperidin-4-yl 
d Doublet 
dA Deoxyadenine 
DATE 1,1 -dianisyl-2,2,2-trichloroethyl group 




DIHT Tetrazole diisopropylammonium salt 
dINPEOC 2,2' -bis(2-nitrophenyl)ethoxycarbonyl 
DMAP N,N-Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMTr 4/4' Dimethoxytrityl 
DNA Deoxyribonucleic acid 
dT Deoxythymidine 
EDTA Ethylene diamine tetraacetic acid 
El Electron impact 
FAB Fast atom bombardment 
FDA Food and drug administration of the USA 
Fmoc 9-Fluorenylmethoxycarbonyl 
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Fpmp 1 (2..Fluoropheny1)-4-methoxyPiPeridifl--4-Yl 
G Guanine 
HCMV Human Cytomegalovirus 
HG Hoogsteen 
HIFA 2-Hydroxyisophthalate formaldehyde acetal 
HIPLC High performance liquid chromatography 
iBu Isobutyrl 
1ev Levulinyl 
LCMS Liquid chromatography mass spectrometry 
M multiplet 
Me Methyl 
MMTr Mono methoxy trityl 
MP Melting point 
mRNA Messenger RNA 
MS Mass spectrometry 
MSC1 2,4,6-trimethylbenzenesulfonyl chloride 
MSNT 2,4,6trimethy1benzenesulfony1-3-nitro-1,2,4-triaZOle 
Mthp 4-Methoxytetrahydropyran-2-yl 
NMR Nuclear magnetic resonance spectroscopy 
NVOC 6-nitroveratryloxycarbonyl 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PGC Porous graphitised carbon 
pixyl 9-Phenylxanthen-9-yl 
ppm Parts per million 
PPTS Pyridinium p-toluenesulfonate 
RNA Ribonucleic acid 
rRNA Ribosomal RNA 
rp-HPLC Reverse phase HPLC 
RT Room temperature 
s Singlet 
SEM (Trimethylsilyl)ethoxymethyl ether 
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S-Pixyl 	 9-Phenylthioxanthen-9-yl 
SPS 	 Solid phase synthesis 
t 	 Triplet 
T 	 Thymidine 
TFA 	 Trifluroacetic Acic 
TBAB Tetrabutylammonium bromide 
TBAF Tetrabutylammonium fluoride 
TBDMS t-butyldimethylsilyl 
Tbf 4-(1 7-tetrabenzo[a,c,g,ifluoromethyl) 
Tbf C8 Tr 4-(8-(1 7' -tetrabenzo [a,c,g,i]fluorenyloctyloxy)-tritYl 
Tbf C8 Tr Cl 4(8(17'tetrabenzo[a,c,g,i]fluorenylOCtylOXy)-tfltyl chloride 
Tbf CIO  Tr 4-(1 O-( 17' -tetrabenzo [a,c,g,i]fluorenyldecyloxy)-trityl 
Tbf C10 Tr Cl 4(10(17'tetrabenzo[a,c,g,i]fluoreflyldeCyloXy)-tr1tYl chloride 
Tbf C10 DMTr 4-( 1 O-( 17' -tetrabenzo [a,c,g,i]fluorenyldecyloxy)- 4' ,4' '- 
dimethyl trityl 
Tbf C10 DMTr Cl 	4-( 1 O-( 17' -tetrabenzo [a,c,g,i]fluorenyldecyloxy)- 4' ,4' '- 
dimethyltrityl chloride 
Tbf DMTr 	4-( 1 7-tetrabenzo [a,c,g,i]fluoromethyl)-4' ,4' '-dimethoxytrityl 
TV DMTr Cl 	4-( 1 7-tetrabenzo [a,c,g,i]fluoromethyl)-4' ,4' '-dimethoxytrityl 
chloride 
Tbfmoc 	 Tetrabenzo[a,c,g,i]fluorenyl- 1 7-methanol 
TEA.3HF 	Triethylamine trihydrogen fluoride 
TEAA Triethylammonium Acetate 
TESC1 1,1 ,3,3-Tetraisopropyl-3-(2- 
(Triphenylmethoxy)ethoxy)disiloxane- l-yl chloride 
TFA Trifluroacetic acid 
THF Tetrahydrofuran 
Thp 	 Tetrahydropyran-2-yl 
TIPDSI 	 1,1,3 ,3-Tetraisopropyldisiloxane 
Tic 	 Thin layer chromatography 
TPSC1 	 2,4,6-triisopropylbenzenesulphonyl chloride 
tRNA 	 Transfer RNA 
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U 	 Uridine 
UV 	 Ultra violet 
5.2 2D J'MR 
All NIvIR experiments were conducted using CDC13 as the solvent and samples 
contained no external reference. Frequencies were 250 MHz for hydrogen, 'H - 
COSY at 360MHz, carbon at 63 and 'H / 13 C Correlation Spectra used 360MHz and 
90MHz. 
Ethy1_4(10_(tetrabenzo[a,c,g,iJfluoreny1)octy1OXY)-benZOate (109) 
H (CDC13 250 MHz) H's assignment COSY correlations 
8.82-8.75 6 A A 
8.70-8.67 2 A A 
7.98-7.92 2 D2 D, 
7.73-7.58 8 A A 
6.81-6.75 2 D, D2 
5.02-4.99 1 B C, 
4.39-4.31 2 E F 
3.75-3.70 2 C8 C7 
2.64-2.56 2 C, B and C2 
1.49-0.75 13 C3 to C7 and F C2 to C8 and F to E 
0.37-0.31 2 C2 C, and C2 
F 
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4.-(10-(17 1 -tetrabenzo [a,c,g,i] fluorenyldecyloxy)-trityl alcohol (115) 
H's assignment COSY correlations 
8.83-8.78 4 A A 
8.71-8.67 2 A A 
8.28-8.24 2 A A 
7.74-7.59 8 A A 
7.35-7.24 10 E E 
7.17-7.11 2 D2 D1 
6.81-6.75 2 DI D2 
5.07-5.03 1 B C1 
3.85-3.80 2 C10 C9 
2.77 1 F 
2.66-2.58 2 C1 B and C2 
1.67-1.56 2 C9 C8 
1.27-1.15 2 C8 C7 and C9 
1.05-0.73 10 C3-C7 C2 to  C8 
0.38-0.32 2 C2 C1 and C3 
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5 '-O-4'-(1O-(17'-tetrabenzo a,c,g,iJfluorenyIdecy1oxy)_trity1-thymidine (117) 
H's Assignment 'H - COSY 
Correlations 
& from 'H / ' 3C 
Correlations 
9.06 1 M - - 
8.81-8.76 4 A A -424 
8.69-8.65 2 A A —128 
8.27-8.23 2 A A --126 
7.72-7.57 9 8A and K AtoA,KtoL A:126to130,L 
-436 
7.41-7.19 12 l0eand2D2 EtoE,D,toD2 128to132 
6.79-6.75 2 D1 D2 113.6 
6.44-6.38 1 J I —85 
5.06-5.02 1 B C1 47.1 
4.59-4.57 1 H G and I 72.2 
4.08-4.02 1 G F and H 87.1 
3.83-3.78 2 C 1 0 C9 67.8 
3.52-3.32 2 F G 64.3 
2.65-2.56 2 C i B and C 1 33.4 
2.45-2.29 2 I H and J 40.8 
1.65-1.53 2 C9 C7 and  C9 —30 
1.41-0.71 17 C3to C8 C2 toC8 --30 
0.33 2 C2 C1 and C3 22.0 
E 
A 	 0 
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5' -O-4'-(10-(17'-tetrabenzo [a,c,g,ifluoreny1decy1oxy)-trity1-N 4-Benzoy1-2'-
deoxycytidme (120) 
H's Assignment COSY correlations 
8.81-8.76 4 A A 
8.69-8.65 2 A A 
8.27-8.23 2 A A 
7.92-7.11 27 8A, 1 OE, 5N,L, 
K, 2132 
A to A, E to E, L to 
K, D2 to D1 
6.83-6.80 2 D1 
6.33-6.24 1 J I 
5.05-5.02 1 B C1 
4.37-4.36 1 H G and I 
4.26-4.25 1 G F and H 
3.86-3.80 2 C 1 0 C9 
3.47-3.46 2 F G 
2.88-2.75 1 I H and J 
2.64-2.56 2 C 1 Band C2 
1.65-1.53 2 C9 C8 and C10 
1.37-0.70 8 C3 to C8 C2 to C9 
0.33 2 C2 C 1 and C3 
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5'-0-4'-(10-(17 1 -tetrabenzo [a,c,g,ijfluorenyldecyloxy)-trityl-N 6-Benzoyl-2'-
deoxyadenosme (121) 













6.75-6.71 2 D1 D2 
6.50-6.42 1 J I 
5.06-5.02 1 B C1 
4.40-4.32 . 1 G F and H 
3.80-3.76 2 C10 C9 
3.44-3.36 2 F G 
2.97-2.75 2 I H and J 
2.69-2.50 2 C1 B and C2 
1.60-1.51 2 C9 C8 and CIO 
1.26-0.69 12 C3 C2toC9 
0.33 2 C2 C 1 and C3 
N 
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5'-O-4'-(1O-(1 7'-tetrabenzo [a,c,g,i] fluorenyl)decyloxy).-trityl-thymidine-3 '-0-
N,N-diisopropyI-3-cyanoethy1 phosphoramidite (124) 
H's Assignment COSY correlations 
8.81-8.67 6 A A 
8.27-8.23 2 A A 
7.72-7.58 9 8A and K A to A, K to L 
7.43-7.24 12 10E and 2D2 E to E, D2 to D 1 
6.81-6.77 2 DI D2 
6.46-6.38 1 J I 
5.04-5.01 1 B C1 
4.66 1 H G(faint) and l 
4.17-4.11 1 G H (faint) and F (faint) 
3.85-3.30 8 C10, F, N and Q C10 to C9,F, N and Q to R 
2.64-2.27 6 I, C1 and P Ito H and J, C1 to B and 
C2, P to N 
1.64-1.56 2 C9 C8 and CIO 
1.43-0.73 27 C3 to C8, L and R C2 to C9, L to K and Q to R 
0.34 2 C2 C 1 and C3 
A 
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4-(10-(17'-tetrabenzo [a,c,g,ilfluorenyloctyloxy)-trityl alcohol (147) 
H's Assignment COSY correlations 
8.83-8.70 6 A A 
8.27-8.23 2 A A 
7.74-7.60 8 A A 
7.38-7.25 10 E E 
7.17-7.13 2 D2 D 1 
6.76-6.71 2 D 1 
5.01-4.98 1 B C1 
3.73-3.67 2 C8 C7 
2.79 1 F - 
2.66-2.57 2 C1 B and C2 
1.57-0.76 10 C3 toC7 C2 toC8 
0.38-0.37 2 C2 C1 and C3 
F 
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5'-O-4'-(1O-(1 7'-tetrabenzo [a,c,g,ifluoreny1octy1oxy)-trity1-uridine (148) 
H's Assignment COSY correlations 
10.38 1 N - 
8.84-8.71 6 A A 
8.29-8.27 2 A A 
8.05-8.02 1 K L 
7.74-7.25 20 8A, 2D2, 1OE A to A, D2 to D1 
and EtoE 
6.78-6.76 2 D I D2 
5.92 1 J I 
5.5 1 NorP - 
5.37-5.34 1 L K 
5.08-5.06 1 B C1 
4.46 1 H I and G 
4.35 1 I H and J 
4.19-4.17 1 G F and H 
3.73-3.69 2 C8 C7 
3.57-3.51 2 F G 
2.64-2.62 2 C1 B and C2 
1.48-0.77 10 C3 to C7 C2 to C8 
0.38 2 C2 C1 and C3 
E 
7 
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5.3 Courses Attended 
Organic Chemistry Department Seminars, University of Edinburgh, 1997-2000, 
various speakers. 
Organic Chemistry Department Colloquia, University of Edinburgh, 1997-2000, 
various speakers. 
Demonstrating course, Teaching and Learning Association, University of 
Edinburgh 1997. 
Royal Society of Chemistry, Perkin Division, Scottish Meeting, Strathclyde 
University 1997, University of St. Andrews 1998, University of Aberdeen 1999. 
Current Awareness in Organic Chemistry, sponsored by Zeneca Grangemouth, 
University of Edinburgh, 1998, 1999, 2000, various speakers. 
Solid Phase Chemistry, University of Edinburgh, Professor R. Ramage, 1997. 
Industrial Inorganic Chemistry Course, University of Edinburgh, Professor P. 
Tasker, 1997 
RSC Medicinal Chemistry Conference, Edinburgh Conference Centre, Edinburgh, 
1998. 
Edinburgh Centre for Protein Technology Lectures, University of Edinburgh, 
1997-1999, various speakers. 
Walker Memorial Lectures, University of Edinburgh, Prof J.M. Lehn (Pasteur 
Institute, Strasbourg) 1998, Dr T. McKillop (Zeneca Pharmaceuticals) 1999. 
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NIvIR Spectroscopy Course, University of Edinburgh Drs Sadler, Barlow, Reed, 
Uhrin, Hewage and Parkinson. 
Merck Safety Lectures, organised by Merck, University of Edinburgh, 1998, 
various speakers. 
Synthons in Organic Chemistry, Prof. E. Vilsmeir (University of Kaiserslautern), 
1998. 
Romanes Symposium, University of Edinburgh, Prof K.C. Nicolaou (Scripps 
Research Institute), Dr K. Hale (University College London), Prof P.J. Kocienski 
(Glasgow University) 1998, Prof A.I. Scott (Texas A&N University), Dr C. 
Schofield (Oxford University), D. W. Young ( Sussex University), 2000. 
9th Scottish Graduate Symposium on Novel Organic Chemistry, University of 
Edinburgh 1998, various speakers. 
Ames Symposium, University of Edinburgh, 1998-1999, various speakers. 
Amino Acids in Organic Chemistry, Dr J. Podlech (University of Stuttgart), 1999. 
5.4 Presentations 
Talks given at Organic Chemistry Department Seminars, University of Edinburgh, 
1998 and 1999. 
Poster presented at Royal Society of Chemistry, Perkin Division, Scottish 
Meeting, University of Aberdeen 1999. 
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5.5 DNA Synthesiser Cycle 





Step 	Active for Bases 
Number 	# 	Name 	 Time (secs) A G C T X 
1 10 #l8towaste 
2 ' 	 9 #l8tocolumn 
3 2 Reverse flush 
4 1 Block Flush 
5 28 Phos Prep 
6 90 Tet to column 
7 19 B+ tet to column 
8 90 Tetto column 
9 19 B+ tet to column 
10 90 Tet to column 
11 19 B+ tet to column 
12 90 Tet to column 
13 9 #18 to column 
14 4 wait 
15 16 Cap prep 
16 2 Reverse flush 
17 1 Block Flush 
18 22 Cap to column 
19 10 #18 to waste 
20 2 Reverse flush 
21 1 Block Flush 
22 81 #l5towaste 
23 13 #15 to column 
24 10 #l8towaste 
25 4 wait 
26 2 Reverse flush 
27 1 Block Flush 
28 10 #l8towaste 
29 9 #l8tocolumn 
30 2 Reverse flush 
31 9 #l8tocolumn 
32 2 Reverse flush 
33 9 #18 to column 
34 2 Reverse flush 
35 9 #l8tocolumn 
36 2 Reverse flush 
37 1 Block flush 
38 33 Cycle entry 
39 10 #18 to waste 
5 Yes Yes Yes Yes Yes 
60 Yes Yes Yes Yes Yes 
10 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
3 Yes Yes Yes Yes Yes 
1 Yes Yes Yes Yes Yes 
4 Yes Yes Yes Yes Yes 
30 Yes Yes Yes Yes Yes 
(wait 600 seconds for final X only) 
3 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
10 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
10 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
12 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
30 Yes Yes Yes Yes Yes 
10 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
15 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
15 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
15 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
15 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
1 Yes Yes Yes Yes Yes 
5 Yes Yes Yes Yes Yes 
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Step Function Step Active for Bases 
Number # Name Time (secs) A G C T X 
40 9 #18 to column 15 Yes Yes Yes Yes Yes 
41 2 Reverse flush 5 Yes Yes Yes Yes Yes 
42 1 Block flush 5 Yes Yes Yes Yes Yes 
43 5 Advance fc 1 Yes Yes Yes Yes Yes 
44 6 waste port 1 Yes Yes Yes Yes Yes 
45 82 #14 to waste 5 Yes Yes Yes Yes Yes 
46 14 #14 to column 10 Yes Yes Yes Yes Yes 
47 2 Reverse flush 1 Yes Yes Yes Yes Yes 
48 14 #14 to column 10 Yes Yes Yes Yes Yes 
49 2 Reverse flush 1 Yes Yes Yes Yes Yes 
50 14 #14 to column 10 Yes Yes Yes Yes Yes 
51 2 Reverse flush 1 Yes Yes Yes Yes Yes 
52 14 #14 to column 10 Yes Yes Yes Yes Yes 
53 2 Reverse flush 1 Yes Yes Yes Yes Yes 
54 14 #14 to column 10 Yes Yes Yes Yes Yes 
55 2 Reverse flush 1 Yes Yes Yes Yes Yes 
56 14 #14 to column 10 Yes Yes Yes Yes Yes 
57 2 Reverse flush 1 Yes Yes Yes Yes Yes 
58 14 #14 to column 10 Yes Yes Yes Yes Yes 
59 2 Reverse flush 1 Yes Yes Yes Yes Yes 
60 14 #14 to column 10 Yes Yes Yes Yes Yes 
61 2 Reverse flush 1 Yes Yes Yes Yes Yes 
62 14 #14 to column 10 Yes Yes Yes Yes Yes 
63 2 Reverse flush 1 Yes Yes Yes Yes Yes 
64 14 414 to column 10 Yes Yes Yes Yes Yes 
65 2 Reverse flush 1 Yes Yes Yes Yes Yes 
66 10 #18 to waste 5 Yes Yes Yes Yes Yes 
67 9 #18 to column 30 Yes Yes Yes Yes Yes 
68 1 Block flush 5 Yes Yes Yes Yes Yes 
69 7 Waste Bottle 1 Yes Yes Yes Yes Yes 
70 2 Reverse flush 5 Yes Yes Yes Yes Yes 
71 10 #18 to waste 5 Yes Yes Yes Yes Yes 
72 9 #18 to column 30 Yes Yes Yes Yes Yes 
73 2 Reverse flush 5 Yes Yes Yes Yes Yes 
74 1 Block flush 5 Yes Yes Yes Yes Yes 
75 34 Cycle end 1 Yes Yes Yes Yes Yes 
Reagent 15: 0.1M Iodine / THF / Pyridine / H20 
Reagent 14: 3% TFA / DCM 
Reagent 18: Acetonitrile 
Cap A: TFIF / Lutidine / Acetic anhydride 
Cap B: methylimidazole / THF 1:9 
Activate: 0.45M tetrazole / Acetonitrile 
154 Chapter 5 Appendices.doc 
5.6 Diagram list 
Title 	 Page 
Figure 1. The DNA to protein pathway 2 
Figure 2. The primary structure of DNA and RNA 5 
Figure 3. IiNA double helix structure showing the base pairs 6 
Figure 4. Hoogsteen hydrogen double bonds 8 
Figure 5. Reverse Hoogsteen hydrogen double bonds 9 
Figure 6. Attempts to improve pyrimidine strand binding 10 
Figure 7. Representation of alternate strand binding 11 
Figure 8. Antisense translation inhibition 13. 
Figure 9. Triplex transcription inhibition 14 
Figure 10. Khorana's phosphodiester approach 19 
Figure 11. The Michelson and Todd phosphotriester approach 21 
Figure 12. Letsinger's phosphotriester approach 21 
Figure 13. Phosphate protection 22 
Figure 14. Cramer's approach 23 
Figure 15. Coupling Reagent MSNT 24 
Figure 16. 111-tetrazole as a catalyst 24 
Figure 17. Letsinger's phosphite triester approach 26 
Figure 18. Caruther's Phosphoramidite method 28 
Figure 19. Phosphitylating agent 28 
Figure 20. Phosphorus protection 29 
Figure 21. Uzanaski's phosphoramidite approach 30 
Figure 22. H-Phosphonate approach 31 
Figure 23. Attachment of the first monomer to CPG 33 
Figure 24. Solid phase general reaction cycle 35 
Figure 25. Nucleic Acid protection 39 
Figure 26. Nucleic Acid photocleaveable protection 40 
Figure 27. Acidic depurination 41 
Figure 28. Hydrophobic 5' protecting groups 42 
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Title Page 
Figure 29. TESC1 and terephthaloyl linker 43 
Figure 30. Thf based protecting groups 44 
Figure 31. Cleavage and Migration of RNA linkages 46 
Figure 32. Thp, Mthp DMTr and pixyl groups 47 
Figure 33. 'Ctmp and Fpmp 48 
Figure 34. TBDMS migration 49 
Figure 35. o-nitrobenzyloxymethyl and p-nitrobenzyloxymethyl 52 
Figure 36. SEM and DATE 2' protection 52 
Figure 37. HIFA deprotection 53 
Figure 38. Markiewicz protection 53 
Figure 39. Thf-C10-DMTr 56 
Figure 40. Steric hindrance at the 2' position 57 
Figure 41. Propargyl system 59 
Figure 42. Baldwin Rules 59 
Figure 43. 5-Exo-Dig reactions 60 
Figure 44. 5-Exo-Dig reactions using silyl protection 60 
Figure 45. Proposed new propargyl group 61 
Figure 46. Deprotection of new propargyl system 61 
Figure 47. Butynol system 62 
Figure 48. Butynol deprotection 64 
Figure 49. O-Creosyl system 65 
Figure 50. O-Creosyl deprotection 65 
Figure 51. Ethyl-4-(10 bromodecyloxy)-benzoate 66 
Figure 52. Synthesis of tetrabenzo[a,c,g,ifluorene 67 
Figure 53. Cyclisation mechanism for Bis-phenanthren-9-yl methanol 67 
Figure 54. Synthesis of (102) and (104) 68 
Figure 55. Attempted synthesis of (106) 69 
Figure 56. Potential mechanism of methyl trityl degradation in base 71 
Figure 57. C8 and C3 linker synthesis 72 
Figure 58. Model monomethoxy system (111) - (114) 74 
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Figure 59. Synthesis of(1 17) 75 
Figure 60. Protected nucleosides 77 
Figure 61. Phosphoramidite synthesis 78 
Figure 62. HPLC traces before and after purification 79-80 
Figure 63. 'Solid Phase synthesis results 81 
Figure 64. Proposed structure derived from the NIvIR evidence 82 
Figure 65: Synthesis of 6-Hydroxy-2-methyl-hex-4ynyl p-nitrobenzoate 84 
Figure 66. Synthesis of alkyl iodide tried and proposed (13 6) 85 
Figure 67. Synthesis of 5-hydroxy-pent-2-ynoate ethyl ester 86 
Figure 68. Mesylate and Tosylate alternative pathways 87 
Figure 69. O-Cresol System synthesis 88 
Figure 70. Coupling to uridine 88 
Figure 71: Coupling to Tbf C10 Tr protected Uridine 90 
Figure 72: Synthesis and coupling of Thf C8 Tr protected Uridine 91 
